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ABSTRACT
Drug-induced nephrotoxicity is a limiting factor to the efficacy and safety of various
therapeutics including the aminoglycoside antibiotics. Aminoglycosides, such as gentamicin,
cause proximal tubule injury in a significant proportion of individuals they are given to. The
onset of this adverse drug reaction is currently managed by the monitoring of serum peak
and trough levels and measurement of the classic renal functional markers serum
creatinine and blood urea nitrogen. The limitations of these biomarkers are well established
but novel, sensitive proximal tubule-specific biomarkers, such as kidney injury molecule-1,
are gradually coming to the fore. Still, management of aminoglycoside nephrotoxicity is
lacking a personalised strategy whereby the risk of a patient developing proximal tubule
injury can be established at the individual level before exposure.
Prior studies of gentamicin nephrotoxicity pin-pointed that HMG-CoA reductase inhibitors,
also known as statins, could inhibit the accumulation of gentamicin in vitro and therefore
reduce the cytotoxicity of the drug. In order to study HMG-CoA reductase and its
relationship to aminoglycoside accumulation further, an LC-MS/MS based assay was
developed and validated to measure the product of the enzyme, mevalonic acid, in the
urine of rats and humans. Urinary mevalonic acid was converted to mevalonolactone at pH
2, extracted alongside a deuterated internal standard using ethyl acetate and quantified by
reversed-phase LC-MS/MS. The assay had a broad dynamic range of 0.0156–10 μg/mL with
precision <15% CV and accuracy 85–115% to suit the natural variation within species and
between non-clinical and clinical samples.
To demonstrate the utility of the assay and to ascertain the natural diurnal oscillations in
HMG-CoA reductase activity, mevalonic acid was quantified in the urine of rats, mice and
healthy children. In rats the excretion of mevalonic acid was significantly greater in urine
collected during 22:00–10:00 h (mean 9.7 ± 2.3 μg/mg UCr) compared with 10:00–22:00 h
(mean 3.4 ± 1.3 μg/mg UCr). In a human paired urine study, in 60% of individuals, morning
collections had significantly greater concentrations of mevalonic acid than evening
collections where the morning excretion was, on average, 105% greater.
The diurnal rhythm of HMG-CoA reductase activity was investigated in relation to
aminoglycoside nephrotoxicity in a repeat-dose gentamicin rat model. A strong positive
relationship between pre-dose mevalonate excretion, gentamicin accumulation and kidney
injury in the renal cortex was observed.  Animals administered gentamicin at 10:00 h
experienced greater gentamicin accumulation and kidney injury, compared to animals on
the 22:00 h dosing schedule which corresponded to greater mevalonate excretion in the
hours prior to 10:00 h compared to 22:00 h. These data support the idea that there is a
contributory relationship between HMG-CoA reductase activity, the uptake of gentamicin
and subsequent nephrotoxicity. Investigations with the aminoglycoside tobramycin did not
reach the same conclusion as no clear relationship was observed.
In contrast to the HMG-CoA reductase focussed research, a non-targeted metabonomic
approach to understanding gentamicin nephrotoxicity was undertaken. Multivariate
analyses of 1H-NMR spectra from gentamicin-exposed rats revealed multiple major
perturbations in the urine and serum metabolome, prior to kidney injury molecule-1
elevation (urine OPLS-DA model 12 h post-dose Q2Y=0.93, p=0.007). Depletion of
metabolites related to energy production and elevation of metabolites implicated in
oxidative stress suggests gentamicin had a profound effect on the mitochondria of the
proximal tubule epithelial cells. Quantification of metabolites such as the TCA cycle
intermediates could be a non-invasive alternative to monitoring the toxicity of
aminoglycosides prior to overt renal functional changes.
Multivariate analyses of 1H-NMR urine spectra were also subjected to a
pharmacometabonomic approach whereby the pre-dose or early post-dose metabolome
vwas integrated with post-dose kidney injury molecule-1 measurements in order to group
individuals based on their differential response to gentamicin. Early-intervention
metabolite signatures were identified to have an inverse relationship to kim-1 excretion,
providing further evidence that the TCA cycle intermediates could be useful prognostic
biomarkers of gentamicin nephrotoxicity. Analysis of pre-dose profiles identified gut-
microbial metabolite 3-HPPA as correlated to the post-dose toxicity of gentamicin; follow
up studies demonstrated that 3-HPPA excretion also had a positive relationship to urinary
mevalonic acid. Hence, the pharmacometabonomic analyses implicated gut microbial and
host HMG-CoA reductase activity as related to the extent of gentamicin nephrotoxicity,
which certainly warrants additional investigations.
The adoption of targeted and non-targeted biomarker identification techniques has proven
successful in this research. Mevalonic acid and HMG-CoA reductase are promising
mechanistic factors which may affect susceptibility to aminoglycoside nephrotoxicity in
man and research will be facilitated by the development of the LC-MS/MS assay described
herein. Certainly, the use of statins as a prophylactic measure against aminoglycoside
nephrotoxicity will be explored. Comprehensive analysis of the metabolome has identified
the importance of the perturbation of energy metabolism and oxidative stress in the onset
and development of gentamicin nephrotoxicity and in addition, integration of these vast
data sets with the novel biomarker kidney injury molecule-1 has revealed that the gut
microbiome could also influence an individual’s susceptibility to this adverse drug reaction.
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41.1 Adverse drug reactions
An adverse drug reaction (ADR) is an undesirable side effect caused by exposure to a drug.
ADRs are diverse and a classification system has been developed to divide ADRs into groups
(Park et al. 1992). Type ‘A’ ADRs are reactions which can be attributed to the
pharmacological action of the drug and they are typically dose-dependent, accounting for
approximately 80% of ADRs (Kalgutkar and Didiuk 2009). Type ‘B’ ADRs are also known as
idiosyncratic ADRs and have complicated dose-response relationships with effects
unrelated to the known pharmacology of a drug. Type ‘C’ ADRs refer to therapeutics that
have chronic adverse effects, whilst Type ‘D’ ADRs have a delayed adverse effect such as
teratogens or carcinogens (Edwards and Aronson 2000).
As a leading cause of drug attrition and a growing public health issue, ADRs are a significant
concern to the pharmaceutical industry, medical professionals, governing authorities and
the general public. Between 1999 and 2005 the number of adverse event reports increased
2.6-fold, with serious adverse event reports increasing 2.7-fold (Moore et al. 2007). Serious
ADRs were estimated to be the cause of 106,000 deaths in 1994 in the US, ranking ADRs as
the fourth to sixth largest cause of death that year (Lazarou et al. 1998).
Not only do ADRs increase the duration of hospitalisation, alongside increased patient
morbidity and mortality, but they are a great financial burden. A prospective analysis of
hospital admissions in two Merseyside National Health Service hospitals between
November 2001 and April 2002 revealed that 6.5% of admissions were caused by ADRs
(93% of the ADRs were Type A) at a projected cost to the National Health Service of £466
million (Pirmohamed et al. 2004). ADRs are also responsible for a significant number of drug
withdrawals; between 1975 and 2000 10% of FDA-approved drugs were either withdrawn
or given black-box warnings as result of unanticipated ADRs (Lasser et al. 2002). Although
some of the epidemiological data available on ADRs are more than a decade old, the
prevalence and importance of ADRs to drug development and public health still remains.
5ADRs can affect any organ system but some organs are more susceptible than others.
Hepato- and cardiotoxicity are the most widely cited reasons for drug attrition during
development and post-marketing (Lasser et al. 2002; Stevens and Baker 2009), yet other
organ-specific ADRs such as nephrotoxicity are of major concern pre- and post-marketing,
limiting the development, efficacy and prescription of treatments.
1.2 The kidney
A single mammalian kidney is a bean-shaped organ with a concave renal hilum, where
blood vessels connect and the ureter exits, and a convex outer surface also known as the
cortex (Deshmukh 2009). The kidney has distinct zones that form a cone shaped renal lobe
comprising the cortex at the widest region, adjoined to the medulla and the papilla at the
tip (Seldin 2008).
The functional unit of the kidney, the nephron, spans the cortex and medulla. The
physiological function of the nephron is to regulate blood entering the kidney by
adjustment of water and salt content, volume and pH and removal of toxins and unwanted
substances (Seldin 2008). A nephron is composed of several structures with specific
functions – the glomeruli and Bowman’s capsule, proximal tubule, loop of Henle and the
distal tubule which adjoins the collecting duct (Deshmukh 2009), see Figure 1.1.
The glomerulus is a tuft of capillaries in the cortex which receives and filters blood from the
afferent arteriole. The fenestrated capillary wall allows passage of molecules up to 70 kDa
(Deshmukh 2009) and pressure is created by the difference in diameter between the
afferent arteriole and the narrower efferent arteriole (although this can also be hormonally
regulated). Collectively, the glomerulus, basement membrane and podocytes of Bowman’s
capsule selectively filter small molecules such as water, ions, low molecular weight
proteins, glucose and amino acids whilst excluding blood cells, platelets and high molecular
weight and anionic proteins (Seldin 2008) producing an ultrafiltrate.
6Figure 1.1 Drug-induced toxicity in the nephron. The nephron consists of distinct functional
parts which are susceptible to injury as a result of exposure to a variety of therapeutic
agents.
Ultrafiltrate is processed further to form urine entering the proximal tubule in the cortex,
which has resorptive (glucose, salt, water, proteins) and secretive (creatinine) functions
(Deshmukh 2009). Proximal tubule epithelial cells are characterised by their dense microvilli
on the apical surface which increases their surface area to facilitate reabsorption. The loop
of Henle extends into the medulla from the proximal tubule and facilitates water and salt
exchange. The remaining filtrate enters the distal tubule which mediates the uptake of
calcium, phosphate, sodium and potassium from the filtrate (Deshmukh 2009) before it
reaches the collecting duct, draining towards the ureter.
1.2.1 Acute kidney injury
Acute kidney injury (AKI), previously known as acute renal failure, is a term used to describe
the acute loss of kidney function which manifests from a variety of clinical scenarios and
can present as mild increases in serum creatinine to complete anuria (Mehta et al. 2007).
7The causes of AKI can be classified into pre-renal, intrinsic and post-renal; pre-renal causes
affect blood flow, post-renal causes are obstructions of the urinary tract and intrinsic
causes damage the kidney tissue, usually by cellular toxicity or nephritis.
1.2.1.1 Drug-induced nephrotoxicity
Drug-induced nephrotoxicity is a type of kidney injury where functional or structural
damage to the organ, pre-renal, intrinsic or post-renal, is caused by exposure to one or
several therapeutic agents. It is a common clinical adverse event and although the true
incidence is difficult to determine, US hospital data suggests that drug-induced kidney
injury accounts for 18-27% of all acute kidney injury cases in the US (Taber and Pasko 2008).
Therapeutics can alter renal perfusion or directly injure glomerular, tubular, vascular or
interstitial cells (Choudhury and Ahmed 2006). Pre-renal kidney injury, observed in the use
of non-steroidal anti-inflammatory drugs (NSAIDs) and angiotensin-converting enzyme
(ACE) inhibitors, arises from a reduction in intraglomerular pressure which is normally
autoregulated by the organ in order to preserve the glomerular filtration rate (GFR) and
urine production (Naughton 2008). The aminoglycosides cause toxicity in the proximal
tubule cells and the beta-lactam antibiotics and the NSAIDs provoke nephritis of the
interstitial cells (D'Agati et al. 1989), see Figure 1.1.
1.2.1.2 Susceptibility to toxicity
The functional characteristics of the kidney render it susceptible to drug exposure and
therefore toxicity. Approximately ¼ of cardiac output is filtered by the kidney and 90-95%
of this blood is in the cortex with the remainder in the medulla. The liver transforms many
drugs to more polar hydrophilic metabolites which will inevitably be filtered from the
systemic circulation at the glomerulus and pass through the tubules for elimination. The
exchange of solutes and reabsorption of low molecular weight proteins and amino acids in
the renal tubules is essential in salt, water and protein homeostasis. However the large
number of transporters and endocytic receptors in the tubules confers a concentrating
8ability which means that although a drug may be in low abundance in the systemic
circulation and the ultrafiltrate, the selective transport of drugs and metabolites into the
tubular cells will cause higher cytosolic concentrations that may be toxic. Furthermore the
progressive concentration of the ultrafiltrate along the nephron could cause precipitation
of compounds resulting in tubular obstruction.  In addition, due to the high metabolic rates
involved in the Na+-K+-ATPase active transport of solutes in and out of renal cells, the cells
have a largely hypoxic environment, rendering them more sensitive to injury. Whilst the GI
tract and liver are major sites of metabolism, the kidney also expresses a large number of
drug metabolising enzymes including the cytochrome P450 family, which are implicated in
various drug-induced toxicities (Perazella 2009).
1.2.1.3 Detection of nephrotoxicity
Whilst animal studies can use histopathology to confirm AKI, clinicians rely on the ‘gold
standard’ established biomarkers serum creatinine and blood urea nitrogen as indicators of
renal function. However, their inherent characteristics limit the timely detection of AKI and
stratification of patient regimens; as such there is a strong research effort towards
identifying and qualifying novel sensitive and specific biomarkers of kidney injury.
1.2.1.3.1 Serum creatinine
Serum creatinine (SCr) is routinely measured in clinical practice as an indicator of renal
function. As a non-specific biomarker of renal function it is relatively uninformative of
kidney injury. The reciprocal relationship of SCr and creatinine clearance is widely used to
estimate the GFR; however, concern over the overestimation of GFR and therefore the
clinical value of this ‘gold standard’ renal biomarker is widespread (Slocum et al. 2012).
Creatinine is the nonenzymatic product of muscle creatine and muscle mass determines the
size of the creatinine pool in an individual, with age and sex being major determinants. As a
low molecular weight cation, creatinine is freely filtered by the glomerulus but it is also
secreted by the renal tubules. In states of renal insufficiency, as much as 60% of urinary
9creatinine is derived from the tubules (Perrone et al. 1992). As a result creatinine clearance
can exceed the GFR and in health and disease this could lead to overestimations of GFR and
overlooking kidney injury.
Extrarenal clearance of creatinine via enterohepatic routes can also lead to overestimation
of GFR (Jones and Burnett 1974). In individuals with normal renal function enterohepatic
creatinine clearance is not observed, however in individuals with a compromised GFR and
theoretically a raised SCr, degradation of creatinine by intestinal microbiota counters the
serum rise causing an overestimation of creatinine clearance.
A major limitation to the use of serum creatinine to detect kidney injury is manifested in
the delayed onset in serum changes. Typically a delay of 24-72 h is observed post-insult, the
so-called ‘accumulation phase’, where serum creatinine reaches a new higher steady state
after kidney injury. The new GFR, extent of tubular secretion, balance between creatine
formation and turnover and the volume of distribution contribute to this delay, which
impedes the early detection of kidney injury in the clinic (Waring and Moonie 2011).
Of further concern to the clinical utility of this biomarker is the sensitivity of serum
creatinine to detect a reduction in GFR, owing to the inter-individual variability in baseline
concentrations. Clinical guidelines suggest ≥1.69 mg/dL or ≥50% increase in baseline serum
creatinine with reduced urine output is indicative of kidney injury (Waring and Moonie
2011). However a wide physiological dynamic range is observed, influenced by age, sex,
muscle mass and consumption of dietary creatine. Vegetarians have been observed to have
a significantly lower creatinine clearance compared to individuals with a greater protein
intake (Bosch et al. 1983). In patients with low muscle mass and low baseline serum
creatinine a modest increase after kidney injury would bring the measurement into the
‘normal’ reference range and without baseline measurements, kidney injury may go
undetected.
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Although AKI may reduce the number of functional nephrons, the remaining nephrons
compensate for this loss by hyperfiltration (Bosch et al. 1983). A patient may have AKI but it
could be subclinical if measured only by GFR and serum creatinine (Ronco et al. 2012). The
renal functional reserve contributes to delayed serum creatinine elevation and
compromises early detection of kidney injury and the prognosis.
1.2.1.3.2 Blood urea nitrogen
Blood urea nitrogen (BUN) is the measure of the nitrogen content of the urea present in
serum and the normal range is 5 to 20 mg/dL. Urea is a physiological waste product of
protein turnover and a large proportion of urea is excreted via the kidney. Although 40 to
60% of urea filtered by the glomerulus is reabsorbed, BUN is also a measure of GFR (Hosten
1990). Similar to creatinine, urea production is affected by high-protein diets, and as urea is
predominantly produced by the liver, blood urea concentrations are affected by liver
function and high catabolic states. BUN can also be modified by processes such as
gastrointestinal bleeding and heart failure (Fuchs and Hewitt 2011). Due to the drawbacks
of these traditional biomarkers, clinical measurements of BUN and SCr are best interpreted
as ratios and can indicate whether disease is pre-renal, post-renal or extra-renal (Hosten
1990).
1.2.1.4 Emerging biomarkers of acute kidney injury
The limitations of SCr and BUN as renal biomarkers have prompted research into novel
biomarkers of AKI. The ideal biomarker of acute kidney injury would be tissue and site-
specific, sensitive, with changes from baseline proportional to the degree of injury allowing
early detection with a wide diagnostic window.  Unlike SCr and BUN, the biomarker should
not be influenced by environmental factors and from a practical and analytical perspective,
can be obtained by non-invasive sampling.
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1.2.1.4.1 Neutrophil-associated gelatinase lipocalin
Neutrophil gelatinase-associated lipocalin (NGAL), also known as lipocalin-2, has been
proposed as an early diagnostic biomarker of AKI that could contend with serum creatinine.
NGAL is a protein expressed in various cell types including epithelial cells and neutrophils
but in the kidney it has been associated with renal development, recovery and regeneration
(Schmidt-Ott et al. 2007). NGAL mRNA and protein are upregulated in the post-ischemic
mouse kidney (Mishra et al. 2003) and it has been validated as a biomarker of AKI in
ischemic and nephrotoxic animal models (Mishra et al. 2004).
Despite the pre-clinical success, the clinical validation of NGAL has been less definitive.
There is large variability in baseline concentrations of serum NGAL in patients who do not
have AKI, complicating the determination of reference ranges. Furthermore, the sensitivity
and specificity of NGAL varies between patient populations, for instance in paediatric
versus adult populations the predictability of AKI by NGAL is age-dependent. Mishra et al
studied serum and urine NGAL changes to predict AKI in children undergoing
cardiopulmonary bypass surgery and observed significant increases in NGAL in both
biofluids just 2 h post-surgery, with sensitivity of 100% and specificity of 98% (Mishra et al.
2005). In contrast, studies of urinary NGAL after adult cardiac surgery revealed less
convincing specificity and sensitivity 1 h post-surgery, at 59% and 80%, respectively
(Wagener et al. 2006). Moreover, NGAL is not specific to the kidney, as exemplified in the
difference between NGAL in septic versus non-septic AKI (Bagshaw et al. 2010); co-
morbidities such as the presence of infection or inflammation modulate NGAL levels and
contribute to the low specificity, which could ultimately lead to false positive diagnosis of
AKI.  These drawbacks mean it is unclear what measurement of urinary or serum NGAL
adds to the clinical decision process.
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1.2.1.4.2 N-acetyl-β-D-glucosaminidase
N-acetyl-β-D-glucosaminidase (NAG) is a lysosomal enzyme found in the proximal tubule
epithelia in abundance. Increased urinary excretion of NAG suggests tubular damage as its
high molecular weight (130-140 kDa) precludes it from glomerular filtration. Urinary NAG
levels are found to remain elevated throughout renal disease and as such, NAG has been
measured experimentally for several decades and could serve as a prognostic biomarker
(Price 1992).
Notwithstanding these attributes, urinary NAG is also observed to increase with lysosomal
activity (Bosomworth et al. 1999) and in glomerular diseases (e.g. diabetic nephropathy)
(Koh et al. 1993). Therefore NAG may lack the specificity for diagnosis of AKI and clinical
decision making.
1.2.1.4.3 Kidney injury molecule-1
Kidney injury molecule-1 (kim-1) is a protein that was recognised as a potential biomarker
of kidney injury in a 48 h adult rat post-ischemic unilateral kidney model by
representational differential analysis (RDA) in which mRNA populations in normal and
regenerating kidneys were compared (Ichimura et al. 1998). The mRNA transcript of kim-1
identified by RDA was present at low levels in sham-operated control kidneys and
embryonic kidneys but was substantially upregulated in the post-ischemic model of kidney
injury. Expression of the kim-1 transcript was co-localised with the apical end of
regenerating (proliferating and dedifferentiated) proximal tubule epithelial cells and cell
debris in the post-ischemic rat kidney as determined by RNA in situ hybridisation and
immunohistochemistry. Importantly, kim-1 was not found in other parts of the nephron, or
in the normal or embryonic kidney.
Further characterisation of rat kim-1 and human KIM-1 indicated that it is a Type 1
transmembrane protein. The cytoplasmic tail is relatively short and contains a
phosphorylation site, indicative of a role for kim-1 in cell signalling, whereas the N-termini
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ectodomain, which characteristically protrudes into the luminal space, contains a six-
cysteine immunoglobulin super family domain (Ichimura et al. 1998) and mucin domain
which confer protein-protein interactions at the cell surface and cell adhesion properties.
The protein has been shown to be cleaved by metalloproteinase and excreted in the urine
(Bailly et al. 2002; Han et al. 2002) which is important to its development as a non-invasive
renal biomarker of injury.
1.2.1.4.3.1 Physiological function of kim-1
KIM-1 is a member of a large family of proteins also referred to as T-cell immunoglobulin
mucin proteins (TIMs) which are extracellular sensors or receptors for cell adhesion and cell
signalling. KIM-1 is also expressed on the T-cell surface and is involved in differentiation of T
helper cells (Meyers et al. 2005), however in renal injury KIM-1 is not localised to the basal
surface (rather, the apical surface) of the proximal tubule epithelial cells where it would
have the potential to interact with infiltrating macrophages. Therefore it is unlikely that
KIM-1 plays a role in the immune reaction to proximal tubule injury.
After nephron damage, the segments can be remodelled and repaired to regain function; a
critical part of this recovery is removal of apoptotic and necrotic cell debris by phagocytosis.
During early characterisation of Kim-1 it was found to be co-localised with markers of cell
proliferation (Ichimura et al. 1998), hence it was postulated that kim-1 plays a role in cell
regeneration. Since then kim-1 has been localised to the phagocytic cup (the site of
apoptotic cell internalisation) on epithelial cells in the tubular lumen of rats with ischemia-
induced proximal tubule injury and has been demonstrated as a phosphatidylserine
receptor to recognise the apoptotic cell surface (Ichimura et al. 2008). The phagocytic
phenotype which kim-1 confers to epithelial cells in the damaged renal tubule is considered
important to enhancing the remodelling process and dampening the inflammatory
response after injury and therefore critical to functional recovery.
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1.2.1.4.3.2 Non-clinical investigations into the utility of kim-1
The establishment of kim-1 as a biomarker of ischemia-induced proximal tubule injury
prompted investigations with model nephrotoxicants. Kim-1 upregulation in S-(1,1,2,2-
tetrafluoroethyl)-l-cystein (TFEC), cisplatin, and high-dose folic acid induced proximal tubule
injury was examined in male rats (Ichimura et al. 2004). Kim-1 protein levels were elevated
in the kidney tissue of TFEC-treated rats 1 day after exposure and persisted for 14 days; in
contrast, serum creatinine was elevated 24 hours post exposure, peaked at day 2 and
returned to baseline levels by day 5. Similarly, kim-1 was detected in the urine of the same
animals from day 1 after TFEC treatment and persisted to day 7. Upregulation of kim-1 was
also demonstrated in the folic acid model (without a rise in serum creatinine) and of
cisplatin (Ichimura et al. 2004), cadmium (Prozialeck et al. 2007), mercury, chromium and
gentamicin (Zhou et al. 2008) nephrotoxicity, where uKim-1 outperformed serum creatinine
through earlier and more sensitive increases. Of particular interest, administration of
gentamicin (subcutaneous 25-400mg gentamicin/kg) in male Sprague-Dawley rats led to
dose and time-dependent increases in urinary kim-1 excretion at doses ≥100 mg/kg which
correlated with renal histopathological severity, whereas significant rises in BUN, SCr and
urinary NAG excretion were only seen at the highest dose of 400 mg/kg (Zhou et al. 2008).
A multi-centre academic and industrial initiative (the Predictive Safety Testing Consortium)
thoroughly investigated kim-1 by replicating the kidney injury specific 100-fold induction of
kim-1 gene expression, induction of protein expression and urinary excretion, and direct
comparison of kim-1 measurements with SCr, BUN, NAG and histopathology in
nephrotoxicant-dosed animals (Vaidya et al. 2010). As a result urinary kim-1 has been
qualified by the US Food and Drug Administration as a biomarker of renal injury in the pre-
clinical development of pharmacologic agents (Dieterle et al. 2010) .
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1.2.1.4.3.3 Clinical evaluation of KIM-1
KIM-1 was evaluated in kidney tissue biopsies from six patients diagnosed with acute
tubular necrosis caused by ischemia or allograft dysfunction (Han et al 2002). Akin to the
localisation seen in the rat, KIM-1 was localised to the apical membrane of human proximal
tubule epithelial cells whereas it was not detected in the glomeruli. Urine analyses
demonstrated that a soluble released form of KIM-1 was detected at higher levels in
patients with confirmed acute tubular necrosis compared to patients with chronic renal
diseases and those without renal disease. Indicative of the early changes in the presence of
urinary KIM-1, in two patients who had experienced an ischemic insult urinary KIM-1 was
raised within 12 hours following injury and notably before any urinary casts were identified.
Likewise in paediatric patients undergoing cardiac pulmonary bypass who developed AKI,
urinary KIM-1 was significantly elevated 12 h after surgery and in adults significance was
reached immediately after cardiac surgery (Han et al. 2009) and at 2 h post-cardiac surgery
(Liangos et al. 2009).
The surge in functional genomics studies has aided the identification and characterisation
of novel biomarkers of kidney injury. Although there has been a promising start to the
qualification of KIM-1/kim-1 as a renal biomarker in clinical/non-clinical research, it is likely
that a panel of biomarkers will make the greatest impact to clinical decisions in the future.
Until then, the qualification of these emerging biomarkers for pre-clinical use will facilitate
the investigation of mechanisms of drug-induced nephrotoxicity for new and existing
chemical entities.
1.3 Methods for identifying putative biomarkers
There are two major approaches that can be chosen to identify potential biomarkers of
health and disease. The first is a targeted approach whereby research focusses on a target
that has been linked to the biological process and the relationship of this putative
biomarker and the disease state is further probed with specific research questions. The
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second approach is a non-biased, comprehensive analysis of the biological system when
challenged with the disease. In this way, novel targets can be identified which can be
further investigated by the targeted approach. Both approaches can be conducted using
human samples if available but it is more common to initiate targeted and non-targeted
biomarker identification using an animal model of the disease and if successful, follow-up
with investigations in humans to ascertain whether the biomarker is translational.
1.3.1 Analytical technologies in biomarker identification
Targeted and non-targeted ‘omics approaches to biomarker identification and investigation
rely heavily on analytical technology, for example, a non-targeted comprehensive analysis
of kidney mRNA by PCR, identified kim-1 as a putative biomarker of kidney injury (Ichimura
et al. 1998). Whilst analysis of nucleic acids is enabled by PCR-based technology, analysis of
the proteome and metabolome is permitted by analytical technologies such as
chromatography coupled to mass spectrometry (LC-MSn) and/or nuclear magnetic
resonance (NMR) spectroscopy.
1.3.1.1 Chromatography
There are a wide range of chromatographic options that can be used to enhance the
separation of complex biological mixtures. The selection of gas (GC) or liquid
chromatography (LC), column chemistry and temperature and mobile phase or carrier gas
can tailor molecular separation to maximise the number of analytes or select for a specific
target, making gas or liquid chromatography useful techniques in non-targeted and
targeted biomarker analysis. LC or GC are typically coupled to detection instruments such
as mass spectrometers or NMR instruments.
1.3.1.2 Mass spectrometry
Mass spectrometry measures the abundance of individual charged molecules according to
their mass-to-charge ratio (m/z). At the ion source, analytes are delivered to the instrument
and ionised to positively charged ions, denoted [M+H]+ or negatively charged ions, denoted
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[M-H]-. Using electrodes and a magnetic field, the charged analytes are directed and
accelerated to the mass analyser where they are sorted based on their m/z. As with
chromatography, instrument and method options, such as charge and magnetic field, can
be optimised to analyse a specific target (i.e. a metabolite of interest) which is termed
selective reaction monitoring (SRM), or, the instrument and method can be selected to
encompass a wide range of analytes (i.e. analysis of a metabolome). Charged analytes can
be fragmented to smaller analytes, or product ions, providing a highly specific molecular
pattern. Ions of interest are selected at the first mass analyser and fragmented in a collision
cell before the product ions are measured in the second mass analyser. This technique,
termed ‘tandem mass spectrometry’, permits structural identification of putative
biomarkers from a non-targeted biomarker approach but also confers the molecular fidelity
of an analytical method when used in a targeted biomarker investigation.
Despite its uses, mass spectrometry is plagued by specific limitations. At the ion source,
components of the matrix can suppress or enhance the ionisation of analytes, which can
skew the abundance of an analyte in the MS spectra, and unless matrix effects are proven
to be eliminated or uniform between samples or absent, the quantitative use of MS for
certain analytes is limited. In addition if a clinically useful biomarker is expected to be
quantified in multiple laboratories the lack of inter-laboratory reproducibility of LC-MS
methods poses an issue.
1.3.1.3 Nuclear magnetic resonance spectroscopy
Nuclear magnetic resonance (NMR) is a phenomenon whereby atomic nuclei that have
rotational momentum in an external magnetic field, such as a proton (1H) or carbon-13
(13C), absorb a specific electromagnetic frequency to align against the external magnetic
field; the re-emission of this energy, typically a radiofrequency, causes fluctuations in the
magnetic field which is measured as a resonance. In NMR spectroscopy, these fluctuations
generate a current in a surrounding sample coil which is measured electronically and
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converted to an NMR spectrum. The atomic nuclei are naturally present in alignment or
opposition to the magnetic field and it is the nuclei naturally in alignment that are exploited
by the technique (James 1998). At room temperature the number of nuclei in alignment, or
‘low energy state’ outnumbers the number of nuclei in opposition, also known as the ‘high
energy state’. This can be described by the Boltzmann equation which relates the nuclei
population ratio to the energy difference at an absolute temperature:ℎ ℎ = −∆ = −ℎ
N = number of nuclei, E= energy difference between the two spin states, k = Boltzmann
constant, T= absolute temperature (Kelvin)
Atomic nuclei that are surrounded by different structural environments will experience the
external magnetic field to different extents. When the external magnetic field is applied,
the electrons of the neighbouring atoms generate a secondary magnetic field which shields
or deshields the nuclei from the external field, thus affecting the radiofrequency required
to align the nuclei against it. NMR spectra are not reported in frequency units, due to
between-instrument differences, but rather parts per million (ppm). Frequency and ppm
are directly proportional such that a proton requiring a lower radio frequency will be
positioned lower on the ppm scale in a spectrum and conversely protons that require a
higher radio frequency to align against the magnetic field will be positioned at the higher
end of the ppm scale. Peaks in NMR spectra appear as singlets, doublets, triplets and
multiplets, with the number of peaks relative to the number of adjacent surrounding nuclei
(James 1998).
NMR spectroscopy has emerged as a fundamental tool in metabolic profiling, circumventing
the inherent issues associated with mass spectrometry such as reproducibility and
ionisation suppression. Whilst the reproducibility of NMR spectroscopy is a strong attribute,
the lower sensitivity of the technique is a long-standing drawback. The sensitivity of NMR
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spectroscopy lies in the population size of nuclei that are aligned with the external
magnetic field (and can therefore be excited by the radiofrequency), compared to the
population size that are already in opposition. It is the difference between these two
populations, only 128 nuclei out of 2,000,128 nuclei for 1H NMR, which delivers sensitivity
at the low micromolar range (James 1998; Robertson et al. 2011).
1.4 Aminoglycoside-induced nephrotoxicity
The aminoglycosides are a class of antibiotics used to treat severe Gram negative bacterial
infections such as those caused by Pseudomonas aeruginosa and also Gram positive
bacterial infections, particularly Mycobacterium tuberculosis. The aminoglycoside class
began as a group of natural compounds; the first aminoglycoside, streptomycin, and the
second, neomycin, were isolated from strains of Streptomyces bacteria in the 1940s and
were found to inhibit bacterial growth (Jones et al. 1944; Waksman and Lechevalier 1949).
Gentamicin (Weinstein et al. 1963) and tobramycin (Stark et al. 1967) were identified in the
following decades alongside the semi-synthetic aminoglycosides amikacin (Price et al. 1974)
and netilmicin (Kabins et al. 1976).
Structurally, the aminoglycosides consist of two or more amino sugars with a glycosidic
linkage to an aminocyclitol ring, see Figure 1.2. Minor differences in substitutions on these
molecules mean that an aminoglycoside can have several conformations, such as for
gentamicin. Multiple hydroxyl groups on the sugar moieties make aminoglycosides
hydrophilic with poor lipid solubility and their amino groups confer a positive charge at
physiological pH.
1.4.1 Mechanism of antibiotic action
The polycationic nature of aminoglycosides allows for high affinity interactions with nucleic
acids and it is this characteristic which affords the antibiotic mechanism of the drug class.
Binding studies of the aminoglycosides with ribosomal RNA (rRNA) of Escherichia coli
demonstrated that the compounds bind to the A site of 16s rRNA within the 30S ribosomal
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subunit (Fourmy et al. 1996), which, with close proximity to the codon recognition site,
interferes with physiological ribosome-RNA interactions and transfer RNA specificity during
translation. As the viability of a bacterial cell is inversely related to the number of mis-
translated proteins, the aminoglycosides have a bactericidal (as opposed to bacteriostatic)
effect.
Figure 1.2 Structural similarities, a central aminocyclitol ring, and differences, modified
amino sugars, of commonly studied and clinically used aminoglycoside antibiotics.
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1.4.2 Pharmacokinetics
The intrinsic hydrophilic nature of the aminoglycosides results in poor oral bioavailability
and they are typically administered parenterally. Once in the systemic circulation, their
poor lipid solubility prevents the aminoglycosides being absorbed into most tissues and the
majority of the drug passes through glomerular filtration and is renally excreted in an
unchanged form. However a significant proportion, typically 5% (Mingeot-Leclercq and
Tulkens 1999), accumulates within the proximal tubule epithelial cells (Vandewalle et al.
1981).
1.4.3 Proximal tubule injury
Nephrotoxicity is one of the most significant side effects and therapeutic limitations of the
aminoglycoside class. The site-specific accumulation of the aminoglycosides within the
epithelial cells of the proximal tubule is a key step in the onset of aminoglycoside-induced
nephrotoxicity.
1.4.4 Uptake
Autoradiography experiments in isolated tubules of rabbits (Vandewalle et al. 1981) and
rats (Wedeen et al. 1983) administered 3H-gentamicin illustrated that increasing amounts
of drug were incorporated into the S1 and S2 tubule segments but not in the S3 segment,
distal tubule or collecting ducts. In addition, radiolabeled gentamicin experimentation in
rats charted the movement of the drug from the apical surface of the proximal tubule cells
to the interior of the cells by endocytosis (Silverblatt and Kuehn 1979). Ligand binding
(Moestrup et al. 1995), mouse knock-out (Schmitz et al. 2002) and competitive ligand
experiments (Nagai et al. 2001) have pin-pointed the endocytic receptor megalin as a major
driver in the endocytosis and accumulation of these drugs within this tissue.
1.4.5 Intracellular trafficking
Once inside the epithelial cells gentamicin is localised initially to the lysosomal
compartment as a result of endocytosis (Wedeen et al. 1983). Intracellular trafficking
investigations of gentamicin utilised the conjugation of gentamicin to the fluorescent dye
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Texas Red and confocal microscopy to track the rapid movement of conjugated gentamicin
in LLC-PK1 cells from the endocytic compartment to the Golgi body (Sandoval et al. 1998)
and to the endoplasmic reticulum (ER) before being released into the cytosol (Sandoval and
Molitoris 2004). A decrease in mitochondrial membrane potential coincided with the
cytosolic release of gentamicin and as a result it is accepted that the presence of high
concentrations of drug within the cytosol causes the cytotoxicity.
1.4.6 Membrane destabilisation
A critical component of the release of high concentrations of the aminoglycosides into the
cell cytosol is the destabilisation of their transporting lysosomes. The polycationic nature of
the aminoglycosides aids their electrostatic interaction with anionic phospholipids of
intracellular membranes, disrupting membrane structure, function and phospholipid
turnover (Josepovitz et al. 1985; Ramsammy et al. 1989). Aberrant accumulation of
phospholipids, also known as phospholipidosis, is a chief manifestation of the effects of
aminoglycosides in the rat (Giuliano et al. 1984) and in man (De Broe et al. 1984). Although
disruption of membrane homeostasis may be contributory and an obligate step in releasing
a concentrated amount of aminoglycoside into the cell cytoplasm, it is not necessarily the
decisive trigger that leads to cell death processes.
1.4.7 Induction of apoptosis
Rupture of lysosomes not only releases high concentrations of drug into the cytosol but
also releases proteolytic enzymes which have been demonstrated to cleave the BH3-
interacting domain death agonist (Bid), a pro-apoptotic member of the Bcl-2 family,
releasing cytochrome C and initiating apoptosis (Stoka et al. 2001). Whilst the initiation of
cell death by the aminoglycosides could be indirect through the release of proteolytic
cathepsins from destabilised lysosomes, much evidence indicates that the aminoglycosides
exert a direct effect on the mitochondria; gentamicin inhibited oxidative phosphorylation in
vitro and in isolated renal cortical mitochondria from rats exposed to the drug causing a
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reduction in ATP levels (Simmons et al. 1980). Gentamicin has also been shown to increase
the production of reactive oxygen species (ROS) in isolated rat mitochondria (Walker and
Shah 1987). As such, numerous attempts to ameliorate the renal toxicity of the
aminoglycosides have involved co-administration of anti-oxidants.
The localisation of aminoglycosides within the endoplasmic reticulum may provide another
route to initiating apoptosis. The mechanism of aminoglycoside antibiotic action relies on
its affinity for nucleic acids, particularly prokaryotic ribosomal RNA; hence an interaction
with eukaryotic ribosomal RNA could provoke disruption to mammalian protein translation.
A study of isolated renal microsomal fractions and cortical homogenates from gentamicin-
treated rats exhibited an inhibition of protein synthesis ascertained by a reduction in 3H-
leucine incorporation (Bennett et al. 1988; Sundin et al. 2001). In addition, disruption to
protein synthesis has been demonstrated for aminoglycoside ototoxicity, another adverse
effect of the drug class, whereby binding to rRNA and cessation of protein translation
results in the activation of the JNK pathway and apoptosis (Francis et al. 2013). However
the affinity of aminoglycosides for prokaryotic rRNA is greater than for human rRNA as
demonstrated by the aminoglycosides paromomycin and G418 (Kaul et al. 2005) with the
adenosine nucleotide at position 1408 conveying prokaryotic specificity; gentamicin and
tobramycin have an IC50 of 1.8 µM and 1.9 µM for the prokaryotic wild-type 16S RNA
whereas mutation of position 1408 to the eukaryotic phenotype (guanosine) gives an IC50
of 230 µM and 240 µM.
As well as perturbing protein translation, the aminoglycosides have been suggested to
initiate apoptosis through the unfolded protein response (UPR) and the binding of
gentamicin to various chaperone proteins has been reported (Horibe et al. 2004; Horibe et
al. 2002). To date, the relative contribution of these intracellular events in initiating cell
death has not been resolved and it may be the case that one mechanism presides over
another or it is that multiple catastrophic events culminate in the cell inducing apoptosis.
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1.4.8 Aminoglycoside-induced nephrotoxicity in the clinic
The incidence of aminoglycoside-induced nephrotoxicity varies in the literature; between 5
and 26% of aminoglycoside courses result in nephrotoxicity (Bailie and Mathews 1987;
Kahlmeter and Dahlager 1984; Laurent et al. 1990) despite the employment of strategies to
minimize risk. This wide range is likely to be caused by differences in the criteria used to
confirm renal injury, the use of different aminoglycosides and demographic factors which
increase the risk such as gender and age. Signs of aminoglycoside-induced renal failure
usually present after 5-7 days following the start of treatment. Patients will typically
experience nonoliguria (>0.5 L urine/day) or polyuria (>2.5 L/day) producing low quality
hypoosmolar urine, which is reflective of the inability of the kidneys to filter blood
efficiently, with appreciable proteinuria, amino aciduria, electrolyte changes, hyaline and
granular casts; gradual increases in serum creatinine are also observed (Mingeot-Leclercq
and Tulkens 1999).
The development and clinical use of any therapeutic agent is a continual balancing act of
risk/benefit assessment. For the aminoglycosides, their clinical importance, even 70 years
after their discovery, in treating serious life threatening infections frequently outweighs the
risk of patients developing nephrotoxicity. The major drivers in the first or second line use
of aminoglycosides in the clinic are the low rates of resistance by prominent pathogens,
their synergism with other antibiotics, their bactericidal efficacy, chemical stability and low
cost (Begg and Barclay 1995). However the onset of nephrotoxicity and management of this
adverse reaction is still an important limiting factor in the successful treatment of bacterial
infections by the aminoglycosides.
1.4.9 Strategies to reduce the incidence of nephrotoxicity
The strategies employed to manage aminoglycoside induced nephrotoxicity include those
which are still in the experimental phase, i.e. molecular intervention, and those which have
been adopted into clinical practice, i.e. optimised dosing regimens.
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1.4.9.1 Extended interval dosing
Traditional dosing regimens for aminoglycosides typically involve multiple intravenous
infusions of the antibiotic every 8-12 h over a 24 h period. The concept of a once-daily high
dose was popularised because of pharmacodynamic advantages, namely the concentration-
dependent killing of bacteria, post-antibiotic effect and low adaptive resistance.
Incidentally once-daily or ‘extended interval’ dosing had favourable toxicokinetics. A 1998
survey of US acute care hospitals found that 75% had adopted extended interval
aminoglycoside dosing (Chuck et al. 2000) which was a 4-fold increase from 1993. This
approach is now widely accepted in clinical practice in a wide variety of patient
subpopulations.
The evidence for the use of once-daily administration of aminoglycosides to reduce the
incidence of nephrotoxicity is closely related to the endocytic uptake mechanism of the
drug into the proximal tubule epithelial cells. Binding and internalisation of some
aminoglycosides at the apical surface is a non-linear saturable process (Giuliano et al.
1986), hence a less frequent but larger aminoglycoside dose reduces the exposure of the
proximal tubule epithelial cells to the drug since more of it is excreted. Studies in animal
models and humans support this hypothesis; adult male F344 rats given a single 40 mg/kg
gentamicin dose had a renal gentamicin concentration of 269 ± 99 µg/g whereas in animals
given the same 40 mg/kg gentamicin dose split into three subcutaneous injections the renal
accumulation reached 820 ± 29 µg/g (Bennett et al. 1979). Similarly, short-term infusion of
netilmicin and gentamicin administration in humans, yielded significantly lower tissue
accumulation of the drugs compared to a 24 h infusion of the same dose (Verpooten et al.
1989). This result was also replicated for tobramycin and amikacin (De Broe et al. 1991). A
prospective clinical trial of extended interval versus multiple daily dosing regimens of
aminoglycosides in adults receiving treatment for ≥72 h found that 15.4% of patients
receiving aminoglycosides twice daily experienced nephrotoxicity whilst none of the 35
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patients on the extended interval regimen experienced nephrotoxicity (Rybak et al. 1999).
This research suggests that the prolonged serum concentration of aminoglycosides leads to
greater renal accumulation and potential for nephrotoxicity.
1.4.9.2 Therapeutic drug monitoring
Active therapeutic drug monitoring is important for both efficacy and safety when using the
traditional dosing regimen. Clinical evidence indicates that frequent patient evaluation of
aminoglycoside serum concentrations, as opposed to measurements at the clinician’s
discretion, resulted in a shorter duration of therapy, a shorter hospital stay, increased
efficacy and a 10.5% lower incidence of nephrotoxicity as well as a lower cost of treatment
(van Lent-Evers et al. 1999).  For extended interval dosing, Nicolau et al reported a 40%
decrease in requests for serum drug measurements for gentamicin and tobramycin
treatment compared to traditional dosing, which, in combination with a reduction in
nephrotoxicity, related to an annual saving of more than US $>100,000 for a 600-bed
occupancy (Nicolau et al. 1996).
1.4.9.3 Molecular intervention
Molecular approaches to reduce and prevent aminoglycoside-induced nephrotoxicity have
focussed on current mechanistic knowledge and are mainly experimental investigations in
animal models of gentamicin exposure rather than clinical-based studies on the whole drug
class. Nonetheless, the approaches to ameliorate experimental gentamicin nephrotoxicity
cover a broad area of pharmacology including anti-oxidants, calcium-channel blockers and
antibiotics. Whilst some of these experimental investigations may one day be clinically
useful in the interim they offer supporting information on the underlying mechanisms by
which the aminoglycosides elicit toxicity.
Fosfomycin, a broad spectrum antibiotic, has been considered as a therapeutic that can be
used to reduce the nephrotoxicity observed in the aminoglycoside class. Research in rat
renal mitochondria indicates that fosfomycin inhibits aberrant iron mobilisation from the
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mitochondria that is caused by gentamicin-induced hydrogen peroxide formation, therefore
preventing lipid peroxidation (Yanagida et al. 2004). Preventing iron release and toxicity has
also been successfully investigated in gentamicin-induced ototoxicity using iron chelators
such as deferoxamine (Song et al. 1997).  Whilst fosfomycin appears to reduced toxicity
through limiting the intracellular effects of gentamicin, other antibiotics such as fleroxacin
(Beauchamp et al. 1997) and ceftriaxone (Beauchamp et al. 1994) are thought to reduce the
renal cortical accumulation and toxicity of gentamicin and tobramycin, respectively.
The dihydropyridine calcium channel antagonists are another drug class which has been
demonstrated to have applications in renal disease. Initially, calcium channel antagonists
became of interest in this field because gentamicin was found to increase intracellular
calcium load causing contraction of the mesangial cells which surround renal blood vessels
(Martinez-Salgado et al. 2000). Co-administration of nifedipine, nitrendipine, and
amlodipine with gentamicin in a rat model of nephrotoxicity showed that nifedipine and
amlodipine had a renoprotective effect, which was actually shown to be through their anti-
oxidant activity rather than their anti-hypertensive pharmacology (Li et al. 2009). However
nitrendipine exacerbated the toxicity of gentamicin as did another calcium channel
antagonist verapamil (Ali et al. 2002). The discrepancies between the effect on gentamicin
nephrotoxicity of drugs of the same pharmacological class highlights that although calcium
channel blockers have potential as prophylactic treatments, more research is required to
understand the precise mechanisms by which they offer protection or worsen injury.
The prominent role of oxidative and mitochondrial related stress in the mechanism of
aminoglycoside nephrotoxicity has mean that a vast number of anti-oxidant based agents
have been employed to attenuate the adverse drug reaction in animal models. These
include vitamins C (Stojiljkovic et al. 2012) and E (Abdel-Naim et al. 1999), plant and herbal
extracts such as curcumin (Ali et al. 2005), trans-resveratrol (Morales et al. 2002) and diallyl
sulfide (Pedraza-Chaverri et al. 2003) and hormones such as melatonin (Shifow et al. 2000).
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The vast majority of these experimental efforts have concentrated on limiting the
intracellular effects of the aminoglycosides on the proximal tubule cell. Research indicates
that the uptake of the aminoglycosides is a key factor in the onset of toxicity hence some
research has attempted to prevent the uptake of the drugs before they can alter cell
physiology.
1.4.10 Megalin as a target to prevent aminoglycoside nephrotoxicity
Numerous investigations have pinpointed megalin as the endocytic receptor of the
aminoglycosides in the proximal tubule epithelial cells. Megalin, also known as gp330 in
rodents, is a 600-kDa transmembrane glycoprotein that, after cloning, was found to be a
part of the low density lipoprotein (LDL) receptor gene family (Raychowdhury et al. 1989).
The protein is localised to the surface of a select number of absorptive epithelia, notably
the apical surface of proximal tubule epithelial cells and, relevant to the mechanism of
ototoxicity, the inner ear epithelium (Kounnas et al. 1994).  The expression of megalin on
the apical surface of both the renal tubule and the inner ear implicated it as a likely
receptor for the aminoglycosides and polymyxin B, which is another cationic antibiotic that
causes nephrotoxicity (Moestrup et al. 1995). Direct evidence for megalin-mediated uptake
of the aminoglycosides was achieved in a key piece of research that included competitive
binding experiments of the aminoglycosides to purified rabbit megalin, equilibrium dialysis
experiments with tritiated gentamicin, and combined binding and uptake studies using rat
proximal tubules and a megalin-expressing rat carcinoma cell line (Moestrup et al. 1995).
Since then there has been a raft of strong evidence that agrees with this research; Nagai et
al demonstrated that in normal male Wistar rats, amikacin accumulated in the renal cortex
but in rats administered maleate, a compound that causes shedding of megalin, amikacin
accumulation was reduced; in addition administration of gentamicin led to increased
urinary concentrations of megalin ligands, calcium and vitamin D binding protein (Nagai et
al. 2001). Crucially, a megalin genetic knock-out mouse was developed to show that
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without the receptor, accumulation of tritiated gentamicin was negligible (Schmitz et al.
2002).
1.4.10.1 Regulation of megalin-mediated endocytosis by G proteins
G proteins are hydrolases that act on guanosine triphosphate and are critical in a wide
range of biological processes including the regulation of endocytosis, from ligand binding to
vesicular budding and intracellular trafficking (Watson et al. 2006). They have also been
shown to regulate the localisation and efficiency of megalin. A large quantity of G proteins
are present on the apical surface of the proximal tubule cells, including heterotrimeric G
protein alpha subunit (Gαi3), GAIP and GIPC (regulatory components of the G protein
pathway) (Brunskill et al. 1991; Lou et al. 2002) and also Arf1 and Arf6 which are small
GTPases that are co-localised with megalin in rat proximal tubule cells (El-Annan et al. 2004;
Maranda et al. 2001). In addition Arf6 played a role in the internalisation of megalin ligands
in a rat proximal tubule immortalised cell line (Wolff et al. 2008) and a study using the G
protein stimulators mastoparan and aluminimum fluoride in LLC-PK1 cells showed they
increased gentamicin endocytosis (Decorti et al. 1999).
The cellular localisation and activity of a G protein is regulated by post-translational
modifications. G proteins are heterotrimers composed of Gα, Gβ and Gγ subunits; the Gγ
subunit is post-translationally modified by lipid moieties, also known as prenylation, in the
form of farnesyl or geranylgeranyl isoprenoids at a cysteine residue located at the C-
terminus of the protein (Choudhury and Ahmed 2006). The properties conferred to the Gγ
subunit by prenylation include higher affinity interaction and stability between the Gβγ
complex and the Gα subunit, greater G protein to receptor recognition (Higgins and Casey
1996) and increased membrane association (Muntz et al. 1992; Simonds et al. 1991).
The isoprenoids, farnesyl and geranylgeranyl pyrophosphate, are metabolites derived from
the mevalonate pathway, more commonly studied in the de novo biosynthesis of
cholesterol. The rate limiting step of this pathway originates with the enzyme 3-hydroxy-3-
30
methyl-glutaryl-CoA reductase (HMGR) which catalyses the conversion of HMG-CoA to
mevalonic acid (Mishra et al. 2003). Mevalonic acid is then further processed in a series of
reactions to generate either sterols, or the non-sterols farnesyl pyrosphosphate and
geranylgeranyl pyrosphosphate which are used to prenylate the Gγ subunit of G proteins.
Studies of lovastatin and compactin, inhibitors of HMGR, helped to identify the
incorporation of tritiated mevalonic acid into prenylated protein (Schmidt et al. 1984) and
also demonstrated that upon HMGR inhibition there was an increase in cytosolic Gβγ G
protein subunits, whilst addition of mevalonate to the system restored their membrane
association (Muntz et al. 1992). Therefore the mevalonate pathway and agents which
modify its activity are linked to G protein prenylation and consequently the physiological
processes, such as megalin-mediated endocytosis, that the G proteins regulate.
1.4.10.2 The mevalonate pathway and aminoglycoside accumulation
The mevalonate pathway and isoprenoid synthesis have been linked to endocytosis in the
proximal tubule. A key study in an opossum kidney cell line used HMGR inhibitors to
confirm the link between the mevalonate pathway and the megalin-mediated endocytic
uptake of megalin ligands albumin and β2-microglobulin (Sidaway et al. 2004).
Rosuvastatin, simvastatin, pravastatin, atorvastatin and fluvastatin inhibited the uptake of
FITC-albumin in a concentration dependent manner and further investigation with
simvastatin demonstrated the inhibition of FITC-β2-microglobulin uptake; the inhibition
was counteracted by addition of mevalonate and geranylgeranylpyrophosphate but not
cholesterol. This relationship was replicated in primary human proximal tubule cells by a
separate research group who investigated simvastatin, rosuvastatin and pravastatin
(Verhulst et al. 2004).
More recently, Antoine et al investigated the potential for HMGR inhibitors to reduce the
megalin-mediated uptake and accumulation of aminoglycosides in an opossum kidney cell
line (Antoine et al. 2010). Statins caused a reduction in cholesterol biosynthesis, as
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determined by incorporation of tritiated acetate, and an increase in unprenylated Rap1A
which is a G protein. Co-administration of simvastatin, pravastatin or rosuvastatin with
gentamicin not only reduced cholesterol biosynthesis and prenylation but reduced the
accumulation and cytotoxicity of gentamicin. To significantly reduce accumulation and
cytotoxicity of gentamicin, cholesterol synthesis had to be reduced by 60% and 70%,
respectively. Again, addition of mevalonate and geranylgeranyl pyrophosphate nullified the
inhibitory effects of the statins on gentamicin accumulation and cytotoxicity.
Whilst these studies show promise that statins could be a prophylactic treatment for
aminoglycoside-induced nephrotoxicity, they also highlight the role of the mevalonate
pathway in the mechanism of accumulation which is vital to the development of proximal
tubule injury, see Figure 1.3. The activity of this pathway and in particular the activity of
HMGR and its relationship to aminoglycoside-induced nephrotoxicity is something that
certainly merits further exploration.
1.4.11 Susceptibility to aminoglycoside nephrotoxicity
Historical research into susceptibility to aminoglycoside-induced nephrotoxicity is limited.
In terms of clinical aminoglycoside nephrotoxicity, risk factors are largely related to
differential pharmacokinetics between demographics such as age (or ‘renal age’), dose and
comorbidities. Hormonal and gender differences have been the major lines of investigation
in animal models of gentamicin nephrotoxicity but there has been little published in the last
decade. In these studies it was identified that susceptibility in the rodent models was
species and strain specific.
Studies of aminoglycoside-induced ototoxicity, however, have identified a maternal
inheritance pattern and a predisposing mutation in mitochondrial DNA (Fischel-Ghodsian
1999). The mutation was identified as an A to G transition at position 1555 of the 12S rRNA
(Fischel-Ghodsian et al. 1997). In individuals with the mutation who have not been exposed
to aminoglycosides, the mutation can lead to deafness. The mutation is considered to allow
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for a novel high affinity binding site for aminoglycosides to the 12S rRNA which is not
present in the wild type (Hamasaki and Rando 1997). The doubling time and translation
rate of cells isolated from patients with this mutation in the presence of paromomycin was,
in comparison to wild type cells, significantly increased and decreased, respectively, which
suggests an inhibitory action of aminoglycoside binding to 12S RNA (Guan et al. 2000). It
has been estimated that 1 in 40000 people have this mutation in the UK but due to
incomplete gene penetrance and variable exposure the figure is likely to be much higher
(Bitner-Glindzicz and Rahman 2007).
Other familial cases have been identified, for example in a family where 5 individuals
became deaf following exposure to aminoglycosides, a mutation around nucleotide 961 of
the mitochondrial DNA was identified (Casano et al. 1999). In addition, the A827G mutant
was identified in the mitochondrial 12S rRNA in related and non-related patients who
developed hearing loss after exposure to aminoglycosides (Xing et al. 2006). Identification
of predisposing mutations can be used in clinical decision making through genetic screening
or assessment of family history and importantly, to inform maternal relatives of patients
with the mutant to avoid exposure to aminoglycosides.
Whilst there has been progress in identifying genetic susceptibility factors for
aminoglycoside ototoxicity, the incidence of aminoglycoside nephrotoxicity could be
improved by identifying patient characteristics which predispose an individual to the
adverse drug reaction. The establishment of the role of megalin-mediated endocytosis in
the mechanism of nephrotoxicity has widened the possibilities of identifying the inter-
individual variation which predisposes a patient to nephrotoxicity. Variation in the activity
of the mevalonate pathway could leave some individuals more or less susceptible to
aminoglycoside nephrotoxicity and warrants thorough investigation.
Figure 1.3 Renal uptake of the aminoglycosides is dependent on the presence of functional GTPases. G protein subunits are post-translationally modified by
isoprenoids pyrophosphates of the mevalonate pathway.
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1.5 Aims & Objectives
The aim of this research was to advance mechanistic knowledge of aminoglycoside
nephrotoxicity and identify factors which affect the susceptibility of individuals to this
adverse event. To achieve these aims a rat model of aminoglycoside nephrotoxicity,
targeted and non-targeted biomarker identification approaches were employed with the
following objectives:
 Targeted biomarker identification
- To develop and validate an assay to measure the activity of the mevalonate
pathway.
- To determine the role of HMG-CoA reductase in aminoglycoside nephrotoxicity.
 Non-targeted biomarker identification
- To determine perturbations in the metabolome upon exposure to the model
aminoglycoside gentamicin.
- To identify pre-disposing factors in aminoglycoside nephrotoxicity using
pharmacometabonomics.
2. DEVELOPMENT AND VALIDATION OF A
QUANTIFICATION METHOD FOR HMG-CO A
REDUCTASE ACTIVITY
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2.1 Introduction
The successful treatment of bacterial infections with aminoglycoside antibiotics is hindered
by the nephrotoxic potential of the drug class. The main management strategy for
aminoglycoside nephrotoxicity is the choice of dosing regimen, therapeutic drug monitoring
and measurement of serum creatinine as an estimate of kidney function. In the early 1990s
once-daily dosing of aminoglycosides became the recommended treatment regimen as it
maintained efficacy and it was suggested that the incidence of toxicity was reduced (Barclay
et al. 1994).
Despite the refinement of the dosing strategy, a significant proportion of individuals still
experience nephrotoxicity when exposed to aminoglycosides, which suggests that patient
characteristics may play a role in susceptibility. Patient factors such as pre-existing medical
conditions (such as liver or renal disease) and concomitant medications can inform clinical
decisions but there is no other method of stratifying individuals based on their risk of
developing nephrotoxicity before the aminoglycoside regime begins. However,
susceptibility factors have been identified for aminoglycoside-induced ototoxicity. Research
into the mechanism of hearing loss led to identification of a susceptibility factor, namely a
genetic predisposition caused by the A1555G mutation in the mitochondrial 12S ribosomal
RNA gene (Fischel-Ghodsian et al 1997, Casano et al 1999). In order to improve antibiotic
efficacy and safety, it is equally important that susceptibility biomarkers are identified for
aminoglycoside-induced nephrotoxicity as has been achieved for ototoxicity.
2.1.1 Approaches to identifying biomarker candidates
Two molecular approaches can be taken to identify a susceptibility biomarker for
aminoglycoside-induced nephrotoxicity. Firstly, an ‘omics approach uses comprehensive
analytical techniques to identify potential biomarkers from a large pool of candidates, such
as in a genome-wide association study, proteomic analysis or metabolomics. Secondly, a
targeted examination of the mechanism of toxicity can be undertaken to select a potential
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biomarker, which, although minimising the number of potentials, increases the likelihood
that the candidates are directly linked to the disease. In this and the following chapter, a
targeted approach is undertaken, whilst in Chapter 4 and Chapter 5 an untargeted
approach is employed.
2.1.2 Targeted biomarker identification
2.1.2.1 HMG-CoA reductase and the mevalonate pathway
Recently, HMG-CoA reductase inhibitors, or ‘statins’ have been shown to inhibit the
accumulation of gentamicin into opossum kidney cells and reduce cytotoxicity (Antoine et
al. 2010). The close relationship of HMG-CoA reductase, megalin-mediated endocytosis and
aminoglycoside accumulation and cytotoxicity suggest a contributory link between HMG-
CoA reductase activity and susceptibility to aminoglycoside nephrotoxicity. HMG-CoA
reductase (HMGR) is the rate limiting enzyme of the biosynthetic mevalonate pathway. This
biosynthetic pathway feeds isoprenoid pyrophosphates into non-sterol and sterol
metabolic fates (Goldstein and Brown 1990). The metabolites of the mevalonate pathway
are therefore potential biomarkers of susceptibility to aminoglycoside nephrotoxicity.
In order to test the hypothetical link between HMGR and aminoglycoside nephrotoxicity it
was essential to select a biomarker candidate and to develop an accurate, precise and
robust quantification method.
2.1.3 Candidate biomarkers in the mevalonate pathway
The metabolites of the mevalonate pathway are illustrated in Figure 2.1. Acetyl-CoA is
condensed with acetoacetyl-CoA to HMG-CoA by HMG-CoA synthase. The rate limiting step
of the pathway is catalysed by HMGR, where HMG-CoA is reduced to mevalonic acid.
Mevalonic acid is phosphorylated by mevalonate kinase to 5-phosphomevalonate, which is
further phosphorylated to 5-pyrophosphomevalonate by phosphomevalonate kinase.
Mevalonate 5-pyrophosphate decarboxylase converts 5-pyrophosphatemevalonate to
isopentenyl pyrophosphate, which can be isomerised to dimethylallyl pyrophosphate, or,
40
converted to geranyl-pyrophosphate and then farnesyl-pyrophosphate by geranyl-
pyrophosphate synthase and farnesyl-phosphate synthase, respectively (Goldstein and
Brown 1990).
Figure 2.1 Metabolites of the mevalonate pathway. The rate limiting step is the conversion
of HMG CoA to mevalonic acid. End-metabolites of the mevalonate pathway, the
isoprenoid pyrophosphates are used for sterol and non-sterol products. IPP -
isopentenylpyrophosphate, DMAPP - dimethylallyl pyrophosphate, GPP - geranyl
pyrophosphate, FPP - farnesyl pyrophosphate, GGPP - geranylgeranyl pyrophosphate.
2.1.3.1 Mevalonic acid
Following consideration of the major metabolites of the mevalonate pathway, mevalonic
acid was selected as a potential biomarker candidate for its physiological and practical
characteristics. The other intermediates of the mevalonate pathway were excluded from
consideration due to the impracticalities of quantification and exogenous influences.
2.1.3.1.1 Physiological properties of mevalonic acid
Mevalonic acid (3, 5-dihydroxy-3-methylpentanoic acid, MVA) is a metabolic intermediate
that is present in human and rat plasma, and excreted into urine (Kopito and Brunengraber
1980; Kopito et al. 1982). It is produced from 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) by HMGR (Friesen and Rodwell 2004). MVA is synthesized predominantly in the
liver (Hellstrom et al. 1973) and most of the metabolite in plasma is taken up by the
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kidneys, where it is incorporated into squalene and sterols, catabolized or excreted in urine
(Hellstrom et al. 1973; McNamara et al. 1985; Parker et al. 1982). Urinary output accounts
for 29% of the total renal flux of MVA (Kopito and Brunengraber 1980).
Although MVA has no known physiological function other than as a metabolic intermediate,
MVA production is the rate-limiting obligatory step in the mevalonate pathway. As the only
precursor of isoprenyl intermediates that is committed to the pathway and present in
accessible biofluids, MVA is effectively the only metabolite that is sensory of HMGR activity
and mevalonate pathway flux.
2.1.3.1.1.1 Regulation and diurnal variation
The mevalonate pathway is tightly regulated by negative feedback inhibition by
downstream intermediates (the isoprenoids pyrophosphates) and sterol-mediated
inhibition of enzyme expression. The HMGR gene promoter region contains sterol
regulatory element (SRE-1) which suppresses transcription of the gene in the presence of
sterols (Goldstein and Brown 1990). Conversely the sterol regulatory-element binding
protein (SREBP) can translocate to the nucleus to initiate HMGR transcription (Goldstein et
al. 2006). At a post-translational level, the rate of translation of HMGR mRNA is governed
by non-sterol isoprenoids and the degradation of HMGR protein is accelerated by the
presence of sterols and non-sterol isoprenoids (Goldstein et al. 2006). HMGR activity is also
regulated at serine residue (S872) near the active site whereby phosphorylation by AMP-
activated protein kinase (AMPK) reversibly reduces enzyme efficiency (Omkumar et al.
1994).
The plasma concentration and urinary excretion of MVA display parallel diurnal variations
that track oscillations of cholesterol synthesis (Parker et al. 1982; Parker et al. 1984; Popjak
et al. 1979), in man (Parker et al. 1984) and in preclinical models (Clarke et al. 1984; Higgins
et al. 1971). Diurnal variations in HMGR activity have been attributed to food intake, with
early investigations noting that cholesterol synthesis in mice was inversely proportionate to
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dietary intake (Schoenheimer 1933). Subsequent studies demonstrate the peak of HMGR
activity occurred 3–6 h post feeding (Carlson et al. 1978; Gregory et al. 1972; Kopito et al.
1982). Likewise, Kopito et al. observed a fourfold, feeding-induced rise in serum MVA
concentration (Kopito et al. 1982).
2.1.3.1.2 Chemical properties of mevalonic acid
MVA is a low molecular weight (C6H12O4;MW 148.16) dihydroxy-monocarboxylic acid. It is a
polar molecule and at low pH undergoes spontaneous cyclisation to its lactone form
(mevalonolactone, MVL, C6H10O3, MW 130.14), see Figure 2.2
Figure 2.2 The chemical structure of mevalonic acid and mevalonolactone. Mevalonic acid
spontaneously converts to mevalonolactone form at low pH.
2.1.4 Fit-for-purpose analytical method validation for biomarkers
Biomarker assays are distinct from pharmacokinetic bioanalysis and therefore long-
established paradigms of drug bioanalysis and bioanalytical method validation do not
wholly apply to the quantification of endogenous molecules such as MVA. Assays for novel
biomarkers frequently pose unique analytical challenges (i.e. the lack of a true blank matrix)
and adherence to validation parameters is often impractical. As a result, biomarker method
development and validation guidelines have been established (Chau et al. 2008; Lee et al.
2006), which include the routine assessment of dynamic range, analytical precision and
accuracy, relative accuracy, but also incorporate the validation of calibration standards
made in surrogate matrices, see Figure 2.3. Traditional regulatory bioanalysis guidelines are
considered as a framework for biomarker assay validation and the process accommodates
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the characteristics of the analyte, the limitations of the analytical platform and the
intended use of the assay with a ‘fit-for-purpose’ approach.
Figure 2.3 Schematic of the iterative fit-for-purpose biomarker method development and
validation process.
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2.2 Aims
 Develop an LC-MS/MS based quantification method for urinary mevalonic acid that
can be used for rat and human urine.
 Validate the method according to fit-for-purpose biomarker guidelines.
2.3 Materials and Methods
2.3.1 Materials
(R)-MVA and mevalonolactone (MVL) were obtained from Sigma-Aldrich (St Louis, MO,
USA). 4, 4, 5, 5-Tetradeuteromevalonolactone (d4-MVL) was obtained from CDN isotopes
(Pointe-Clare, Quebec, Canada). Methanol, ethyl acetate and formic acid were of analytical
grade and were obtained from Fisher Scientific (Loughborough, UK). Human urine for
method development was obtained by spot collection from five healthy human volunteers
(two male, three female, mean age 23.2±1.3 yrs) not subject to dietary or beverage
constraints and from adult male Sprague-Dawley rats (150-250g, 12 donors) (Alderley Park,
AstraZeneca). Protocols were undertaken in accordance with a licence granted under the
Animals (Scientific Procedures) Act 1986 and approved by the University of Liverpool Ethics
Committee.
2.3.2 Method development
2.3.2.1 Optimisation of the LC-MS/MS method
LC-MS/MS was chosen as the analytical platform as it would provide the sensitivity,
specificity and rapid analysis that the method requires.  MS/MS conditions were optimised
using automatic and manual tuning methods (Analyst software) by direct infusion (10
µL/minute) of a 1 µg/mL solution of MVL dissolved in methanol (positive ion mode) and a 1
µg/mL solution of MVA dissolved in methanol (negative ion mode) into an API 4000 Qtrap
instrument.
The following columns were screened for suitability to retain either MVL or MVA detected
by either positive or negative ion mode, respectively: Luna 3µ HILIC (50 x 2.00 mm), Gemini
5µ C18 (50 x 2.00 mm), Aqua 3µ C18 (100 x 2.00 mm), Synergi Hydro-RP 2.5µ (100 x 2.00
mm) (all Phenomenex). Chromatographic separation was achieved on an Acquity UPLC®
(Waters, Millford, MA, USA) and a range of solvents were tested in isocratic or gradient
conditions: 100 mM ammonium formate and acetonitrile, 10 mM ammonium formate 0.1%
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formic acid and methanol, 20 mM ammonium formate pH 8, 0.5 mM formic acid in
water/methanol 70:30, 0.1% formic acid in water and 0.1% formic acid in methanol.
2.3.2.2 Optimisation of the pH dependent conversion of MVA to MVL
The lactone of mevalonic acid, mevalonolactone, was selected as the analyte for the
method as it is less polar than the acid and therefore more amenable to simple extraction
procedures and reversed-phase chromatography.
Under acidic conditions MVA is known to convert to a less polar lactone, mevalonolactone
(MVL). The optimal pH was selected by incubation of MVA standards (0.01, 0.1 and 0.5
μg/mL in water-methanol 9:1 v/v) adjusted to pH 2 to pH 6 with formic acid. Following
incubation at ambient temperature for 90 min 10 µL aliquots of each standard were
injected on to the LC-MS/MS method. The peak area of MVA and MVL was calculated
(Analyst software) and the optimal pH (pH 2) for the production of MVL was selected for
further development.
The rate of conversion of MVA (0.1 µg/mL in water-methanol 9:1 v/v) to MVL was
determined by LC-MS/MS analysis of 10 µL aliquots of each standard incubated at pH 2 and
ambient temperature, 37°C or 60°C for 180 min. The temperature at which the conversion
to MVL equilibrated in the shortest time was selected for the method. MVL yield was also
determined by overnight incubation at ambient temperature and pH 2. The optimal
temperature (60°C) and incubation period (minimum of 15 min) for the extent of the
reaction were chosen. Aliquots of MVL (0.1 μg/mL in water-methanol 9:1 v/v at pH 2) were
incubated at 60°C for 120 min to establish analyte stability.
2.3.2.3 Selection of extraction method
Extraction of MVA and MVL from urine was investigated using solid-phase and liquid-liquid
extraction methods. The following SPE sorbents were investigated for retention of MVA
and MVL: Oasis MAX, Oasis HLB (Waters) Strata-XCW, Strata-XC (Phenomenex), Hypersep
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VERIFY XC (ThermoScientific), EVOLUTE-CX (Biotage). SPE cartridges were used in
accordance to the manufacturer’s instructions.
A LLE procedure using ethyl acetate was also tested for recovery of MVL. 800 µL of ethyl
acetate was added to 200 µL of 0.1 µg/mL MVL (prepared in pH 2 buffer) and shaken
vigorously for 10 minutes. The ethyl acetate layer was recovered (600 µL), dried down
under oxygen-free-nitrogen, and reconstituted in water-methanol 9:1 v/v (0.1% formic
acid) before analysis by LC-MS/MS. To correct for between sample variation in extraction
efficiency, an internal standard d4-MVL was spiked into the MVL aliquot at a concentration
of 0.15 µg/mL, prior to the addition of ethyl acetate.
2.3.3 Method validation
2.3.3.1 Determining % conversion of MVA to MVL under selected conditions
The percentage of MVA converted to MVL was calculated from the concentration of MVL in
MVA standards (4 and 6 μg/mL in distilled water) and in rat (n = 3) and human (n = 3)
donors, that had been acidified (pH 2) and incubated at 60°C for a minimum of 15 min.
Intra-day (n = 3 analyses per standard) and inter-day (n = 18, representing three analyses
per standard, two standards and analyses on 3 days) variation of the conversion was also
determined. The endogenous presence of MVL in human and rat urine was determined by
analysis of 10 μL aliquots of unprocessed urine (from three rat and three human donors)
using LC–MS/MS.
2.3.3.2 Determining the % extraction of MVL and IS by ethyl acetate
Recovery of MVL from urine (50 μL) was achieved by LLE with ethyl acetate (1:4, v/v). The
recoveries of MVL (0.4–6.0 μg/mL) and the IS, d4-MVL (0.15 μg/mL), were determined by
spiking MVL and IS (dissolved in acidified methanol 3% formic acid) into buffer (0.1 M
potassium phosphate, adjusted to pH 2 with orthophosphoric acid) or into acidified rat (n =
3) or human (n = 3) urine. Samples were shaken vigorously for 10 min at ambient
temperature and centrifuged at 8700 g for 10 min. Approximately 600 μL of the organic
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layer was taken and evaporated under oxygen-free nitrogen. The samples were
reconstituted in 200 μL of water-methanol (9:1, v/v) containing 0.1% formic acid (pH 2.4)
before injection of 10 μL of solution on to the HPLC column. The extracted compounds
were assayed by comparison with standards (water-methanol 9:1, v/v, 0.1% formic acid) of
the same concentration. For the urine extraction recovery, the endogenous concentration
of MVL was factored into the calculation.
2.3.3.3 Assay performance
To determine the sensitivity, range, precision and accuracy of the LC–MS/MS method, MVL
standards (0.078–10 μg/mL in pH 2 buffer; n = 3) were spiked with IS (final concentration,
0.15 μg/mL), extracted with ethyl acetate, reconstituted in water-methanol-formic acid
(9:1:0.1, v/v) and quantified by LC–MS/MS. Independently prepared QC MVL standards and
a validation sample (VS, a small population sample, in this case pooled human or rat urine,
that is representative of the individual analytical samples) were prepared at the beginning
of the validation, and analysed alongside analytical samples and calibration standards to
confirm batch acceptability and between-batch reproducibility of precision, accuracy and
stability. Pooled human urine was prepared by mixing equal volumes of urine from five
donors.
The LOD was designated to be the concentration of extracted MVL with a peak height
greater than three-times the background signal. The LLOQ and ULOQ were, respectively,
the lowest and highest concentrations of extracted MVL with acceptable accuracy and
precision. The acceptance criterion of precision was 15% coefficient of variation, or 20% for
the low QC and LLOQ, while the acceptance criterion of accuracy was 85–115% or 80–120%
for the low QC and LLOQ, which was determined by extraction of each of the nine calibra-
tion standards (three replicates) or three QC (six replicates) in three independent batches.
A batch was deemed acceptable if more than four of the six QC replicates were within 85–
115% of the set value, in accordance with biomarker assay validation guidelines (Lee et al.
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2006). LC–MS/MS carryover was determined by repeat injection of 10 μL of a 10 μg/mL
MVL standard followed by injection and analysis of 10 μL of a blank reconstitution solution.
2.3.3.4 Validation of the surrogate matrix
Rat and human urine (50 μL aliquots from five donors) was acidified, extracted and recon-
stituted, and spiked with MVL and IS (final concentration 5 μg/mL) and serially diluted
(water-methanol 9:1 v/v, 0.1% formic acid). The effect of dilution on the analyte/IS ratio
was measured by the LC–MS/MS method. An ionization suppression/enhancement
experiment was conducted using the post-column infusion method. Due to the endogenous
presence of the analyte in acidified urine, a solution of d4-MVL (0.1 μg/mL) in water-
methanol containing formic acid (9:1 v/v, 0.1%) was infused directly into the MS source at a
constant rate of 10 μL/min (HPLC eluate entered the source at 280 μL/min) and 10 μL of a
reconstituted ethyl acetate extract of an acidified human or rat urine sample (10 μL) was
injected on to the HPLC column. The continuous MS/MS response to the d4-MVL (m/z
135→75) was monitored.
Human or rat urine was spiked with a high concentration of MVA (in order to minimize the
contributory effect of endogenous MVA) and the percentage recovery was used to evaluate
relative accuracy. MVA in spiked (0.1, 0.5 or 4 μg/mL) and non-spiked human and rat urine
(multiple donors) was converted to MVL, extracted, reconstituted and quantified by the LC–
MS/MS method. The concentration of MVA in non-spiked urine was subtracted from the
concentration determined in the aliquot of spiked urine and the percentage recovery was
calculated.
2.3.3.5 Stability
Stability of MVL in the QC standards was determined by storage at room temperature, 4°C
and at -20°C for 14 days. Freeze–thaw cycles of QC standards at -20°C and room
temperature were also carried out. The stability of MVL in reconstituted extracts of urine
samples at 4°C in the autosampler was also determined.
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2.3.4 Validated method
Calibration standards were prepared on the day of analysis from 0.0156 to 10 μg/mL at pH
2 with IS (0.15 μg/mL). Aqueous QC standards (0.045, 2 and 6 μg/mL at pH 2) and a pooled
rat urine or human urine VS were prepared at the start of the validation process and stored
at -20°C. Urine or MVL calibration standards (50 μL) were incubated with 148 μL of buffer
(0.1 M potassium phosphate, pH 2) at 60°C for 25 min. After cooling to ambient
temperature, samples and standards were spiked with 2 μL of d4-MVL solution (15 μg/mL
acidified aqueous stock, final concentration 0.15 μg/mL). The analytes were extracted with
800 μL of ethyl acetate: the samples were shaken vigorously for a minimum of 10 min at
ambient temperature before centrifuging at 8700 g for 10 min. Approximately 600 μL of the
organic layer were removed, evaporated to dry residue under oxygen-free nitrogen and
reconstituted in 200 μL of water-methanol (9:1, v/v) containing 0.1% formic acid before
injection of 10 μL of solution on to the HPLC column.
Chromatographic separation was achieved on an Acquity UPLC® (Waters, Millford, MA,
USA) (laboratory 1) with a Synergi™ 2.5-μm Hydro RP column (100 × 2.0 mm; Phenomenex,
Macclesfield, UK). The LC method employed solvent A (water-0.1% formic acid) and solvent
B (methanol-0.1% formic acid), see Table 2.2. The LC–MS/MS analysis time was 5 min per
sample. A MRM method was optimized on an AB Sciex 4000 QTRAP® instrument (Foster
City, CA, USA) in positive-ion mode using automatic and manual tuning with aqueous
standards of MVL. The precursor ion for MVL was m/z 131, and the transition m/z
131→69.4 was used for the quantification of MVL with reporter transitions at m/z
131→113 and m/z 131→71. The reporter transitions and retention time of MVL conferred
specificity. The IS d4-MVL was monitored at m/z 135→75. The following conditions were
used for LC–MS/MS acquisition: curtain gas setting, 10.0; collision gas, 4.0; IonSpray volt-
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age, 5500 V; temperature, 450°C; ion source gas 1, 90; ion source gas 2, 20; interface
heater, on; dwell time, 150 ms; declustering potential, 50 V; Q1 and Q3 resolution, high.
Individual transition parameters are given in Table 2.1
2.4 Results
2.4.1 Method development
2.4.1.1 LC-MS/MS method
Mevalonolactone (MVL) and d4-MVL MS settings were automatically tuned then adjusted
manually using Analyst Software. Declustering potential, curtain gas, collision gas, collision
energy and collision exit potential were optimised to maximise the MS response, see Table
2.1. The precursor ion chosen was m/z 130.956 and the product ions selected were m/z
69.4, m/z 71.0 and m/z 113.1. Figure 2.4 depicts a typical ion chromatogram from the API
Qtrap 4000 of the product ions of MVL from which the MS/MS method transitions were
selected.
Figure 2.4 Ion chromatogram of product ions of MVL, m/z 131, on the API Qtrap 4000
instrument.
Table 2.1 MS/MS parameters for each transition in the MRM method
Following the optimisation of the MS/MS method, several HPLC columns were tested for
retention of MVL. The Luna HILIC and Gemini C18 columns did not retain MVL (or MVA) and
the analyte eluted with the solvent front. The Aqua C18 and Synergi Hydro-RP columns
retained MVL, with the Synergi Hydro-RP column providing the best peak shape and
retention. HPLC conditions were optimised with the Synergi Hydro-RP column, see Table
2.2. An example chromatogram of MVL eluting can be seen in Figure 2.5.
Table 2.2 HPLC conditions for the analysis of extracted urine samples, standards and QCs.
Time %A %B Flow rate (mL/min)
Initial 95 5 0.300
2.00 95 5 0.300
2.01 90 10 0.300
2.70 90 10 0.300
2.80 95 5 0.300
5.00 95 5 0.300
Phenomenex Synergi Hydro-RP column (2.5µ 100A 100 x 2.00 mm) linked
to an Acquity UPLC and the API4000 Qtrap.
Q1 mass Q3 mass collision energy collision exitpotential
MVL
130.956 113.1 13 8
130.956 71.0 20 12
130.956 69.4 15 10
d4-MVL 134.945 75.0 20 12
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Figure 2.5 Extracted ion chromatogram of mevalonolactone (MVL) extracted from rat urine
and analysed by the optimised LC-MS/MS method. An isobaric compound elutes after MVL.
2.4.1.2 Optimisation of the conversion of mevalonic acid to mevalonolactone
Figure 2.6 pH and temperature-dependent conversion of mevalonic acid to
mevalonolactone. Aqueous standards of mevalonic acid were incubated at pH 2-6 and the
amount of (A) mevalonic acid and (B) mevalonolactone was measured by LC-MS/MS peak
area. Aqueous standard of mevalonic acid was incubated at pH 2 and the increase in
mevalonolactone was measured over 180 minutes at (A) ambient and 37°C and (B) ambient
and 60°C.
Mevalonic acid can be converted to its lactone form, mevalonolactone, in a pH-dependent
manner. The acid-catalysed formation of MVL from MVA was optimised by incubating
aqueous standards at a range of pH values. Below pH 3 the amounts of MVA and MVL
decreased and increased, respectively, see Figure 2.6A and 2.6B. Based on these results, pH
2 was selected as the optimal condition to promote the production of MVL from MVA.
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The production of MVL at pH 2 was examined over 180 min at ambient temperature, 37°C
and 60°C. No significant difference was observed between the rate of MVL production at
ambient and physiological temperature, see Figure 2.6C; incubations at 60°C for 25 min had
a greater rate of MVL production Figure 2.6D. The percentage of MVA converted to MVL
overnight at ambient temperature was not significantly different from the yield of MVL
after 25 min at 60°C: 70.8± 3.9% (n=6) versus 67.5± 1.3% (n=6), respectively; therefore an
overnight incubation offered no advantage.
Incubation of mevalonic acid at pH 2 for 25 minutes was selected as the optimal conditions.
The percentage conversion of MVA to MVL in aqueous standards under the optimal
conditions was 69.5± 4.4% (day 1; n=6), 66.0± 3.9% (day 2; n=6) and 67.5± 1.3% (day 3;
n=6). In three rat urine donors the percent conversion of MVA to MVL was 73.8±6.5% and
in three human donors 70.6 ±2.7%; aqueous standards in this experiment gave an
equivalent conversion of 71.1±2.5%.   Data are given as mean ± SD. Inter-day variation of
3.6% was observed and, as a result, aqueous MVA standards were converted at the same
time as study samples to determine percentage conversion for each batch. The presence of
MVL in human and rat urine was measured by the analysis of 10 µL of unprocessed rat
(n=3) and human (n=3) urine by the LC-MS/MS method and MVL was not detected.
2.4.1.3 Extraction method
SPE and LLE were considered for the extraction of MVL (and MVA) from processed urine.
Various sorbents (strong and weak cation exchange, strong anion exchange, mixed mode)
were tested for their suitability for the assay. The Oasis MAX cartridges gave the best
recovery of MVA from an aqueous standard, see Table 2.3. However the analyte was not
recovered from the Oasis MAX sorbent when the recovery experiments were performed
with rat urine. Similarly, MVL was not detectable when rat urine was processed with the
STRATA XCW sorbent. Due to the lack of reproducibility between aqueous and urine
analyte recovery, solid phase extraction was not pursued further.
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Table 2.3 Recovery of MVA or MVL from various SPE cartridges
Sorbent Type Analyte
Recovery of
analyte (%)
Oasis MAX
(10 ng/mL analyte) Mixed mode RP and SAX MVA 86.85
Oasis MAX
(100 ng/mL analyte) as above MVA 83.29
Strata-XCW Mixed mode RP and WCX MVL 37.15
Strata-XC Mixed mode RP and SCX MVL 18.44
Hypersep VERIFY XC Mixed mode RP and CX MVL 10.74
EVOLUTE-CX Mixed mode RP and SCX MVL 10.29
Oasis HLB Hydrophilic and Lipophilic MVAMVL ND
RP - reversed phase, SAX - strong anion exchange, WCX - weak cation exchange, SCX -
strong cation exchange, CX - cation exchange.
An alternative to SPE of mevalonolactone is LLE. Published methods have successfully used
ethyl acetate to extract mevalonolactone (Kindt et al. 2010) and an internal standard, d4-
mevalonolactone (IS), was employed to correct for between-sample variation in extraction
recovery. During method development, the LLE and IS approach was investigated for MVL.
MVL and the IS were not extracted by ethyl acetate to the same extent, with 72.7±2.1%
(n=6) of the analyte recovered compared to 34.4±3.5% IS, but the analyte-IS peak area
relationship was still reproducible, linear and accurately quantifiable by LC-MS/MS. The
extraction recovery of the analyte and IS was assessed in human (n=3) and rat (n=3) donors.
The mean extraction recovery of 0.4, 1.0 and 6.0 µg/mL MVL from three rat urine donors
was 64.0±8.1%, 62.5±4.8% and 54.3±5.0%, respectively, and the mean recovery of 0.15
µg/mL IS was 27.9±3.3%. The mean extraction recovery of 0.4, 1.0 and 6.0 µg/mL MVL from
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three human donors was 72.8±16.1%, 62.1±4.4% and 64.7±8.7% and the mean recovery of
0.15 µg/mL IS was 31.5±3.3%.
2.4.2 Method validation
2.4.2.1 Assay performance
Several weighted regression models (1/x, 1/x2, 1/x3) were tested to improve the residuals in
the calibration model.  The best model was the linear and forced through the origin, with
acceptable precision and accuracy across the analytical range with R2>0.99 without the
need to weight the data. The LOD of extracted MVL was 0.0078 µg/mL. The LLOQ was
0.0156 µg/mL; the ULOQ was 10 µg/mL. Independently prepared QC standards also
reached acceptable precision and accuracy; individual data are shown in Table 2.4.
Carryover of the analyte to subsequent blank injections on the LC-MS/MS was not
detected.
2.4.2.2 Internal standard
The peak area ratio of analyte to internal standard corrected for the variability in the
extraction recovery between samples, enabling the accurate quantification of MVL. The
peak areas of MVL and the IS in calibration standards and samples of equivalent
concentration were similar. As an example the mean peak area of MVL in one rat study
sample was determined to be 2.5 x106±5.2 x 104 and, using the analyte/internal standard
peak area ratio, was calculated to be 5.9 µg/mL MVL. The closest standard, a QC at 6 µg/mL
had a similar MVL peak area of 2.8x106± 2.7x105. The internal standard peak area for the rat
urine sample was 1.2x105±3.2x103 and for the QC was 1.3x105±7.0x103, giving ratios of 20.8
and 21.5, respectively.  The extracted internal standard peak areas varied by 7.9% across
the rat urine study and by 16.0% across the human urine study.
Table 2.4 Intra-day validation of the extraction, reconstitution and LC-MS2 analysis of MVL calibration and QC standards across three batches. Accuracy is
within 85-115% and precision is within 15% coefficient of variation (CV)
Batch 1 Batch 2 Batch 3
QC
Nominal
Concentration
(ng/mL)
Calculated
Concentration
(ng/mL)
Accuracy Precision(%CV) n=
Calculated
Concentration
(ng/mL)
Accuracy Precision(%CV) n=
Calculated
Concentration
(ng/mL)
Accuracy Precision(%CV) n=
LOW 45 44.0 97.8% 5.3% 6 45.2 100.4% 3.2% 6 41.1 91.4% 2.7% 6
MID 2000 1991.0 99.5% 2.1% 6 2048.1 102.4% 4.9% 5 1855.7 92.8% 3.4% 6
HIGH 6000 5881.7 98.0% 4.2% 6 6199.3 103.3% 6.7% 5 5427.7 90.5% 4.1% 6
STD
1 15.6 16.6 106.0% 8.3% 3 16.2 103.9% 5.6% 3 16.3 104.4% 3.8% 2
2 31.3 31.0 99.3% 2.5% 3 33.9 108.5% 4.1% 3 29.6 94.8% 1.3% 2
3 62.5 65.8 105.3% 10.8% 3 62.3 99.7% 5.2% 3 58.5 93.6% 4.3% 3
4 625 610.5 97.7% 1.6% 3 644.9 103.2% 10.5% 3 629.4 100.7% 4.1% 3
5 1250 1221.4 97.7% 1.9% 3 1255.5 100.4% 5.2% 3 1130.2 90.4% 0.9% 3
6 2500 2475.9 99.0% 3.1% 3 2589.0 103.6% 9.8% 3 2338.4 93.5% 0.6% 3
7 5000 5416.7 108.3% 5.1% 3 4930.5 98.6% 6.6% 3 4535.7 90.7% 4.2% 3
8 8000 7914.6 98.9% 2.7% 3 8149.9 101.9% 5.4% 3 7830.4 97.9% 6.4% 3
9 10000 10129.3 101.3% 5.2% 3 10093.6 100.9% 1.5% 3 10489.1 104.9% 7.8% 3
59
Figure 2.7 Linear relationship between nominal concentration and the analyte/IS peak area ratio. Independently prepared QC standards are within ±15% of
the nominal concentration; data shown are mean values of three batches (n=3 for each batch).
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2.4.2.3 Parallelism of rat urine to surrogate matrix
To validate the utility of a surrogate matrix for the calibration standards rat (n=5) and
human (n=5) urine which had been acidified, extracted and reconstituted was serially
diluted and the analyte and IS response was determined by LC-MS/MS. The observed
analyte response remained within 20% of what was expected in both rat and human urine
up to a dilution of 1 in 128, see Figure 2.8A and 2.8B. The observed IS response only
remained within 20% of the expected response in both rat and human urine up to a dilution
of 1 in 16, as further dilution reduced the IS response below the limits of detection. These
data suggest that the rat and human urine matrix has no significant effect on the MS
detection of MVL and the IS.
2.4.2.4 Matrix effects
Matrix effects were further investigated by post-column infusion of d4-MVL and injection of
10 µL of a reconstituted ethyl acetate extract of acidified human or rat urine. The MS/MS
response of the IS was monitored throughout the elution and there was no significant
suppression or enhancement of the signal for d4-MVL at or around the retention time of the
analyte, see Figure 2.8C and 2.8D.
2.4.2.5 Relative accuracy
Rat and human urine spiked (0.1, 0.5 or 4 µg/mL MVA) and non-spiked was extracted and
assayed to determine relative accuracy. The mean concentration of MVL in the non-spiked
urine (human 222.6± 5.7 ng/mL, rat 3532.4± 171.9 ng/mL) was subtracted from that of the
spiked urine. The recovery of the 0.1, 0.5 or 0.4 µg/mL spike in rat urine was 96.0±7.6%,
111.0±6.9% and 105.9±2.3%, respectively. Recovery of the 0.1, 0.5 or 0.4 µg/mL spike in
human urine was calculated to be 96.0±4.8%, 118.2±3.5 and 107.3±0.4%, respectively.
Data are mean ± SD. Full recovery of the spiked analyte from multiple donors suggests that
this method can be used for the accurate quantification of MVA in both human and rat
urine.
Figure 2.8 Validation of the surrogate matrix. Dilutional linearity of MVL extracted from (A) rat urine (n=5 donors) and (B) human urine (n=5 donors)
Dilutional linearity of the analyte/IS peak area ratio confirms the parallelism of the surrogate matrix. The absence of ionisation suppression/enhancement
of the IS signal (m/z 135 → 75 for d4-MVL; retention time (RT), 2.05 min) by co-eluting materials extracted from the acidified rat (C) and human (D) urine
matrix with ethyl acetate.
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2.4.2.6 Reproducibility
Reproducibility of the full extraction and analysis method was determined by quantifying
MVA in rat and human urine (VS) divided into three batches stored at -20°C. MVA was
quantified on three separate occasions from each of these batches (n=3 per analysis) over
20 days. Within-batch variation was 2.01-4.58% coefficient of variation; while between-
batch variation was 6.15%.
2.4.2.7 Stability
MVL QC standards were stable at room temperature, 4°C and at -20°C across 14 days, and
at 60°C for 120 min. Freeze-thawing did not affect the integrity of aqueous standards.
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2.5 Discussion
A contributory link between HMG-CoA reductase (HMGR) activity and the accumulation
and cytotoxicity of aminoglycosides has been made recently (Antoine et al. 2010). As such,
the physiological variation in HMGR between individuals could render them more or less
susceptible to aminoglycoside accumulation and nephrotoxicity. In order to investigate this
hypothesis, a reliable quantification method for HMGR activity in both non-clinical and
clinical samples was required.
A literature search of methods of quantification and physiological properties of key
metabolites of the mevalonate pathway and related products was undertaken in order to
select the best candidate for quantification. The end-products of the mevalonate pathway,
the isoprenoid pyrophosphates, are derived from isopentenyl-5-pyrophosphate and
dimethylallyl-pyrophosphate and include farnesyl pyrophosphate (FPP),
geranylpyrophosphate (GPP) and geranylgeranylpyrophosphate (GGPP). These metabolites
are responsible for the production of ubiquinone (electron transport chain), squalene
(precursor for cholesterol synthesis), dolichol (N-glycosylation of protein) (Goldstein and
Brown 1990) and, important to aminoglycoside nephrotoxicity, the prenylation of multiple
proteins including the small GTPases which regulate megalin localisation and activity.
FPP, GPP and GGPP are attractive biomarker candidates for mevalonate pathway activity
and aminoglycoside uptake due to their metabolic proximity to prenylated small GTPases
that affect megalin-mediated endocytosis of the aminoglycosides. However quantification
of the isoprenoids pyrophosphates is difficult as they have a rapid turnover and are
intracellular, requiring a complex extraction and analytical procedure and furthermore,
their rapid degradation by phosphatases does not lend to rapid analysis (Holstein et al.
2009; Tong et al. 2008).
Another metabolite that was considered was squalene. Squalene is produced by
condensation of two FPP units and is the precursor for steroid synthesis, most notably
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squalene is a close precursor to cholesterol. Although HPLC methods for quantifying
squalene are available (Lu et al. 2004), accurate quantification of endogenous squalene is
hampered by significant contributions of dietary squalene and it is also present in
cosmetics. Mevalonic acid was chosen as the most suitable candidate because of its direct
relationship to HMGR and it is an existing biomarker of cholesterol synthesis, indicating its
sensory potential. In addition, mevalonic acid is present in the serum and is excreted into
the urine, allowing ease of sample collection for research purposes.
A simple, cross-species quantification method for urinary mevalonic acid (MVA) was not
present in the literature. The only published LC-MS/MS assay of urinary MVA has a short
dynamic range of 20 ng/mL-1000 ng/mL validated in human urine; in addition the protocol
requires an initial sample volume of 125 µL (Jemal et al. 2003). In this chapter, the
development and validation of an assay for MVA by LC-MS/MS that can be used for the
analysis of rat and human urine is described.
The assay has a substantial dynamic range (0.0156 µg/mL-10 µg/mL) sufficient to determine
normal biological and perturbed concentrations of MVA in both rat and human urine.
Administration of statins is known to reduce the production of mevalonic acid by 30-40%
(Beil et al. 1990; Naoumova et al. 1996; Woollen et al. 2001a). Given that the physiological
urinary concentration of mevalonic acid in humans ranges between 116-1227 ng/mL the
validated dynamic range of this assay will comfortably address perturbed mevalonic acid
biosynthesis.  The assay also benefits from requiring only a sample volume of 50 µL of
urine, making the assay applicable where sample volumes are limited (e.g. rodent studies),
and a short analytical run-time of 5 min.
This method builds upon published methods, incorporating acid-catalysed conversion of
MVA to its lactone form MVL (Abrar and Martin 2002; Jemal et al. 2003; Kindt et al. 2010),
extraction of the lactone and the IS with ethyl acetate (Kindt et al. 2010), and analysis by
positive-ion LC-MS/MS (Abrar and Martin 2002; Kindt et al. 2010), but it is validated to a
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large dynamic range to encompass MVA quantification in human and rat urine, has an
optimised MVA → MVL conversion step and is without matrix eﬀects.
The IS (internal standard) was chosen to correct for between sample inconsistencies.
Ideally, the IS should behave in the same manner as the analyte throughout the analytical
method. Our data have shown that the extraction recovery of the d4-MVL was
approximately 50% lower than MVL, and had a fractionally earlier elution time of (2.05 min)
relative to the analyte (2.10 min) in the polar reversed-phase HPLC method which could
suggest that d4-MVL is more polar than MVL. Similar observations of reversed-phase HPLC
resolution and different extraction recoveries between a low molecular weight analyte and
its d4-IS have been reported (Tranfo et al. 2008; Weiling 2002). Despite this, the analyte-IS
relationship was consistent and linear, as shown by the validation. Therefore, these
differences in behaviour between analyte and IS are not limiting for the quantification of
MVA, and d4-MVL, which was also used successfully in another published method (Kindt et
al. 2010) is a suitable IS.
The use of MS/MS to assay MVL derived from MVA in urine encountered a significant
selectivity challenge. In extracts of rat urine single-reaction monitoring with m/z 131 →
69.4 detected an uncharacterised isobaric compound which differed from MVL in retention
time (Figure 2.5). This compound was left uncharacterised as its presence did not interfere
with the quantification of the MVL. However, we used a combination of chromatographic
retention time and MRM reporter transitions to confer enhanced specificity on our assay.
MVA is a very polar compound, and was found to be incompatible with a number of widely
used reversed-phase columns. Screening of several column chemistries identified a
reversed-phase polar end-capped column which retained MVA and MVL satisfactorily.
The high endogenous concentrations of MVA in rat and human urine negate the use of
‘blank’ matrix for calibration standards. Calibration standards of MVL were prepared in pH
2 buffer, extracted and reconstituted in the same manner as urine. The use of a surrogate
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matrix was validated by demonstrating that the presence of co-extracted components of
the human and rat urine matrix did not affect the percentage of MVA converted to MVL,
the extraction recovery of MVL and the IS, and the MS response of the analyte and IS, a
phenomenon termed “parallelism”.  By analysing the effect of matrix compared to aqueous
standards at each stage of the assay, we found that dilution of the urine matrix had no
effect on the analyte-IS ratio, indicating that the matrix has no appreciable bearing on the
processing, detection and quantification of MVA.
Matrix effects are commonly encountered in electrospray ionisation when a matrix
component which co-elutes with the analyte(s), but may not be detected in the MRM
channel, attenuates or enhances the MS signal, and consequently compromises accuracy.
Jemal et al. experienced extensive suppressive matrix effects when they used negative-ion
detection of MVA regenerated from MVL to quantify MVA in human urine. In the current
method, the [M+H]+ precursor ion generated abundantly by an eluent containing formic
acid was exploited, instead of the [M+NH4]+ precursor generated by ammonium formate
eluents (Abrar and Martin 2002; Kindt et al. 2010). There was no suppression or
enhancement of the positive-ion d4-MVL signal in the post-column infusion experiment and
the addition recovery experiment gave near 100% recovery from rat and human urine.
The stability of MVA in various matrices, including urine, has been widely cited in the
literature. In human plasma there was <6.7% change from baseline over 16 months over
various storage conditions (Abrar and Martin 2002). Similarly in water, urine and plasma
there was <8.2% change from baseline for at least 7 weeks (Jemal et al. 2003). Interim
stability data from storage and freeze-thaw experiments for our QC standards composed of
MVL are included herein and the method has a safeguard against potential analyte
instability by analysis of a urine validation sample in each batch. However additional long-
term studies should be carried out to confirm previous reports of analyte stability.
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The development of a validated analytical method for MVA in rat and human urine allows
for the investigation of HMGR activity as a susceptibility factor in the accumulation and
cytotoxicity of aminoglycosides and in particular, it permits for the testing of MVA’s
biomarker potential in rats and humans. In the following chapter, this method will be
employed to demonstrate the diurnal variation of MVA excretion and explore the role of
HMGR activity in aminoglycoside nephrotoxicity.
3. URINARY MEVALONATE AS A POTENTIAL
SUSCEPTIBILITY BIOMARKER OF
AMINOGLYCOSIDE-INDUCED PROXIMAL TUBULE
INJURY
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3.1 Introduction
Aminoglycosides such as gentamicin and tobramycin are clinically effective antibiotics used
to treat life threatening bacterial infections. The inherent nephrotoxic potential of this drug
class limits their clinical efficacy and as such, mechanistic research has focussed with the
impetus of improving aminoglycoside safety. It is widely accepted that the aminoglycosides
accumulate within the proximal tubule epithelial cells (PTEC) through receptor mediated
endocytosis. Knock-out studies (Schmitz et al. 2002), competitive ligand experiments (Nagai
et al. 2006) and structural investigations (Dagil et al. 2013) have demonstrated the critical
role of the multi-ligand endocytic receptor megalin (LRP2, gp330) to this process.
Megalin is known to be regulated by small GTPases (El-Annan et al. 2004; Lou et al. 2002)
which have been prenylated by metabolites of the mevalonate pathway. The plausibility of
reducing megalin-mediated aminoglycoside uptake by chemical inhibition of the rate
limiting enzyme of the mevalonate pathway, HMG-CoA reductase (HMGR), was
investigated in vitro (Antoine et al. 2010). In this study, opossum kidney (OK) cells primed
with the HMGR inhibitors simvastatin, rosuvastatin and pravastatin, and then incubated
with gentamicin, had lower levels of prenylated proteins in conjunction with a reduced
gentamicin accumulation and cytotoxicity in comparison to OK cells with basal HMGR
activity.
If such a metabolic relationship were to translate in vivo and between animal models and
man, patients could be stratified according to their risk of developing aminoglycoside-
induced kidney injury and furthermore, statins could be utilised as a prophylactic strategy.
In order to translate the findings of the in vitro study, the relationship of basal mevalonate
pathway activity to aminoglycoside nephrotoxicity must be investigated.
In Chapter 2 the development and validation of an accurate and precise analytical method
for urinary mevalonate, the product of HMGR, was described and published recently
(Rodrigues et al. 2014). In the following experiments, this method is employed to explore
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the known diurnal rhythm of HMG-CoA reductase activity (Higgins et al. 1971; Parker et al.
1984) in rats, mice and healthy human volunteers and to investigate the relationship of
HMGR activity to aminoglycoside nephrotoxicity in a repeat-dose rat model. The extent of
gentamicin-induced kidney can be measured with established biomarkers of renal function
serum creatinine and blood urea nitrogen and also the novel biomarker kidney injury
molecule 1 (kim-1), which is a sensitive and specific marker of proximal tubule injury and its
excretion correlates with the extent of renal injury (Zhou et al. 2008).
3.2 Aims
 To establish whether or not the diurnal rhythm of HMG-CoA reductase activity can
be monitored via mevalonate excretion in rat, mouse and human urine using the
validated LC-MS/MS method described in Chapter 2.
 Investigate the quantitative and diurnal relationship between HMG-CoA reductase
activity and the extent of nephrotoxicity induced by aminoglycosides in vivo.
 Investigate mevalonate as a predictive mechanism-based biomarker of
susceptibility to nephrotoxicity pre-aminoglycoside exposure in vivo.
3.3 Materials and methods
Gentamicin sulphate, (R)-MVA (purity ~96%) and MVL (purity~97%) were obtained from
Sigma-Aldrich (St Louis, MO, USA). Tobramycin sulphate was obtained from Discovery Fine
Chemicals (Bournemouth, UK). 4,4,5,5-Tetradeutero-MVL (d4-MVL, purity 97%) was
obtained from CDN Isotopes (Pointe-Clare, Quebec, Canada). Methanol, ethyl acetate and
formic acid were of analytical grade and were obtained from Fisher Scientific
(Loughborough,UK).
3.3.1 Diurnal rhythm of mevalonate excretion
Urine was collected from 16 adult male Sprague-Dawley rats (age approx. 8 weeks) via
single housing in metabolic cages for 12 h between 10.00-22.00 h (n=8) or 22.00-10.00 h
(n=8) and stored at -80°C until analysis. Urine was also collected from 5 adult male CD-1
mice (aged 8-10 weeks) in 4 h intervals over a 24 h period starting at 10:00 h. The animals
had free access to food and water throughout the collections. The phases of the
illumination cycle in the animal accommodation were 08:00-20:00 h (light) and 20:00-08:00
h (dark). Protocols were undertaken in accordance with a licence granted under the
Animals (Scientific Procedures) Act 1986 and approved by the University of Liverpool Ethics
Committee. Urine for the human investigation was obtained by spot collection in the
morning (range 05.15- 08.50 h) and evening (range 17.30-22.30 h) from 25 healthy children
(mean age 9.10 yrs, range 0.9 to 16.7 years). Children were recruited from schools and a
nursery with informed written consent obtained from carers or guardians on the behalf of
the participating children. The study was conducted with the approval of the Liverpool East
Research Ethics Committee. Urine samples were collected from each child by an age-
appropriate method, normally a clean catch urine sample into a sterile container. Samples
were centrifuged, aliquoted into smaller volumes, then frozen and stored at -80˚C.
Mevalonic acid and urine creatinine were quantified from the urine samples.
74
3.3.2 Gentamicin study
Sixteen adult male Sprague-Dawley rats were randomly assigned to either gentamicin or
0.9% saline dosing groups and further divided into AM or PM dosing schedules. Animals
were housed individually in metabolic cages for 12 h either between 10.00-22.00 h (PM
groups n=8 per group) or 22.00-10.00 h (AM groups, n=8 per group) where urine was
collected and subsequently stored at -80°C until analysis. Following the pre-dose urine
collection animals were administered 200 mg/kg gentamicin or 0.9% saline I.P according to
their dosing group; the PM groups were dosed at 22:00 h and the AM groups at 10:00 h.
The dosing schedule was repeated for 9 days. Urine was collected over 12 h following the
final dose and animals were culled humanely by a rising concentration of CO2 and
exsanguination.
3.3.3 Tobramycin study
Thirty adult male Sprague-Dawley rats (age approx. 8 weeks) were randomly assigned to
either tobramycin (n=16), gentamicin (n=8) or 0.9% saline (n=6) treatment groups. Animals
were housed individually overnight prior to the first dose of tobramycin sulphate (120
mg/kg I.P) or gentamicin sulphate (120 mg/kg I.P) or 0.9% saline at approximately 10.00 h.
The dosing schedule was repeated for 7 days and urine was collected overnight following
the final dose. Animals were culled humanely using a rising concentration of CO2 and
exsanguination.
Protocols were undertaken in accordance with a licence granted under the Animals
(Scientific Procedures) Act 1986 and approved by the University of Liverpool Ethics
Committee.
3.3.4 Histology
Tissues were collected into a solution of 10% formalin before slicing and processing for H&E
staining. Kidney tissue was scored for damage according to a system used previously (Zhang
et al. 2009). All organs were removed and rinsed in ice cold saline. Renal tissue samples
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were fixed in 10% neutral buffered formalin or snap frozen. For histological assessment of
toxicity and immunohistological examination, formalin-fixed tissue sections were routinely
paraffin wax embedded. 3-5µm sections were prepared and stained with hematoxylin and
eosin (H&E) or used for immunohistology.
Immunohistology was performed to identify cells undergoing apoptosis (staining for
cleaved caspase-3) as well as cells in the cell cycle as a tool to identify regenerative
attempts (staining for PCNA) as previously described (Antoine et al. 2010; Piron et al. 1998).
Briefly, H&E stained sections were examined for any histopathological features and sections
stained for caspase-3 and PCNA for semi-quantitative analysis blind and independently by a
pathologist (A.Kipar).
3.3.5 Biomarkers
3.3.5.1 Quantification of urinary mevalonic acid
Mevalonic acid was quantified according to the method described in Chapter 2. In brief, 50
µL of urine was acidified with a pH 2 buffer to lactonize mevalonic acid. An internal
standard, tetra-deuterated mevalonolactone was added to samples and standards, and
both compounds were extracted with ethyl acetate. The extract was dried down and
reconstituted in 90% water 10% methanol 0.1% formic acid before 10 µL was injected on to
an LC-MS/MS instrument. Samples were analysed and quantified in relation to calibration
standards. The concentration of mevalonic acid was normalised to urine creatinine.
3.3.5.2 Quantification of urinary creatinine
Urine (25 µL of urine diluted 1 in 25) was incubated with 125 µL of alkaline picrate solution
(0.14 M NaOH, 10 mM Na2HPO4, 90 mM sodium borate, 10 mM sodium dodecyl sulphate,
25% v/v picric acid, 2.7% v/v DMSO) for 2 min at room temperature. An acid solution (5 µL
of 10:2:88 v/v acetic acid: concentrated H2SO4:distilled water) was added and incubated at
room temperature for a further 10 min with shaking. Plates were read at 490 nm and
creatinine was estimated using creatinine calibration standards.
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3.3.5.3 Quantification of urinary kim-1
For the initial gentamicin study, urinary kim-1 was quantified using a sandwich ELISA as
described previously (Vaidya et al. 2006) in collaboration with the Bonventre lab (Harvard
University). In brief, the antibody monoclonal, anti-rat Kim-1 ectodomain, served as a
primary antibody and coated the wells of the ELISA plate. The wells were blocked with 3%
BSA/PBS with 0.02% sodium azide and washed with PBST. One hundred microliters of
standard or sample were incubated in duplicate for 1.5 h at 37°C. Following three washes
with PBST, the secondary antibody (biotinylated monoclonal anti-rat Kim-1 ectodomain)
and HRP-conjugated streptavidin was added for 15 min. The reaction was stopped by
addition of 1 N HCl and absorbance was read at 450 nm. Urinary kim-1 was calculated using
a calibration curve and expressed as ng/mL.
For the tobramycin study, urinary kim-1 was quantified using the rat kim-1 singleplex assay
kit (MesoScaleDiscovery, Rockville, MD). Urine was thawed, vortexed and centrifuged at
13,000 rpm for 5 min before an aliquot was diluted 1 in 5 with the diluent supplied in the
kit. Plates were blocked for 1 h with shaking and rinsed three times with 300 µL of PBS-T. To
each well, 25 µL of diluent and 25 µL of diluted sample were added; the plate was sealed
and incubated at ambient temperature for 2 h with shaking.  After the incubation the plate
was washed again with PBS-T before addition of 25 µL of the detection antibody. The plate
was incubated for a further 2 h with shaking, then washed with PBS-T before addition of
150 µL of read buffer. The 96-well plate was analysed using the SECTOR Imager
(MesoScaleDiscovery, Rockville, MD). Calibration standards were also analysed with a
dynamic range of 0.0137 – 10 ng/mL.
3.3.5.4 Serum creatinine
Serum creatinine was quantified by the Jaffe reaction according to a method optimised for
serum (Sabbisetti et al. 2014) with collaborators in the Bonventre Lab (Harvard University).
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3.3.6 Renal HMG-CoA reductase activity
HMG-CoA reductase was assayed in microsomal fractions derived from renal tissue. Rats
were sacrificed by rising CO2 and the kidneys were removed and immediately placed in an
ice-cold homogenization medium (50 mM KH2PO4 (pH 7.0), 0.2M sucrose, 2 mM
dithiothreitol (DTT)). The kidneys were homogenized in the medium. The homogenate was
centrifuged at 15,000×g for 10 min and the supernatant obtained was centrifuged at
100,000×g for 75 min to obtain microsomal pellets, which were then resuspended in the
homogenization medium containing 50 mM EDTA and centrifuged at 100,000×g for 60 min.
The supernatant containing the microsome was used as an enzyme source.
The activity of HMG-CoA reductase was determined by employing 14C-HMG-CoA (Shapiro et
al. 1974) as follows. The enzyme in the supernatant containing the microsomes was
activated at 37° C for 30 min. Added to a reaction tube were 20 μl of HMG-CoA reductase
assay buffer (0.25M KH2PO4 (pH 7.0), 8.75 mM EDTA, 25 mM DTT, 0.45M KCl and 0.25
mg/ml BSA), 5 μl of 50 mM NADPH, 5 μl of 14C-HMG-CoA (0.05 μCi/tube, final conc. 120
μM) and 10 μl of activated microsomal enzyme (0.03-0.04 mg), and the mixture was
incubated at 37° C for 30 min. The reaction was terminated by adding 10 μl of 6 M HCl to
the mixture and the mixture was incubated at 37° C for 15 min to allow complete
lactonisation of the product (mevalonate). The precipitate was removed by centrifugation
at 10,000×g for 1 min and the supernatant was applied to a Silica gel 60 G TLC plate (Altech
Inc, Newark, USA) and then developed with benzene:acetone(1:1, v/v). A region having a Rf
value ranging from 0.65 to 0.75 was removed by scraping with a disposable cover slips and
assayed for radioactivity with 1450 Microbeta liquid scintillation counter (Wallacoy,
Finland). Enzyme activities were calculated as picomoles mevalonic acid synthesised per
min per mg protein (pmoles/min/mg protein). The assay was conducted by A.Srivastava
(Department of Pharmacology and Therapeutics, University of Liverpool)
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3.3.7 Gentamicin quantification
Gentamicin content in the renal cortex was determined by an LC-MS method as reported
previously (Antoine et al. 2010) and was conducted by A.Srivastava (Department of
Pharmacology and Therapeutics, University of Liverpool).
3.4 Results
3.4.1 Diurnal variation in mevalonate excretion
3.4.1.1 Rat
MVA was quantified in urine collected from adult male Sprague-Dawley rats during two 12
h collections, 10:00-22:00 h and 22:00-10:00 h, see Figure 3.1. The excretion of MVA was
significantly greater (unpaired T test; p<0.0001) in urine collected during 22:00-10:00 h
(6.2-13.0 µg/mg UCr; mean 9.7±2.3 µg/mg UCr) compared to 10:00-22:00 h (1.6-5.2 µg/mg
UCr; mean 3.4 ±1.3 µg/mg UCr). When expressed as total MVA excretion by factoring in
urine volume the diurnal differences remained and urine collected 22:00-10:00 h
represented a mean excretion of 110.0±27.8 µg MVA/12 h (81.7-153.2 µg) compared to
urine collected 10:00-22:00 h with a mean excretion of 21.5±6.6 µg MVA/12 h (12.8-33.1
µg).
3.4.1.2 Mouse
MVA was quantified in urine collected over 24 h in six 4 h intervals from 5 adult male CD-1
mice, see Figure 3.2.  MVA excretion throughout the collections ranged from 4.90 - 25.05
µg/mg UCr with urine MVA output undergoing a mean 1.7-fold change (range 1.4 to 2.1-
fold). The maximum MVA excretion was in either the 02:00-06:00 h or 06:00-10:00 h
collections in the majority of the mice whilst the one animal had a reverse rhythm with
peak and trough MVA excretion at 18:00 h and 06:00 h, respectively.
3.4.1.3 Human
MVA was also quantified in paired morning and evening urines obtained by spot collection
from healthy children (n=25), see Figure 3.3. The excretion of MVA in evening spot
collections had a median of 292.4 ng/mg UCr (n=25, inter quartile range 245.4ng/mg UCr),
whereas the median concentration of MVA in morning spot collections was 427.0 ng/mg
UCr (n=25, inter quartile range 230.1 ng/mg UCr). The paired and mean data are
represented in Figure 3.3; in 15 out of 25 pairs, morning collections had significantly greater
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concentrations of MVA than evening collections (p<0.05; T Test, paired, two-sided) where
the morning excretion was, on average, 105% greater; however in four individuals the
concentration of MVA was significantly greater in the evening collection (p<0.005; T Test,
paired, two-sided). The remaining six morning and evening pairs had numerical differences
but were not statistically significant.
Figure 3.1 MVA excretion in adult male Sprague-Dawley rats in two 12 h collections (n=8
per group). Data are plotted as dot plots with the group mean (-). Individual data points are
the mean of three analytical replicates.
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Figure 3.2 24 h diurnal variation in MVA excretion in adult male CD-1 mice. Data plotted are
mean values of three analytical replicates from six 4 h urine collections (n=5).
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Figure 3.3 MVA excretion in human urine obtained by spot collection from healthy children
(n=25). (A) Data are presented as change in urinary MVA from evening to morning per
individual and (B) group means ± standard deviation.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Ch
an
ge
in
uri
ne
MV
A
fro
m
ev
en
ing
co
lle
cti
on
(ng
/m
gU
Cr
)
83
3.4.2 Gentamicin study
3.4.2.1 Serum creatinine
Blood samples were obtained from 4 rats per dosing group. Creatinine was quantified in the
sera of rats administered 200 mg/kg gentamicin daily at either 10:00 h or 22:00 h for 9
days. The mean serum creatinine concentration in the 22:00 h dosing group was 0.60±0.08
mg/dL and for the 10:00 h dosing group 2.13±0.34 mg/dL (p<0.0001, one-way ANOVA with
Bonferroni correction). The mean serum creatinine in the saline animals dosed at 22:00 h
was 0.30±0.14 mg/dL and for the 10:00 h group was 0.20±0.08 mg/dL, see Figure 3.4.
3.4.2.2 Histology
A dose of 200 mg/kg administered at 10:00 h for 9 days induced histological changes typical
for gentamicin-induced nephrotoxicity (average score 3; Figure 3.5A). Immunohistology for
cleaved caspase-3 demonstrated tubular epithelial cell death via apoptosis (Figure 3.5B) in
association with toxic changes. When administered at 22:00 h, however, the same
gentamicin doses did not lead to any histological evidence of nephrotoxicity; histological
features were identical to those seen in untreated control animals (Figure 3.5C).
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Figure 3.4 Serum creatinine levels after 9 days of I.P. 200 mg/kg gentamicin or 0.9% saline,
administered once daily at either 22:00 h or 10:00 h. Data are presented as box plots with
means, upper and lower quartiles and the minimum and maximum values (n=4). NS - not
significant **** - p<0.0001 (One-way ANOVA with Bonferroni correction).
Figure 3.5 Histological changes in rats treated with gentamicin at 10:00 h or 22:00 h. (A)
H&E stain of renal tissue from a rat treated with gentamicin (10:00 h group), there are
numerous dying tubular epithelial cells (arrow). Other tubules show evidence of epithelial
cell regeneration (arrowhead); score 4. (B) Tubular epithelial cell death is via apoptosis, as
the expression of cleaved caspase-3 in small groups (arrows) or individual (arrowheads)
tubular epithelial cells confirms. (C) H&E stain of renal tissue from a rat treated with
gentamicin (22:00 h group), there are no significant pathological changes. B: Peroxidase
anti-peroxidase method, Papanicolaou's hematoxylin counterstain. Bars = 20 μm.
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3.4.2.3 Urine kim-1
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Figure 3.6 Urine kidney injury molecule 1 excretion after 9 days of I.P 200 mg/kg gentamicin
administered daily at either 22:00 h or 10:00 h. Data are presented as box plots with
means, upper and lower quartiles and the minimum and maximum values (n=8). NS - not
significant **** - p<0.0001 (One-way ANOVA with Bonferroni correction).
The urinary excretion of kim-1 was significantly greater in animals dosed gentamicin at
10:00 h compared to the corresponding saline treated animals (p<0.0001, one-way ANOVA
with Bonferroni correction). This difference was not seen in animals dosed saline or
gentamicin at 22:00 h. Kim-1 excretion was significantly greater in animals administered
200 mg/kg gentamicin daily for 9 days at 10:00 h compared to the animals dosed at 22:00 h
(mean 6.23±1.80 vs. 1.14±0.61 ng/mg UCr, respectively, p<0.0001 one-way ANOVA with
Bonferroni correction), see Figure 3.6.
3.4.2.4 Renal HMG-CoA reductase activity
A B
Figure 3.7 Regression of (A) pre-dose urinary mevalonic acid and (B) urinary kidney injury molecule 1 with renal HMG-CoA reductase activity from animals
administered I.P 200 mg/kg gentamicin daily at either 10:00 h or 22:00 h. Data points are from individual animals (10:00 h n=8, 22:00 h n=8).
Renal activity of HMG-CoA reductase was measured and regressed against end-point
urinary kim-1 excretion. A strong positive relationship was observed with R2 =0.9277
(p<0.0001). The data points of the two dosing groups were clearly separated, see Figure
3.7.
3.4.2.5 Regression of urine kim-1 and pre-dose mevalonate
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Figure 3.8 Regression of pre-dose mevalonate and end-point urine kidney injury molecule 1
from animals administered I.P 200 mg/kg gentamicin daily at either 22:00 h or 10:00 h. Data
points are from individual animals (10:00 h n=8, 22:00 h n=8).
Pre-dose urinary mevalonate concentration was regressed against end-point urinary kim-1
excretion for each animal administered gentamicin. A significant positive relationship was
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observed with a strong goodness of fit (p<0.0001, R2=0.8846). Data points for animals
administered gentamicin at 10:00 h were separated from those administered gentamicin at
22:00 h, see Figure 3.8.
3.4.2.6 Renal accumulation
Ge
nta
mi
cin
 in
 re
na
l c
ort
ex
 (n
g/m
g p
rot
ein
)
22:00 h 10:00 h
500
750
1000
1250
Administration Time
****
Figure 3.9 Accumulation of gentamicin in the renal cortex after repeat dose gentamicin at
either 10:00 h or 22:00 h. Data are box plots of the means, upper and lower quartiles and
the minimal and maximal values (n=8 per group), **** - p<0.0001.
The accumulation of gentamicin was measured by quantification of gentamicin in the renal
cortex, see Figure 3.9. Animals administered gentamicin at 22:00 h had a mean renal cortex
concentration of 647.3±89.7 ng/mg protein whereas animals administered gentamicin at
10:00 h had a mean renal cortex concentration of 954.0±97.6 ng/mg protein (p<0.0001,
unpaired T test).
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3.4.3 Tobramycin study
3.4.3.1 Urine Kim-1
Before administration of the aminoglycosides, kim-1 excretion was minimal ranging from
0.92 ng/mg UCr to 4.31 ng/mg UCr. After 7 days of repeat dose gentamicin or tobramycin
(120 mg/kg) urine kim-1 significantly increased relative to pre-dose, reaching a mean of
37.82±19.54 ng/mg UCr and 24.77±20.73 ng/mg UCr for the gentamicin (p=0.0012) and
tobramycin (p=0.0006) groups, respectively (paired, two-tailed T test). Although there was
a numerical difference between the mean kim-1 excretion in gentamicin and tobramycin
groups it was not statistically significant, see Figure 3.10.
Figure 3.10 Urine kidney injury molecule 1 excretion pre-dose and after 7 daily injections of
120 mg/kg gentamicin or tobramycin. Individual data points are presented with a horizontal
line to indicate the group mean (gentamicin n=8, tobramycin n=16, ** - p<0.005, *** -
p<0.001).
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3.4.3.2 Regression of kim-1 and pre-dose mevalonate
Tobramycin and gentamicin were administered at equal doses (120 mg/kg) once daily for 7
days. The positive relationship observed for gentamicin in the 200 mg/kg experiments was
also observed at 120 mg/kg for 7 days but was not statistically significant (R2=0.3839,
p=0.19), see Figure 3.11. One animal was excluded from regression analysis because the
histology score, BUN and kim-1 were not simultaneously elevated. An inverse relationship
was observed for pre-dose mevalonate and tobramycin toxicity (as determined by kim-1
excretion) but it was not statistically significant, see Figure 3.12.
Figure 3.11 Linear regression of pre-dose mevalonate and end-point kidney injury molecule
1 from animals administered 7 daily injections of 120 mg/kg gentamicin at 10:00 h. Data
points are from individual animals (n=7).
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Figure 3.12 Regression of pre-dose mevalonate and end-point kidney injury molecule 1
from animals administered 7 daily injections of 120 mg/kg tobramycin at 10:00 h. Data
points are from individual animals (n=16).
3.5 Discussion
Gentamicin nephrotoxicity demonstrates a strong relationship with megalin-mediated
endocytosis and the mevalonate pathway. Reduction of megalin endocytosis via inhibition
of the mevalonate pathway’s rate limiting enzyme HMG-CoA reductase (HMGR) has been
shown to reduce the accumulation and cytotoxicity of gentamicin (Antoine et al. 2010). As
such, the diurnal and inter-individual variation in HMGR activity could influence the amount
of aminoglycoside that accumulates within proximal tubule cells. The aims of this chapter
were to establish urinary mevalonic acid as a biomarker of HMGR activity and to explore
the relationship between the diurnal rhythm of HMGR, mevalonate excretion and
aminoglycoside nephrotoxicity in a rat model.
The mevalonate assay developed in Chapter 2 was applied to the quantification of MVA in
urine from rats, mice and healthy human children at various time points in a 24 h period.
Each species demonstrated diurnal flux in urinary MVA consistent with the known diurnal
activity of HMG-CoA reductase. In rats MVA excretion was significantly different between
two 12 h rat urine collections, with 22:00–10:00 collections containing more than 3-fold the
amount of MVA than 10:00–22:00 collections. The diurnal variation of HMGR activity is well
established and has been previously examined in hepatic microsomal fractions of rats
(Parker et al. 1982; Popjak et al. 1979) and plasma and urine MVA content in human
subjects (Beil et al. 1990; Parker et al. 1982; Parker et al. 1984). However studies were
unable to demonstrate statistically significant diurnal variation in plasma MVA in rats
(Kopito et al. 1982). The lack of significance of the flux in rat plasma MVA in studies by
Kopito et al. is likely to do with study design; in comparison to the present study, rats were
allowed access to food between 09:00 h and 12:00 h and plasma mevalonate was
measured across nine time points with different groups of animals at each time point (n =
5–6 per group). Given the inter-individual variation displayed between the animals in the
present study, it is more likely that significant diurnal fluctuations would have been seen if
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the concentration of plasma MVA over time had been compared in paired samples
obtained from the same animals.
In the human data where the samples were paired, the trend was similar to that found in
the rat study.  In 60% of individuals the concentration of MVA was greater in the morning
spot collection ranging from 27% to 469%. In four individuals a significantly lower urinary
MVA content was observed in the morning compared with the evening collection. These
human data conform to published urinary MVA data on a study of healthy volunteers which
observed increases of up to 122% in MVA excretion in eight of 11 volunteers in 12 h urine
collected between 19:00 and 07:00 h compared with 07:00 and 19:00 h; in the remaining
three volunteers this trend was reversed (Lindenthal et al. 1996). Similarly, plasma MVA
was observed to vary 5-fold in a 40 year old male with a maximum at 07:00 h and a
minimum at 22:00 h (Beil et al. 1990).
CD-1 mice did not display a clear diurnal rhythm in urinary MVA excretion whereby a
maximum 2.1-fold difference between the minimum and maximum MVA excretion in a 24 h
period was measured. One animal demonstrated a reverse rhythm like that seen in the
human volunteers, with peak excretion during 18:00-22:00 h. Although the diurnal activity
of HMGR activity is widely accepted as a mammalian phenomenon, literature on HMGR
activity and mevalonate excretion in the mouse is scarce with the majority of rodent studies
focused on the manipulation of HMGR in rat models and the clinical measurements of
mevalonate in plasma. Still, the quantification of mevalonate in non-clinical and clinical
samples is vital to the investigation of the relationship of HMGR and the toxicity of
aminoglycosides in animal models.
Whilst further investigations on HMGR and aminoglycoside nephrotoxicity were carried out
in rats, studies were not pursued in mice due to negative results in a dose-ranging
nephrotoxicity study; a repeat dosing regimen of once-daily intraperitoneal gentamicin
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(200 mg/kg for 7 days) in C57BL/6 and CD-1 adult male mice did not cause kidney injury
(see Appendix 1), hence a mouse model of gentamicin nephrotoxicity could not be
established. The literature on aminoglycoside nephrotoxicity in mice is conflicting, with
early studies suggesting that aminoglycosides accumulate within murine proximal tubule
epithelial cells but the mice are resistant to toxicity (Suzuki et al. 1994; Suzuki et al. 1995),
whereas multiple research groups demonstrate amelioration of aminoglycoside-
nephrotoxicity by co-administering other compounds in Swiss albino background mice
(Nabavi et al. 2012; Nitha and Janardhanan 2008; Whiting et al. 1981). The reason for this
discrepancy is unclear but it could be that species differences between rats and mice and
strain differences between C57BL/6 and albino background mice result in differential
intracellular handling of the aminoglycosides. Although it appears that mice are not a
reliable model for studying aminoglycoside nephrotoxicity, investigation into the
mechanism behind their resistance to the intracellular adverse effects of aminoglycoside
accumulation could offer new strategies and biomarkers for the stratification of patients
based on risk.
Susceptibility to aminoglycoside-induced nephrotoxicity is long-established in rats (Luft et
al. 1975). We investigated the relationship of pre-dose HMGR activity with the end-point
toxicity of gentamicin in adult male Sprague-Dawley rats, by quantifying the product of
HMGR, mevalonic acid, and quantifying a biomarker of proximal tubule injury, kidney injury
molecule 1. Animals were assigned to one of two dosing regimens – either a 10:00 h or
22:00 h schedule to exploit the diurnal variation in HMGR activity. A strong positive
relationship between pre-dose mevalonate excretion, kidney injury and gentamicin
accumulation in the renal cortex was observed, with animals administered gentamicin at
10:00 h experiencing greater kidney injury and gentamicin accumulation, compared to
animals on the 22:00 h schedule. Correspondingly, mevalonate excretion was greater in the
hours prior to 10:00 h compared to 22:00 h supporting the idea that there is a contributory
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relationship between HMGR activity, the uptake of gentamicin and subsequent
nephrotoxicity.
The strong relationship between pre-dose mevalonate and gentamicin toxicity suggests
that mevalonate could be a predictive biomarker of an individual’s susceptibility to
aminoglycoside nephrotoxicity and supports the further research into the use of statins as a
prophylactic treatment (Antoine et al. 2010). In the study of 200 mg/kg gentamicin, animals
with greater pre-dose mevalonate demonstrated the greatest extent of gentamicin
nephrotoxicity; the trend was similar at 120 mg/kg gentamicin but the regression was not
significant due to one animal with high pre-dose mevalonate and comparatively low urine
kim-1 excretion. Although these data strongly suggest HMGR activity plays a significant part
in gentamicin-induced nephrotoxicity, this anomaly illustrates that susceptibility is likely to
be multifactorial. At present the management of this adverse drug reaction is based on
monitoring trough serum levels and kidney function tests but, other than patient
demographics and a history of renal disease, there is no method of predicting which
patients are susceptible. Therefore it is important to examine whether the role of HMGR
translates to a clinical setting, and if successful, measurement of an individual’s HMGR
activity could help stratify patients based on their risk for nephrotoxicity and suitability for
prophylaxis.
The greater level of toxicity observed when gentamicin was administered once daily at
10:00 h may have wider implications for clinical dosing strategies. Guidance for clinical
practice suggests that once-daily or extended interval dosing regimens reduce the
incidence of aminoglycoside nephrotoxicity compared to the historical twice or thrice-daily
regimens (Chuck et al. 2000; Rybak et al. 1999). Whilst a multiple-dosing strategy would
circumvent the clinical issue of circadian toxicity, a once-daily regimen would not. There is
no general consensus on the importance of the time of day at which it is best to administer
aminoglycosides but a clinical study of 179 patients has identified the time of day as an
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independent risk factor for toxicity; the incidence of nephrotoxicity was greatest when
aminoglycosides were administered between midnight and 7 am (34.6%) whilst the
incidence of nephrotoxicity when aminoglycosides were administered between 4.30 pm
and 11.30 pm was 9.3% (Prins et al. 1997). The published data in conjunction with the data
presented here indicates that administration of gentamicin when HMGR activity is at its
peak has greater potential for nephrotoxicity than administration of gentamicin when
HMGR activity is at its lowest. In addition, the data from our healthy volunteer children
demonstrates that the diurnal rhythm of HMGR is not uniform between individuals
(Rodrigues et al. 2014) with some children having an inverse rhythm to the majority.
Although this information could be incorporated into clinical practice, it is recognised that it
may not be efficacious to delay the start of an antibiotic regimen until HMGR activity falls.
Whilst a susceptibility relationship has been demonstrated between mevalonate and
gentamicin, our investigations with the aminoglycoside tobramycin did not reach the same
conclusion as no clear relationship was observed. Tobramycin nephrotoxicity has been
studied in concert with gentamicin nephrotoxicity to show that they both accumulate
within the renal cortex in non-clinical species (Nieminen et al. 1978; Sairio et al. 1978) and
patients (Schentag et al. 1978), although tobramycin consistently accumulates to a lesser
extent than gentamicin (Schentag et al. 1981). Later studies of the mechanism of proximal
tubule uptake with gentamicin, netilmicin and amikacin established a role for megalin-
mediated endocytosis (Decorti et al. 1999; Moestrup et al. 1995; Nagai et al. 2001; Schmitz
et al. 2002), however a direct connection between tobramycin and megalin has not been
published. Tobramycin also has different binding kinetics to gentamicin and netilmicin.
Continuous infusion experiments with the aminoglycosides in conscious rats demonstrated
that, while gentamicin and netilmicin had saturable Michaelis-Menten uptake kinetics,
tobramycin demonstrated a linear relationship between serum level and cortical
accumulation without saturation, suggesting that tobramycin has a different mechanism of
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uptake to gentamicin and netilmicin (Giuliano et al. 1986). This is further supported by
experiments that show netilmicin, when co-administered at an equi-molar concentration,
inhibited the accumulation of gentamicin by >20% whereas a ratio of 2:1 tobramycin to
gentamicin was required to cause a similar inhibition (Josepovitz et al. 1982). In light of the
strong relationship between pre-dose mevalonate and gentamicin, the absence of a
relationship with tobramycin and the different uptake kinetics of tobramycin compared to
gentamicin, it is probable that the majority of tobramycin molecules are taken up into the
proximal tubule by an alternative mechanism. Therefore although pre-dose mevalonate is a
suitable susceptibility biomarker for gentamicin nephrotoxicity, these data suggest it is not
suitable for tobramycin. Given the positive result with gentamicin and the indication that
some aminoglycosides are taken up by alternative means, it would be prudent to
investigate the mechanistic relationship of pre-dose mevalonate and nephrotoxicity with
other clinically relevant aminoglycosides such as amikacin.
In order for urinary mevalonate measurement to be incorporated into clinical practice as a
susceptibility biomarker for gentamicin nephrotoxicity, further research must be
undertaken in order to satisfy biomarker qualification guidelines (Goodsaid and Frueh
2007). Qualification is the process of collecting evidence that supports the use of a
biomarker in a specific context. Guidance for the active qualification of biomarkers is a
relatively new process and much of the guidance refers to biomarkers which assist in the
development of safer drugs by detecting adverse outcomes earlier than the gold standard
biomarkers used clinically. Whilst mevalonic acid could be further investigated as a
potential predictive biomarker, many of the concepts suggested for safety biomarkers
apply.
Fundamental to the qualification process, the proposed context of use must be defined and
non-clinical and clinical evidence is gathered within that framework. It may be the case that
a wider context of use is identified as more research mounts. For mevalonic acid, the
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demographic, population and drug regimen would need to be well-defined. In this research,
time- and HMGR- dependent aminoglycoside nephrotoxicity was identified in rats and
although the diurnal rhythm of HMGR in man has been shown herein, the translation of this
relationship to human subjects exposed to the aminoglycosides needs to be explored.
Any data supporting the use of a novel biomarker in a disease area should be underpinned
by existing biomarkers to demonstrate its performance. In terms of susceptibility
biomarkers, demonstrating performance is more difficult than comparing two end-point
biomarkers as was achieved in comparing urinary kim-1 with serum creatinine and blood
urea nitrogen in its qualification as a pre-clinical biomarker of proximal tubule injury
(Vaidya et al. 2010). The data collection supporting a susceptibility biomarker would be a
lengthy process and is case-dependent and therefore may require a larger cohort of both
animal and clinical data.
Underlying the value of any biomarker is its analytical method. The guidelines for
qualification suggest that the evaluation of the biomarker should be considered
conceptually independent to the assay which performs the measurements, that is to say
the assay must be validated alone, and a biomarker cannot become qualified without an
appropriate validated method of quantification. The assay developed and validated
according to fit-for-purpose biomarker guidelines that is described in Chapter 2 can
quantify mevalonic acid in urine of rodent and human urine. However it does take several
hours to perform the assay which in the clinical context of a patient with a serious infection
needing urgent treatment, may not be appropriate. Therefore a more rapid method of
determining mevalonic acid and/or HMGR activity would be essential to its clinical
implementation.
In summary, urinary mevalonic acid is a biomarker of HMGR activity in vivo and temporal
changes in HMGR activity and mevalonic acid excretion are related to the extent of
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gentamicin accumulation and nephrotoxicity. Although mevalonic acid needs to be
investigated in more detail with regards susceptibility to aminoglycoside induced
nephrotoxicity, the initial research presented here provides a framework for entering the
in-depth biomarker qualification process. These data will be built upon in Chapter 4 and
Chapter 5 by adopting an alternative approach to targeted biomarker identification - the
comprehensive multivariate metabolite analyses of biofluids in animals exposed to
gentamicin.
4. METABONOMIC ANALYSIS OF GENTAMICIN
EXPOSURE
Contents
4.1 Introduction ................................................................................................................. 104
4.1.1 Analytical platforms for metabonomic analysis .......................................... 104
4.1.2 Multivariate analysis .................................................................................... 105
4.1.3 Metabonomics of gentamicin exposure ...................................................... 106
4.2 Aims.............................................................................................................................. 107
4.3 Methods ....................................................................................................................... 108
4.3.1 Study protocol.............................................................................................. 108
4.3.2 Histology ...................................................................................................... 108
4.3.3 Biochemical measurements......................................................................... 110
4.3.3.1 Blood urea nitrogen ................................................................................. 110
4.3.3.2 Urine creatinine ....................................................................................... 110
4.3.3.3 N-acetyl-β-glucosaminidase..................................................................... 110
4.3.3.4 Kidney injury molecule-1 ......................................................................... 111
4.3.4 Metabolic profiling....................................................................................... 111
4.3.4.1 Sample processing ................................................................................... 111
4.3.4.2 Acquisition of 1H NMR spectra................................................................. 112
4.3.4.2.1 Urine and aqueous faecal extracts .................................................... 112
4.3.4.2.2 Sera .................................................................................................... 112
4.3.4.3 Spectral processing .................................................................................. 112
4.3.4.4 Multivariate analysis ................................................................................ 113
4.3.4.4.1 Principal component analysis ............................................................ 113
4.3.4.4.2 Orthogonal partial least squares - discriminant analysis................... 113
4.3.4.5 Estimation of gentamicin excretion from 1H-NMR spectra ..................... 114
4.4 Results .......................................................................................................................... 115
4.4.1 Body weight changes ................................................................................... 115
4.4.2 Kidney and liver observations ...................................................................... 116
4.4.3 Urine volume................................................................................................ 117
4.4.4 Histology ...................................................................................................... 118
4.4.5 Biochemical measurements......................................................................... 118
4.4.5.1 β-N-acetyl-glucosaminidase..................................................................... 118
4.4.5.2 Kidney-injury molecule 1 ......................................................................... 118
4.4.5.3 Blood urea nitrogen ................................................................................. 119
4.4.5.4 Gentamicin excretion............................................................................... 119
103
4.4.6 Principal component analysis ...................................................................... 120
4.4.6.1 Urine......................................................................................................... 120
4.4.6.1.1 Pre-dose and gentamicin-treated animals ........................................ 120
4.4.6.1.2 Saline control animals........................................................................ 123
4.4.6.2 Serum....................................................................................................... 124
4.4.6.2.1 PCA models of pre-dose and day 10.................................................. 124
4.4.6.3 Aqueous faecal extracts ........................................................................... 126
4.4.6.3.1 Pre-dose and gentamicin-treated animals ........................................ 126
4.4.6.3.2 Saline-treated and gentamicin-treated animals ................................ 126
4.4.7 OPLS-DA models........................................................................................... 128
4.4.7.1 Urine......................................................................................................... 128
4.4.7.1.1 Pre-dose and gentamicin-treated animals ........................................ 128
4.4.7.1.2 Saline control animals........................................................................ 130
4.4.7.2 Serum....................................................................................................... 134
4.4.8 Summary heat map...................................................................................... 136
4.5 Discussion..................................................................................................................... 137
4.5.1 TCA cycle metabolites and the mitochondria .............................................. 138
4.5.2 Oxidative stress............................................................................................ 139
4.5.3 Gut microbial metabolites ........................................................................... 141
4.5.4 Metabolites of renal tubule dysfunction ..................................................... 141
4.5.5 Metabonomics in drug toxicity .................................................................... 142
4.5.6 Concluding remarks ..................................................................................... 143
4.1 Introduction
Metabonomics is the study of metabolic profiles from complex biological samples, such as
serum, urine or tissue, providing information on the perturbation of metabolites in
response to pathophysiological conditions. These metabolic ‘fingerprints’ can be used to
study drug toxicity. Analysis of the metabolome is complementary to the other ‘omics
approaches (genomics, transcriptomics, proteomics), giving a more accurate description of
the phenotypic response to a chemical through direct measurements of the products of
genes, transcripts and proteins (Nicholson et al. 2002). Another advantage of a
metabonomics approach is that it enables the study of environmental influences, such as
the diet or gut microbes, on a phenotype.
4.1.1 Analytical platforms for metabonomic analysis
Spectral methods provide the means to generate high-resolution metabolic profiles. Mass
spectrometry (MS) coupled to Gas or Liquid Chromatography (GC or LC) and Nuclear
Magnetic Resonance (NMR) spectroscopy are the most commonly employed,
complementary, analytical tools for assessing metabolic changes. The hyphenation of
chromatography and MS allows for partial sample clean-up by firstly separating metabolites
chromatographically, followed by mass spectrometric ionisation and detection according to
their mass to charge ratio (m/z). NMR spectroscopy exploits the property of atomic nuclei
in a magnetic field where they absorb and re-emit electromagnetic radiation. The response
of the nuclei, also known as the free induction decay (FID) is mathematically transformed
by Fourier transformation to produce a spectrum, see Figure 4.1. Whilst NMR has the
benefit of being non-destructive and provides information rich spectra (structural
information and metabolite range) from complex mixtures, MS has greater analytical
sensitivity, albeit plagued by metabolite-dependent ionisation suppression issues and
general inter-laboratory reproducibility issues (Nicholson et al. 2002).
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Figure 4.1 A typical 600 MHz 1H-NMR spectrum of rat urine. Spectral peaks represent
metabolites present in the urine and are calibrated to TSP (0 ppm). TSP - sodium 3-
trimethylsilyl-[2,2,3,3,-2H4]-1-propionate, 1-MN - 1-methylnicotinamide.
4.1.2 Multivariate analysis
A wealth of metabonomic data can be generated in a relatively short amount of time;
whilst data analysis and pattern recognition is rapid, metabolite identification can be a rate-
limiting step. The multidimensional data generated by metabolic profiling is commonly
analysed using multivariate statistical methods including Principal Component Analysis
(PCA) and Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA). PCA is an
unsupervised statistical technique that is employed to find patterns and outliers in
multivariate data (data with many dimensions) and it is useful when highlighting the
similarities and differences within data sets. The data are compressed into new vectors, or
principal components, which describe the relationships within the multivariate data, more
specifically where the variance is large. PCA is an unsupervised method in that the origin of
the data or prior information on class membership is not considered in the analysis. In
contrast, OPLS-DA is a supervised method whereby data are categorised, the ‘Y’ variable,
and the discriminating features of the data sets are identified, the ‘X’ matrix. Variation in
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the data is dissected into two parts, variation in ‘X’ that is correlated with ‘Y’ also termed
‘predictive’ information and variation that is not, termed uncorrelated or ‘orthogonal’
information.
4.1.3 Metabonomics of gentamicin exposure
Various efforts have been made to characterise the mechanism of gentamicin
nephrotoxicity using a metabonomic approach although a limited number of metabolites
were identified as perturbed. An initial study used both LC-MS and 1H-NMR technology to
study urine from a twice-daily regimen of 120 mg/kg gentamicin for 7 days. Significant
increases in urinary NAG and BUN were observed on day 3 and day 9, respectively, but,
aside from a decrease in trimethylamineoxide (TMAO) and a rise in citrate, they did not
detect major changes by 1H-NMR until after the dosing ceased when glucosuria, raised
lactate, and a reduction in urinary betaine was reported (Lenz et al. 2005). Complementary
LC-MS analysis identified the depletion of xanthurenic acid and kynurenic acid. This study
also focused on PCA as a tool for detecting metabolites responsible for separation from
controls. Similarly, a study of age-related gentamicin nephrotoxicity in rats used PCA and
found changes in glucose, hippurate and 6-hydroxymelatonin (Espandiari et al. 2007).
Another study used a combined 1H-NMR and GC-MS approach, analysing urine from rats
given 60 and 120 mg/kg gentamicin, also dosed twice daily, for 7 days (Sieber et al. 2009).
Dose-dependent significant increases NGAL were observed after 2 days and although kim-1
appeared to be raised after 1 day, it did not reach statistical significance.  Pattern
recognition by PCA and OPLS-DA picked out an increase in glucose excretion as the major
driver between the metabolic separation of control and treated animals but the 1H-NMR
analysis also detected citrate, hippurate, trigonelline and 3-indoxylsulfate as having dose-
dependent decreases.
It is likely that the limited number of metabolites detected as perturbed in these studies is
largely caused by the dependence on PCA as a pattern recognition tool and/or the
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restriction of analysing only the urine of these animals. Furthermore in order to detect
perturbations, the metabolite profiles of treated animals were compared to control animals
and although this is a good approach, inter-individual metabolic variation may dwarf more
subtle drug-related changes. Therefore many other metabolite changes may be caused by
exposure to gentamicin but go undetected.
4.2 Aims
To characterise the impact of once-daily exposure to gentamicin on the rat
metabolome in order to gain insight into the mechanism of gentamicin nephrotoxicity.
The methods employed will be:
 1H-NMR spectroscopy to profile pre-dose and post-dose rat urine, sera and
aqueous faecal extracts
and
 Multivariate statistical analyses and metabolite identification.
4.3 Methods
4.3.1 Study protocol
Ten male 8-week old Sprague-Dawley rats were randomly divided into two dosing groups of
5 animals. Blood was obtained by sampling from the tail vein prior to the first injection. One
group (n=5) received an intraperitoneal (IP) injection of 0.9% saline once daily for 9
consecutive days and served as healthy controls. The remaining 5 animals received 200
mg/kg gentamicin (dissolved in 0.9% saline) via I.P injection once daily for 9 days. Dosing
occurred between 10.00 am and 12.00 pm. Animals were housed individually in metabolic
cages 12 hours prior to the first injection and 12 hours after the first injection; animals were
housed in metabolic cages again for the 24 hours after the fourth injection and finally for 24
hours after the final (ninth) injection, see Figure 4.2. 12 hour urine was collected into
chilled vessels with a minimum of 0.1% wt/v sodium azide. Faeces were also collected into
chilled containers and along with the urine aliquots were stored at -80°C until analysis.
Body weight and overall condition were recorded daily. Animals were kept on a 12 h
light/dark cycle throughout the study with free access to food and water. On day 10 of the
study all animals were culled by an overdose of pentobarbitone followed by cardiac
puncture. Blood was collected and allowed to clot at 4°C overnight and serum was collected
and stored at -80°C. The kidneys and liver were removed and weighed; half of the right
kidney and a section of the large lobe of the liver were snap frozen. The remainder of the
kidney, liver and carcass was preserved in 4% paraformaldehyde for histological analysis.
4.3.2 Histology
The kidney that was tissue fixed in 4% paraformaldehyde was sagittally cut and divided into
dorsal and ventral halves. The two tissue sections were embedded in paraffin, sectioned at
a thickness of 5 μm, and stained with hemotoxylin-eosin. Renal lesions were assessed by
microscopic examination, recording the frequency and severity using a semi-quantitative
scoring scale of 0 to 5 as in Zhang et al (2009):
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Figure 4.2 Schematic of the study protocol. Urine and faeces were collected in 12 h periods
at the beginning, middle and end of the study where gentamicin or saline were
administered daily.
The criteria of the scoring scale were as follows:
0 = Normal tubules, glomerulus, interstitium, and vessels.
1 = Scant number of tubular epithelial cells showing minimal degeneration, mild tubular
dilatation, small number of proteinaceous casts, no regeneration, no definitely significant
necrosis or apoptosis. No changes in the glomerulus, interstitium, and vessels.
2 = < 25% of tubular epithelial cells showing mild degeneration (large cytoplasmic vacuoles,
a few hyaline droplets in the cytoplasm), mild degree of tubular dilation and proteinaceous
casts, slight change in tubular brush border loss, acute tubular necrosis in individual cell or
small group of cells, a few apoptotic cells, and no regeneration. No changes in the
glomerulus, interstitium, and vessels.
3 = 25%-50% of tubular epithelial cells showing moderate degeneration (multiple large-
sized vacuoles, multiple foci of hyaline droplets), mild regeneration, moderate tubular
brush border loss, moderate acute tubular necrosis in small group of tubules, and increased
number of apoptotic cells. Little involvement of mild glomerular vacuolization. No changes
in the interstitium and vessels.
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4 = 51%–75% of tubular epithelial cells showing extensive moderate degeneration;
moderate regeneration; severe tubular brush border loss; severe acute tubular necrosis;
and a large number of apoptotic cells, with apoptotic bodies in clusters of tubules. Little
involvement of mild glomerular vacuolization and interstitial lymphocytic infiltration.
5 = > 75% of tubular epithelial cells showing severe degeneration, regeneration, severe
tubular brush border loss, acute tubular necrosis, and a large number of apoptotic cells
with numerous apoptotic bodies. Mild involvement of glomerular injury (vacuolization,
mesangial cell proliferation, and increase in mesangial matrix) and interstitial lymphocytic
infiltration. No significant changes in the vessels.
4.3.3 Biochemical measurements
4.3.3.1 Blood urea nitrogen
Blood urea nitrogen (BUN) was measured using the QuantiChrom Urea Assay kit (Bioassay
Systems, Hayward, CA). Serum samples were diluted 1 in 2 with distilled water before
running the colorimetric assay and quantified using urea calibration standards (0.78-50
mg/dL).
4.3.3.2 Urine creatinine
Urine (25 µL of urine diluted 1 in 25) was incubated with 125 µL of alkaline picrate solution
(0.14 M NaOH, 10 mM Na2HPO4, 90 mM sodium borate, 10 mM sodium dodecyl sulphate,
25% v/v picric acid, 2.7% v/v DMSO) for 2 min at room temperature. An acid solution (5 µL
of 10:2:88 v/v acetic acid: concentrated H2SO4:distilled water) was added and incubated at
room temperature for a further 10 min with shaking. Plates were read at 490 nm and urine
creatinine (UCr) was estimated using creatinine calibration standards (2.5-40 mg/dL).
4.3.3.3 N-acetyl-β-glucosaminidase
N-acetyl-β-glucosaminidase (NAG) was quantified using a colorimetic assay kit (Roche, West
Sussex UK). Urine samples were diluted up to 1 in 5 with distilled water to fit within the
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quantifiable range (Optical density <1). NAG concentration was quantified using the
following equation:
Concentration (U/mL) = (absolute-blank)* 33.33/1000
4.3.3.4 Kidney injury molecule-1
Urinary kidney injury molecule-1 (kim-1) was quantified using a sandwich ELISA as
described previously (Vaidya et al. 2006). In brief, the antibody monoclonal anti-rat Kim-1
ectodomain, served as a primary antibody and coated the wells of the ELISA plate. The
wells were blocked with 3% BSA/PBS with 0.02% sodium azide and washed with PBST. One
hundred microliters of standard or sample were incubated in duplicate for 1.5 h at 37°C.
Following three washes with PBST, the secondary antibody (biotinylated monoclonal anti-
rat Kim-1 ectodomain) and HRP-conjugated streptavidin was added for 15 min. The reaction
was stopped by addition of 1 N HCl and absorbance was read at 450 nm. Urinary kim-1 was
calculated using a calibration curve, expressed as ng/mL and normalised to UCr.
4.3.4 Metabolic profiling
4.3.4.1 Sample processing
Urine samples from each animal were thawed, vortexed and allowed to settle for 10
minutes before 400 µL of urine was mixed with 200 µL of 0.2 M phosphate buffer (with
3mM NaN3, 1mM TSP in 100% D2O). The mixtures were centrifuged at 13 000 rpm for 10
minutes at 4°C and 550 µL was transferred into 5 mm NMR tubes. Serum samples were
processed in the same manner except for 200 µL of serum was mixed with 400 µL of saline
(0.9% NaCl in 100% D2O).
For faecal processing, approximately 50 mg of each faecal pellet was weighed, mixed with
750 µL of 0.2 M phosphate buffer and homogenised in a bead beater in two cycles (6500
Hz, 45 seconds per cycle). The homogenate was centrifuged at 13 000 rpm for 10 minutes
at 4°C and 550 µL of supernatant was transferred to 5 mm NMR tubes.
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4.3.4.2 Acquisition of 1H NMR spectra
4.3.4.2.1 Urine and aqueous faecal extracts
One-dimensional (1D) 1H-NMR spectra were acquired on a Bruker 600 MHz spectrometer
(Bruker Biospin, Rheinstetten, Germany) operating at a temperature of 300 K using the
standard 1D solvent suppression pulse sequence (relaxation delay, 90° pulse, 4 μs delay,
90° pulse, mixing time, 90° pulse, acquire FID) (Beckonert et al. 2007). 256 scans were
collected into 64,000 data points using a spectral width of 12 MHz, a relaxation delay 4 s, an
acquisition time of 2.72 s and a mixing time of 0.1 s. A line broadening factor of 0.3 Hz was
applied to all spectra prior to Fourier transformation (FT).
4.3.4.2.2 Sera
The CPMG (Carr-Purcell-Meiboom-Gill) spin-echo pulse sequence (spin-spin relaxation
delay, 2 n  of 80 ms; n= 200,  = 200 µs) with water presaturation was applied to profile
sera in order to attenuate broad resonances from high molecular weight compounds
(Beckonert et al. 2007). 384 scans were collected into 64,000 data points using a spectral
width of 12 MHz with a relaxation delay 4 s, an acquisition time of 2.72 s and a mixing time
of 0.1 s. Presaturation of the water signal was applied during the relaxation delay and
mixing time. A line broadening factor of 0.3 Hz was applied to all spectra prior to Fourier
transformation (FT).
4.3.4.3 Spectral processing
Spectra were manually phased and base-line corrected using TopSpin 3.2 software. Urine
and faeces spectra were calibrated on the chemical shift scale using TSP (sodium 3-
trimethylsilyl-[2,2,3,3,-2H4]-1-propionate) set to 0 ppm. Spectra derived from sera were
calibrated to the anomeric proton resonance of alpha-glucose (5.25 ppm). All spectra were
imported into MATLAB 2013 using MetaSpectra 4.1.1. Regions containing urea and water
were removed and in the urine and faeces spectra, TSP-related peaks were also removed.
Several urinary spectra were excluded from further processing and analysis due to poor
quality spectra dominated by a urea peak. Spectra were aligned to account for between
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sample chemical shift variations caused by differences in pH by recursive segment-wise
peak alignment (Veselkov et al. 2009) and normalised using probabilistic quotient
normalisation (Dieterle et al. 2006) using in-house scripts.
4.3.4.4 Multivariate analysis
Urine spectra were subjected to unsupervised and supervised multivariate methods:
Principal Component Analysis and Orthogonal Partial Least Squares-Discriminant Analysis.
4.3.4.4.1 Principal component analysis
PCA analysis was carried out on the control and gentamicin groups to identify inherent
clustering and outliers. PCA was performed using SIMCA 13.0 software using unit variance
(UV) scaling.
4.3.4.4.2 Orthogonal partial least squares - discriminant analysis
OPLS-DA analysis generated models by comparison of two groups of samples at a time.
Models were generated using MATLAB 2013 and in-house scripts (Imperial College,
London). Models were validated by permutation tests (1000 permutations) and calculation
of the Q2Y (the predictive capacity of the model) and the R2Y (the goodness of fit to the Y
data) values. Metabolites which contributed to significant models were identified using
Chenomx Profiler software (Chenomx NMR Suite), ‘spike-in’ experiments with pure
compounds and databases - the Human Metabolome Database
(www.hmdb.ca/spectra/nmr_one_d/search), the Biological Magnetic Resonance Data Bank
(www.bmrb.wisc.edu/metabolomics).
Data are presented as OPLS-DA loadings coefficient plots (Cloarec et al. 2005b) where the
loadings are back-scaled to highlight the urinary metabolites which are discriminant
between the two groups and displays the associated correlation coefficient with a colour
scale demonstrating the strength of the correlation; dark red indicates a very significant
correlation between the groups and at the other end of the scale, dark blue indicates little
variation between the groups.
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4.3.4.5 Estimation of gentamicin excretion from 1H-NMR spectra
The integral of the gentamicin singlet at 2.76 ppm in the urine 1H-NMR spectra was
adjusted according to the number of protons; excretion was estimated using the calculated
creatinine excretion which was based on the proton-adjusted integral of the creatinine
singlet at 4.04 ppm and the concentration of creatinine as measured by the Jaffe assay.
Integration was achieved using MATLAB 2013 and in-house scripts (Imperial College,
London) by selecting the upper and lower ppm scale boundaries of the region of interest.
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4.4 Results
4.4.1 Body weight changes
Overall body weight (BW) increased from initial BW in all animals throughout the 10 day
study except for animal 9 (gentamicin group) on day 10 where there was a decrease of
1.2%, see Figure 4.3. Body weight increases between groups were statistically different
from day 4 of the study (T test, unpaired, p=0.019) where the control group had a mean BW
gain of 12.6±3.7% (n=5) whereas the gentamicin group had a mean BW gain of 8.0±2.1%
(n=5). This trend continued to the end of the study where on day 10 the mean BW gain of
the control animals (mean BW on day 10, 336.2±17.0g, n=5) was 28.1±4.4% and in the
gentamicin animals (mean BW on day 10, 286.9±12.3g, n=5) the mean BW gain was
7.7±4.7% (T test, unpaired, p<0.00005).
Figure 4.3 Body weight changes of male Sprague-Dawley rats given daily I.P injections of
0.9% saline or 200 mg/kg gentamicin for 9 days.
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4.4.2 Kidney and liver observations
The mean weight of both kidneys at the end of the study in saline-treated animals
(2.52±0.15g, n=5) was 0.75±0.06% of total BW whereas in the gentamicin-treated animals
(3.18±0.31g, n=5) it was 1.15±0.11% of total BW (p<0.001), see
Figure 4.4A. During the necropsy the kidneys of the saline group were dark-reddish in
colour whilst the kidneys of each animal in the gentamicin group appeared blanched and
pale and were surrounded by an oedematous fluid filled sac. The mean weight of the liver
of saline-treated animals was 10.03±1.68g (n=5), representing 4.16±0.32% of total BW; in
the gentamicin group the mean liver weight was lower at 7.21±0.79g (n=5), which
represented a smaller proportion of total BW, 3.45±0.38% (p<0.05), see
Figure 4.4B. Although there was a disparity in liver weight between the control and
gentamicin groups, there were no lesions and they were a dark-red colour.
Figure 4.4 Kidney (A) and liver (B) weight as a percentage of total body weight in animals
administered 0.9% saline or 200 mg/kg gentamicin for 9 days. Data are presented as the
mean ± standard deviation (n=5). * p<0.05, **** p<0.0005 (Unpaired T Test).
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4.4.3 Urine volume
Urine output was recorded in six 12 h collections prior to the first dose and throughout the
study.  Pre-dose animals (n=10) had a mean urine output of 3.25±1.32 mL over a 12 h
overnight period (10pm-10am). In the 12 h period (10am-10pm) immediately after the first
dose the mean urine output of the saline-treated animals was 2.04±0.00 mL (n=5) and in
gentamicin treated animals 2.27±0.55 mL (n=5). On subsequent collections gentamicin-
treated animals had a greater mean urine output than saline-treated animals in the
equivalent 12 h collection. Despite the greater mean urine output in the gentamicin group
in the day 10 collection (10pm-10am) there was also greater variation within the
gentamicin group with a urine output range of 4.0-29.0 mL (n=5) compared to 3.5-6.0 mL
(n=5) in the saline group. Animals 1 and 3 in the gentamicin group had a more than 7-fold
greater urine output compared to animal 9, see Figure 4.5.
.
Figure 4.5 Recorded urine production throughout the study of rats administered either
0.9% saline or 200 mg/kg gentamicin daily for 9 days.
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4.4.4 Histology
In control animals no histological abnormalities were observed in the liver and kidney tissue
except for animal 4 which had random multifocal interstitial infiltration, see Appendix 2 for
a detailed description of the liver and kidney tissue of each animal. In the gentamicin group
apoptotic cells were observed. Vacuolation, hyaline (protein) droplets and tubular protein
casts were present in all animals. Animals 3 and 5 had a tubular protein cast score of 2.5
whilst animals 1, 7 and 9 had a score of 3. In all animals receiving gentamicin, examination
of the kidney tissue revealed multifocal mononuclear (lymphocytes or macrophages)
interstitial infiltration. Animals 7 and 9 had occluded glomeruli. The liver tissue of animal 9
had a mild increase in leukocytes between hepatic chords and animals 5 and 9 had low liver
glycogen. Animals 3 and 5 had a histology score of 3.5 whilst animals 1, 7 and 9 had a
histology score of 4.
4.4.5 Biochemical measurements
A detailed description and discussion of the biochemical measurements is given in Chapter
5.
4.4.5.1 β-N-acetyl-glucosaminidase
Pre-dose urinary NAG excretion was 14.88±3.18 U/mg UCr (n=10). NAG excretion in the 12
h period immediately following the initial dose was statistically greater in animals
administered 200 mg/kg gentamicin compared to 0.9% saline (T test, unpaired p<0.0005)
and throughout the study where on day 10 an overnight urine collection gave a mean NAG
excretion of 15.97±5.99 U/mg UCr in the saline group compared to 307.50±114.7 U/mg UCr
in the gentamicin group.
4.4.5.2 Kidney-injury molecule 1
Pre-dose urinary excretion of kim-1 was measured as 0.39±0.22 ng/mg UCr. Throughout the
study the excretion of kim-1 ranged from 0.25 – 1.73 ng/mg UCr in the saline group. Kim-1
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excretion was significantly greater in the gentamicin group relative to the saline group from
day 4 (p=0.044) to the end of the study on day 10 (T test, unpaired, p=0.001).
4.4.5.3 Blood urea nitrogen
The mean pre-dose BUN was determined to be 30.06±12.71 mg/dL (n=10). For the saline
treated group, mean BUN at the end of the study was 20.97±2.82 mg/dL (n=5). After 9
doses of 200 mg/kg/day gentamicin, the mean BUN measured was 191.93±61.84 mg/dL
(n=5). The animal with the largest change in BUN was animal 9 with a 15-fold increase
whereas animal 7 had the smallest at 4.3-fold.
4.4.5.4 Gentamicin excretion
The urinary excretion of gentamicin was greatest in the 12 h collection following the initial
dose (day 1) but varied between animals (range of 43.1-100.2 mg/h). In the subsequent
daytime collection on day 4, urine gentamicin excretion was considerably lower with a
range of 4.6-10.6 mg/h, see Figure 4.6. On day 9 gentamicin excretion in animals 1 and 7
increased relative to day 4 (37.8-71.7 mg/h), whereas gentamicin excretion for animals 3, 5
and 9 remained low (2.2-13.2 mg/h).
Figure 4.6 Urine gentamicin excretion in daytime collections on day 1, 4 and 9, calculated by
the integral of 2.76 ppm and urine creatinine concentration and integral of 4.04 ppm.
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4.4.6 Principal component analysis
4.4.6.1 Urine
4.4.6.1.1 Pre-dose and gentamicin-treated animals
Principal Component Analysis (PCA) was performed on the 1H NMR urine spectra acquired
from animals pre-gentamicin dose (n=5) and on day 1 (12 h), day 4 (120 h), day 5 (132 h),
day 9 (228 h) and day 10 (240 h) of the study. A PCA scores plot for this model is shown in
Figure 4.7 where 27.3% of the variance can be explained by the latent variable PC1 and
15.1% by PC2. Pre-dose, day 1, day 4 and day 5 animals form group clusters whilst the day 9
and day 10 samples show within group variation. The metabolic profiles shift away from the
pre-dose profiles from day 1 (12 h after the first dose) and continue to shift throughout the
study. Day 9 urine from animals 3 and 9 and day 10 urine from animals 3 and 7 are isolated
from the metabolic space occupied by the other animals at the same time points and are
closer to pre-dose profiles.
Diurnal variation is also evident between the two 12 h collections from the same 24 h
period as exemplified by pre-dose and day 1, day 4 and day 5, and by day 9 and day 10. As
such, PCA was performed on matching 12 h collections (10:00-22:00 h or 22:00-10:00 h).
The PCA scores plot of pre-dose, day 4 and day 10 (22:00-10:00 h) is shown in Figure 4.8A.
In this model 38.3% of the variance can be explained by the first latent variable PC1, and
14.2% can be explained by PC2. The separation between pre-dose and day 4 clusters is
greater whilst the variation on day 10 is evident by the spread of animals 1, 5 and 9 and the
clustering of animals 3 and 7 between the pre-dose and day 4 samples. In the PCA model of
matched time points day 1, day 5 and day 9 (10:00-22:00 h) 27.4% of variance can be
explained by the first latent variable PC1 whilst 19.8% can be explained by PC2, see Figure
4.8B. Day 1 urines (12 h after the first dose) are clustered whilst the metabolic space
occupied by day 5 urines (5 doses) is greater. On day 9 (9 doses), animals 3 and 9 are
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clustered near day 1 and animals 1 and 5 are separated, with animal 7 distinct from the
others.
Figure 4.7 PCA scores plot of PC1 vs PC2 obtained from 1H-NMR spectra from pre-dose
urine and gentamicin treated animals; R2=0.655, Q2=0.405.
AB
Figure 4.8 PCA scores plot of PC1 vs PC2 obtained from 1H-NMR spectra from (A) pre-dose
urine and urine from gentamicin treated animals on day 4 and day 10 of the study,
R2=0.525, Q2=0.267. Samples were collected overnight, 22:00-10:00 h, and (B) urine from
gentamicin treated animals on day 1, day 5 and day 9 of the study, R2=0.639, Q2=0.287.
Samples were collected during the day, 10:00-22:00 h.
123
4.4.6.1.2 Saline control animals
PCA was performed on all 1H NMR urine spectra obtained from the 5 animals dosed 0.9%
saline throughout the study. In this model 30% of the variance could be explained by PC1
and 16.3% by PC2. The majority of the control animals clustered throughout the study,
whilst animals 2, 8 and 10 on day 9 and animal 2 on day 10 were outliers, see Figure 4.9.
A
B
Figure 4.9 PCA scores (A) and loadings (B) plot of PC1 vs PC2 obtained from 1H-NMR spectra
from pre-dose urine and urine from saline treated animals, R2=0.64, Q2=0.311.
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4.4.6.2 Serum
4.4.6.2.1 PCA models of pre-dose and day 10
PCA models of pre-dose and terminal time-points from saline-treated animals are displayed
in a scores plot in Figure 4.10A, PC1 explains 25.2% of the variance and PC2 accounts for
23.2%. The pre-dose and day 10 metabolic profiles of animals 8 and 10 show little variation
whereas animals 2, 4 and 6 occupy a different metabolic space compared to pre-dose. In a
PCA model of pre-dose and day 10 sera from gentamicin-treated animals PC1 explained
31.3% of the variance and PC2 17.6%. Animals 3, 5, 7 and 9 cluster at pre-dose with animal
1 separated along PC1. On day 10 animals 1 and 9 are occupy a different metabolic space
compared to pre-dose whilst animal 3, 5 and 7 are clustered with the pre-dose sera, see
Figure 4.10B.
AB
Figure 4.10 PCA scores plot of 1H-NMR spectra of sera obtained (A) pre-dose and day 10 in
the saline group, R2=0.484, Q2=0.044 and (B) from the gentamicin group, R2=0.489, Q2=0.-
0.1.
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4.4.6.3 Aqueous faecal extracts
4.4.6.3.1 Pre-dose and gentamicin-treated animals
PCA was performed on all 1H NMR data acquired from aqueous faecal extracts from animals
pre-gentamicin dose (n=5) and on day 1 (12 h), day 4 (120 h), day 5 (132 h), day 9 (228 h)
and day 10 (240 h) into the study. A PCA scores plot for this model is shown in Figure 4.11A
where 17.6% of the variance can be explained by the latent variable PC1 and 13% by PC2.
Clustering of animals at corresponding time-points was not achieved indicative of large
metabolic variation in the sample matrix. Animals 5 and 7 did not produce faeces during the
day 10 collection.
4.4.6.3.2 Saline-treated and gentamicin-treated animals
PCA was performed on the 1H-NMR spectra of aqueous faecal extracts obtained from
animals treated with 0.9% saline and with 200 mg/kg/day gentamicin. A PCA scores plot of
control (n=5) and gentamicin-treated (n=5) animals on day 9 of the study is shown in Figure
4.11B. In this model 21.6% of the variance can be explained using PC1 and 18.9% in PC2.
Saline-treated animals cluster with gentamicin-treated animal 7 whereas the remaining
gentamicin-treated animals are dispersed along PC1.
The large amount of variability seen in the PCA models did not allow for meaningful
interpretation of OPLS-DA models; therefore OPLS-DA models of faecal extract metabolites
were not examined.
AB
Figure 4.11 PCA scores plot of PC1 vs PC2 obtained from 1H-NMR spectra from (A) pre-dose
faeces and faeces from gentamicin treated animals, R2=0.573, Q2=0.183 and (B) day 9
faeces from gentamicin and saline treated animals, R2=0.404, Q2=-0.1.
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4.4.7 OPLS-DA models
PCA indicated that substantial changes in urinary, serum and faecal metabolite composition
had occurred due to the administration of gentamicin. OPLS-DA models of urine and sera
were computed to determine which metabolites were most discriminatory by comparing
the post-dose spectra to pre-dose spectra. Changes specific to gentamicin administration
were determined by examining metabolic changes in saline treated animals at matched
time-points.
4.4.7.1 Urine
4.4.7.1.1 Pre-dose and gentamicin-treated animals
OPLS-DA models of pre-dose and day 1 urine spectra were analysed in order to establish
early changes in the 12 hours following the first 200 mg/kg dose of gentamicin. The Q2
value, which describes the predictive capacity of the model, was high at 0.9346 and the R2Y,
indicating the goodness of fit to the Y data (pre-dose or day 1), was also high at 0.9978.
Permutation analysis of this model with 1000 random permutations gave a significant
model with p=0.007. Figure 4.12 displays an OPLS-DA loadings coefficient plot of pre-dose
compared to day 1 spectra. Metabolites in greater abundance in the day 1 urine include
glucose, 1-methylnicotinamide and allantoin. Gentamicin was also present in the urine at
12 h following the initial dose.
Metabolites found to be depleted on day 1 in comparison to pre-dose were
leucine/isoleucine, 3-hydroxyisobutyrate, acetate, succinate, 2-oxoglutarate, citrate, cis-
aconitate, choline, TMAO, trigonelline, fumarate, hippurate and formate. Several
resonances that were highlighted as discriminant between the groups remain unassigned;
1.295 ppm (m), and 5.15 ppm were increased relative to pre-dose whereas 3.6 ppm (s),
3.65 ppm and 7.09 ppm (s) were less abundant. The OPLS-DA scores plot (Figure 4.12) for
this model illustrates the separation between pre-dose and day 1 urine; the Tcv axis
explains the major sources of biological variation in the data (predictive) where pre-dose
129
and day 1 form distinct clusters, whilst the TY(osc) axis explains the variation which is not
related (uncorrelated) to discrimination of the classes pre-dose or day 1.
Models comparing pre-dose urine spectra with mid-study (day 4 and 5) samples were also
performed to provide information on the progression of gentamicin-induced kidney injury.
The OPLS-DA model of pre-dose compared to day 4 urine also had good predictive ability
(Q2 =0.771) and goodness of fit to the groups (R2Y=0.9896), see Figure 4.13. In this model
putrescine was increased relative to pre-dose as well as two unidentified resonances at
7.17 ppm and 7.23 ppm. Similarly to the pre-dose/day 1 model, 3-hydroxyisobutyrate,
citrate, cis-aconitate, 3.6 ppm, 7.09 ppm and hippurate were reduced compared to pre-
dose. Methylamine, 3-indoxylsulfate and unassigned resonances at 1.69 ppm, 3.16 ppm,
7.31 ppm were also reduced on day 4.
Analysis of the OPLS-DA model of pre-dose and day 5 urine spectra highlighted a reduction
in leucine/isoleucine, 3-hydroxyisobutyrate, acetate, succinate, citrate, methylamine, 2-
oxoglutarate, cis-aconitate, choline, TMAO, fumarate, 3-indoxylsulfate, hippurate, formate
and trigonelline, relative to pre-dose, see Figure 4.14. Several unassigned metabolites were
also found to be raised on day 5 relative to pre-dose at 1.295 ppm (m), 2.93 ppm (s) and
3.52 ppm (thought to be a sugar) and multiple unassigned resonances were found to be
reduced relative to pre-dose at 3.16 ppm, 3.6 ppm, 3.73 ppm and 3.91 ppm.
OPLS-DA models comparing pre-dose and end-point urine spectra were analysed for
metabolite changes following once-daily intraperitoneal injections of 200 mg/kg gentamicin
for 9 days. The model statistics for pre-dose/day 9 were robust; Q2 =0.8053 R2Y =0.9701,
permutation test p=0.007. Succinate, 2-oxoglutarate, citrate, methylamine, cis-aconitate,
choline, TMAO, hippurate, allantoin, fumarate and unassigned resonances 1.69 ppm, 2.26
ppm, 3.16 ppm, 3.6 ppm were reduced compared to pre-dose. Putrescine was increased.
The models statistics of pre-dose urine spectra compared to day 10 yielded similarly robust
statistics; Q2 =0.8666 R2Y =0.9806, permutation test p=0.002. In this model putrescine was
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found to be significantly increased compared to pre-dose whilst succinate, 2-oxoglutarate,
citrate, hippurate, allantoin, fumurate, formate, trigonelline and the singlet at 3.6 ppm
were reduced relative to pre-dose. Glucose was raised in two spectra.
4.4.7.1.2 Saline control animals
OPLS-DA models of the control animals at the same time points were analysed to identify
changes in urine metabolites that were not attributable to daily administration of
gentamicin. On day 1 there was an increase in 1.18 ppm (d) and a decrease at 3.6 ppm (s),
5.41 ppm and a small decrease in trigonelline (9.13 ppm (s)) compared to pre-dose. Small
decreases in trigonelline were also observed on day 5 and day 9 in the control animals. On
day 5 there was a decrease in the peak area of the unassigned singlets at 2.93 ppm and
3.91 ppm compared to pre-dose. On day 9, choline was decreased compared to pre-dose.
Models of day 4, day 5 and day 10 highlighted the singlet at 3.16 ppm as significantly
decreased compared to pre-dose; in the gentamicin animals 3.16 ppm was also shown to
be depleted on days 4, 5 and 9. Hippurate was depleted compared to pre-dose on days 4,
5, 9 and 10, see Table 4.1 for a summary of these changes. Model statistics are summarised
in Table 4.2
AB
Figure 4.12 OPLS-DA loadings coefficient plot of pre-dose compared to day 1 urine spectra.
(A) Loadings coefficients plot showing metabolites responsible for discrimination between
the groups. (B) Cross validated scores (Tcv1) versus TYosc. An increase relative to pre-dose
is depicted by a positive coefficient whilst a decrease is depicted by a negative coefficient.
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Figure 4.13 OPLS-DA loadings coefficient plot of pre-dose compared to day 4 urine spectra.
(A) Loadings coefficients plot showing metabolites responsible for discrimination between
the groups. (B) Cross validated scores (Tcv1) versus TYosc. An increase relative to pre-dose
is depicted by a positive coefficient whilst a decrease is depicted by a negative coefficient.
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Figure 4.14 OPLS-DA loadings coefficient plot of pre-dose compared to day 5 urine spectra.
(A) Loadings coefficients plot showing metabolites responsible for discrimination between
the groups. (B) Cross validated scores (Tcv1) versus TYosc. An increase relative to pre-dose
is depicted by a positive coefficient whilst a decrease is depicted by a negative coefficient.
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Table 4.1 Summary of discriminant metabolites identified by OPLS-DA analysis of urine and
sera from 0.9% saline treated animals during the course of the study.↑ indicates an
increase and -dose spectra
Day of
study
Urinary metabolites identified as discriminant between saline-treated and
pre-dose cohorts from OPLS-DA models
Day 1 Trigonelline↓r2=-0.78
1.18 ppm (d)↑ r2= 0.84
3.6 ppm (s)↓ r2= -0.71
5.41 ppm ↓ r2= -0.88
Day 4 Hippurate↓r2= -0.63
3.16 ppm (s) ↓
r2= -0.76
Day 5 Trigonelline↓r2=-0.82
Hippurate↓
r2=-0.84
2.93 ppm (s)↓ r2=-0.90
3.16 ppm (s) ↓r2=-0.83
3.91 ppm (s)↓ r2=-0.82
Day 9 Trigonelline↓r2=-0.79
Hippurate↓
r2=-0.69
Choline↓
r2=-0.81
Day 10 Hippurate↓r2=-0.58
3.16 ppm (s) ↓
r2=-0.76
Serum changes:
Acetate ↑r2=0.74
Glucose ↑r2=0.77
4.4.7.2 Serum
OPLS-DA models of pre-dose and day 10 sera were analysed for differences in metabolite
composition. The model had robust statistics; Q2 =0.7825, R2Y=0.9753, p=0.009. Valine,
leucine, isoleucine, alanine, lipids, glutamate, choline, TMAO, tyrosine, and formate were
reduced compared to pre-dose. 1.05 ppm (d) (potentially 2-methylglutarate/3-
hydroxyisobutyrate or isobutyrate), acetate, citrate, dimethylamine, creatinine, glucose, 3-
hydroxyisobutyrate and allantoin were increased on day 10.
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Table 4.2 Summary statistics of the urine and sera OPLS-DA models in gentamicin treated
and saline treated animals. Models were performed comparing spectra from each day of
the study with pre-dose.
Gentamicin
treated
Urine Sera
Q2Y R2Y Permutation
test
Q2Y R2Y Permutation
test
Pre-dose Day 1 0.9346 0.9978 0.007
Day 4 0.7710 0.9896 0.009
Day 5 0.9431 0.9974 0.011
Day 9 0.8053 0.9701 0.007
Day 10 0.8666 0.9806 0.002 0.7825 0.9753 0.009
Saline-treated
Pre-dose Day 1 0.6236 0.9791 0.031
Day 4 0.4051 0.9641 0.090
Day 5 0.6375 0.9917 0.011
Day 9 0.6474 0.9744 0.027
Day 10 0.7278 0.9333 0.007 0.6021 0.9865 0.022
4.4.8 Summary heat map
Fluctuations in the urine and serum metabolomes over the course of the study are summarised in Figure 4.15 and Figure 4.16.
Figure 4.15 Heat map of the changes associated with discriminant metabolites from OPLS-DA models of pre-dose spectra and gentamicin treated animals.
Data are loadings correlation coefficients (r2) plotted by colour where red signifies a coefficient of +1 and blue signifies -1.
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4.5 Discussion
Metabolic changes after exposure to the experimental model aminoglycoside gentamicin
could give insight into the mechanism of proximal tubule injury and the progression of the
toxicity. 1H-NMR and multivariate analyses were performed on biofluids and aqueous faecal
extracts from various time points in a study of rats treated with a high dose of gentamicin
for 9 days. Gross metabolic disturbances were visualised by PCA of urine and sera from
gentamicin treated rats. Unfortunately a large amount of metabolic variation within groups
was identified in the PCA of faecal extracts. This may be owing to the inherent nature of the
sample, and sample collection and processing methods employed. The intra-group variation
did not favour further analyses using OPLS-DA.
During the study, metabolic disturbances were also identified in the control saline-treated
rats. Subtle depletion of trigonelline, choline and hippurate were evident and although
changes in these metabolites were also identified in the gentamicin group, it is likely that
these are stress related changes as a result of repeat dosing and housing within metabolism
cages which contributed to a reduction in feeding and subsequent decrease in these
metabolites.
Nevertheless, widespread perturbations in the urine and sera metabolomes were identified
by multivariate analyses which were symptomatic of the pharmacological activity of
gentamicin, the off-target adverse effects associated with the mechanism of toxicity and
the functional impairment of the kidneys. Depletion of metabolites associated with gut
microbial metabolism demonstrates the antibiotic action of gentamicin whilst substantial
depletion of metabolites involved in energy production and elevation of metabolites
implicated in oxidative stress suggests gentamicin had a profound effect on the
mitochondria of the proximal tubule epithelial cells.
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4.5.1 TCA cycle metabolites and the mitochondria
The depletion of TCA cycle intermediates is an established phenomenon of gentamicin
administration. Urinary citrate and 2-oxoglutarate excretion were identified as depleted
(Sieber et al. 2009) after rats were exposed to gentamicin, whereas in another study citrate
excretion was cited as increased (Lenz et al. 2005). OPLS-DA of urine spectra in the present
study identified a more comprehensive number of TCA cycle intermediates, 2-oxoglutarate,
citrate, fumarate, succinate, acetate, cis-aconitate and formate, as depleted 12 hours after
the initial dose and at mid and late time points in the study. Analysis of the sera revealed
elevations of acetate and citrate and a reduction in formate. The early and sustained
disruption of TCA cycle intermediates indicates that gentamicin had a potent effect on the
mitochondria and energy metabolism as a whole; furthermore the OPLS-DA urine and sera
models highlighted a reduction and an increase in 3-hydroxyisobutyrate, respectively,
which is a substrate of 3-hydroxyisobutyrate dehydrogenase, a mitochondrial enzyme
involved in the degradation of branched-chain amino acids (BCAAs). After a series of
reactions degradation of BCAAs produces acetyl CoA or succinyl CoA, which are fed into the
TCA cycle. Accordingly we observed significant decreases in the presence of the branched-
chain amino acids valine, leucine and isoleucine in the OPLS-DA models of pre-dose and day
1 urine and day 10 sera. Other amino acid changes were observed in the sera: tyrosine,
glutamate and alanine were depleted on day 10 of the study. Glutamate and alanine are
associated in the glucose-alanine cycle where pyruvate and glutamate form alanine and 2-
oxoglutarate (also depleted in the sera) which feeds into gluconeogenesis and the TCA
cycle, respectively. It is likely that the depletion of tyrosine is also associated with
gluconeogenesis.
Gentamicin could also act indirectly on mitochondrial function to affect the TCA cycle,
specifically through initiating apoptosis. Accumulation of gentamicin within and the
subsequent rupture of lysosomes releases cathepsins into the cytosol (Servais et al. 2005),
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causing cleavage of the pro-apoptotic protein BH3 interacting-domain death agonist (Bid),
destabilisation of the mitochondrial membrane and the release of Cytochrome C (Mather
and Rottenberg 2001), a obligate step for formation of the apoptosome and cell death.
Retention of gentamicin was evident in the 1H-NMR urine spectra of treated animals where
excretion of gentamicin after the initial dose was high but measurements on day 4 showed
lower excretion of the drug. Although from the NMR data alone it was not possible to
determine which mechanism was responsible for the mitochondrial distress, the early
changes in the TCA cycle intermediates seen here support findings in comparable studies in
which mitochondrial disturbances occur before morphological changes and loss of renal
function.
The metabolic disturbances observed in the OPLS-DA models coincided with a raised
urinary level of NAG in the gentamicin-treated animals at the 12 h time-point. Conversely,
kim-1, which is a more sensitive, proximal tubule injury-specific biomarker, was not raised
at 12 h. Although increased NAG excretion is typically associated with proximal tubule
injury, the excretion of NAG, which is a lysosomal enzyme, is known to increase with
lysosomal activity too (Bosomworth et al. 1999). Given the adsorptive endocytosis of
gentamicin and accumulation of the drug within lysosomes, the increase in NAG seen at this
early time point is likely to be indicative of increased turnover of proximal tubular
lysosomes driven by an increase in the activity of the endocytic system brought about by an
influx of gentamicin in the tubular lumen, rather than the onset of proximal tubule injury.
4.5.2 Oxidative stress
Early studies on gentamicin exposure and the mitochondria were completed in isolated
renal cortical mitochondria and clearly showed that gentamicin directly inhibits oxidative
phosphorylation (Simmons et al. 1980) and increases production of reactive oxygen species
(ROS) (Nakajima et al. 1994; Walker and Shah 1987); in addition many attempts to
ameliorate gentamicin nephrotoxicity have involved co-administration of antioxidants
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(Morales et al. 2002; Morales et al. 2010). Metabonomic analysis of post-dose urine spectra
highlighted several endogenous metabolites which suggest an increase in oxidative stress
after exposure to gentamicin. A significant rise in urine and serum allantoin was identified
in OPLS-DA models of pre-dose and day 1 urine spectra and in day 10 sera. Allantoin is a
non-enzymatic product of the oxidation of uric acid (derived from purine catabolism) and
both uric acid and allantoin have been implicated in diseases with increased oxidative stress
such as Down’s syndrome (Zitnanova et al. 2004) and chronic renal failure (Kand'ar and
Zakova 2008). In addition, perturbation of trigonelline, choline, glutamate and polyamine
(putrescine) excretion suggests changes in glutathione (GSH) homeostasis, with each of
these metabolites linked to the methionine cycle and the biosynthesis of cysteine, a
precursor of GSH. Trigonelline is produced from the methylation of nicotinic acid during
nicotinamide metabolism, generating by-products of s-adenosylhomocysteine (from
consumption of s-adenosylmethionine). Depletion of trigonelline was noted by a previous
study (Sieber et al. 2009) and could be linked to GSH depletion as suggested in the
metabonomic analysis of acetaminophen-induced liver injury (Sun et al. 2008). However
control animals also experienced perturbations in urine trigonelline so the significance of
this metabolite to gentamicin exposure is uncertain.
Similarly, choline metabolism feeds into GSH synthesis via betaine and s-
adenosylmethionine therefore the depletion of this metabolite in early and mid-point urine
and day 10 sera could also reflect the disturbance in GSH homeostasis. Whilst choline
catabolism has also been linked to gut microbiota (see section 4.5.3), the concomitant
decrease in its metabolite trimethylamine N-oxide (TMAO) suggests that if the gut
microbiota were responsible for the overall change in choline, then choline excretion
should increase after exposure to an antibiotic. Therefore the observation that serum and
urine choline has decreased in this study indicates that it is likely to be catabolised by the
rat in a compensatory mechanism for the increased demand for GSH. However it should be
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noted that GSH depletion is known to occur when feeding is reduced, i.e. during periods of
stress. Therefore the interpretation of these changes related to GSH must be regarded with
caution.
4.5.3 Gut microbial metabolites
The depletion of several metabolites in the urine and sera after gentamicin exposure can be
attributed to the antibiotic pharmacological action of the drug. Hippurate, TMAO and
methylamine are co-metabolites of the gut microbiome and mammalian metabolism and
the depletion of hippurate and TMAO has been noted in previous studies of gentamicin
exposure (Espandiari et al. 2007; Lenz et al. 2005; Sieber et al. 2009). Hippurate is a product
of the biotransformation of dietary aromatics that are initially metabolised by gut bacteria
to benzoate before being conjugated to glycine by mammalian mitochondrial enzymes in
the liver and kidney to form hippurate (Gatley and Sherratt 1977). Likewise, TMAO is the
product of the oxidation of trimethylamine, a product of gut microbial choline metabolism
(Zeisel et al. 1989). Although methylamine production is largely viamammalian degradation
of creatine and sarcosine (Davis and De Ropp 1961; Zeisel et al. 1985), studies of germ-free
rats demonstrate reduced excretion of methylamine (Zeisel et al. 1985), suggesting that the
depletion of methylamine identified in the OPLS-DA models of mid-study urine spectra is as
a result of the antibiotic pharmacology of gentamicin.
4.5.4 Metabolites of renal tubule dysfunction
The OPLS-DA model comparing pre- and post-dose spectra of biofluids highlighted an
increase in urinary 1-methylnicotinamide, urinary and serum glucose and serum creatinine.
In previous metabolic studies of gentamicin nephrotoxicity glucosuria has been identified
(Lenz et al. 2005; Sieber et al. 2009) but the elevation of 1-methylnicotinamide has not
been noted. A product of nicotinamide metabolism, 1-methylnicotinamide is an organic
cation generated by nicotinamide-N-methyltransferase. Its precursor nicotinamide is itself a
precursor of NAD and NADP, whilst its co-product is s-adenosyl cysteine, a pre-cursor for
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cysteine synthesis. The elevation in 1-methylnicotinamide represents an early biochemical
change in nicotinamide metabolism or excretion which, apart from a single animal with
raised 1-methylnicotinamide in day 4 and day 5 urine, is not seen in the mid and end-point
urine spectra. Given the diverse physiological roles of nicotinamide as a precursor for the
co-enzymes NAD and NADH, the biochemical significance of this perturbation is unclear.
However, 1-methylnicotinamide has been investigated as a non-invasive biomarker of renal
tubular function (Shim 1984, Maiza 1992) and therefore the increase in its excretion may be
an indication of early renal tubular dysfunction following a single dose of gentamicin.
Likewise, despite the wide-ranging physiological function of glucose, the increase in its
excretion is likely to be linked to changes in its reabsorption in the proximal tubule. The
multivariate analyses of urine spectra also highlighted urinary 3-indoxylsulfate (3-IS) as
significantly depleted mid-study compared to pre-dose. 3-IS is a uremic toxin (a substance
which is retained in the circulation as a result of renal failure) which is physiologically taken
up by organic anion transporters at the basolateral membrane and secreted by the
proximal tubule (Deguchi et al. 2002), thus the reduction in its excretion could suggest
dysfunction in the uptake and/or secretion mechanisms. Although it would have been
thorough to determine a concomitant increase in 3-IS in the sera, 3-IS is protein bound
hence it was not visible in serum spectra. However 3-IS and 1-methylnicotinamide have also
been shown to be gut-microbial metabolites therefore their depletion could be related to
the antibiotic action of gentamicin. Nonetheless the perturbation in the excretion of
glucose and creatinine charts the early perturbation in proximal tubule function with a
prominent loss of renal function by day 4.
4.5.5 Metabonomics in drug toxicity
Many of the metabolites identified in this study are common to a number of types of
toxicity and therefore, rather than biomarkers unique to gentamicin and proximal tubule
injury, they may reflect the non-specific effects of toxicity as a whole (Robertson et al.
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2011). It has been proposed that a reduction in food intake and body weight loss would
account for the changes in energy-related and gut microbial metabolites (Connor et al.
2004) and pair-feeding could circumvent this limitation. Whilst a reduction in food intake
and body weight loss could in part explain the reduction in several energy and gut-related
metabolites, it may not account for metabolites which were identified as elevated after
gentamicin exposure such as allantoin in the day 1 and day 10 urine. In addition, metabolic
perturbations in the gentamicin group preceded body weight gain differences between
gentamicin and saline-treated animals.
Whilst body weight changes and feeding are an explanation for some metabolic
perturbations in toxicity studies, these metabolites still offer useful information about
mechanisms of toxicity; certainly the commonalities in response to a toxin are just as
interesting as the differences. It is important that these metabolites are not disregarded as
they reflect the global changes in the metabolome in response to a toxin and it is this
inclusive quality which is at the core of the metabonomic approach.
4.5.6 Concluding remarks
 The metabonomic analysis of a once-daily dosing schedule of gentamicin has
identified major mitochondrial disturbances from as little as 12 hours following the
first dose. These changes precede elevations in kim-1, a proximal tubule-specific
biomarker of injury and were sustained until the end of the study and therefore
demonstrate an early mechanistic response to gentamicin exposure.
 Given that the TCA cycle metabolites’ excretion is elevated prior to kim-1 and
certainly before serum creatinine or BUN, clinical quantification of these
metabolites could be a valuable, non-invasive alternative to monitoring the toxicity
of aminoglycosides, although this would require additional targeted investigations
into specificity, sensitivity and the physiological levels in different demographics.
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 After several days exposure, renal function was deteriorating as evidenced by
glucosuria and polyuria. Certainly, day 4 appears to be the tipping-point of the
study where the toxicity began to affect daily body weight gain and the gentamicin
group no longer gained weight at the same rate as the saline control animals.
 Aside from toxicity, the unbiased 1H-NMR analysis has enabled the measurement of
changes in the mammalian-microbial co-metabolome, namely the reductions in co-
metabolites hippurate, TMAO, methylamine and 3-IS. It is likely that the role of the
gut microbiome and metabolome will become increasingly important to the study
of drug efficacy and safety, which is something that is further explored in Chapter 5.
Figure 4.16 Metabolic perturbations in the urine and serum as a result of gentamicin exposure and accumulation within proximal tubule epithelial cells.
TMAO – trimethylamineoxide, kim-1– kidney-injury molecule 1, NAG – N-acetyl-β-glucosaminidase, BUN – blood urea nitrogen, GSH – glutathione, SAM –
s-adenosylmethionine, TCA – tricarboxylic acid.
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5. INTEGRATED METABOLITE-BIOMARKER ANALYSIS
OF GENTAMICIN-INDUCED PROXIMAL TUBULE
INJURY
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5.1 Introduction
Metabonomic studies of drug exposure, such as described in Chapter 4, can provide a
comprehensive list of metabolites associated with toxicity. Establishing the metabolic
perturbations caused by exposure to a toxin not only gives insight into the mechanism of
toxicity but can also drive targeted candidate biomarker experiments. Early changes in
metabolites due to toxicity could have a predictive capacity for the onset, progression and
prognosis of renal injury, and may precede changes in renal functional biomarkers such as
rises in BUN and serum creatinine. In addition, identification of metabolites prior to
administration that predict differential responses to therapy could help stratify patients on
a risk/benefit basis. This concept is known as pharmacometabonomics and is discussed
below. By identifying panels of predictive metabolites from urinary pre-treatment or early
intervention spectral profiles, clinicians could not only circumvent the requirement of
therapeutic drug monitoring and renal function testing throughout the use of
aminoglycosides, but also reduce the prevalence of aminoglycoside-induced nephrotoxicity
altogether.
5.1.1 Pharmacometabonomics
Pharmacometabonomics is defined as, “the prediction of outcome of a drug or xenobiotic
intervention in an individual based on a mathematical model of pre-intervention metabolite
signatures,” and was coined after metabonomics-based studies into drug-induced liver
injury (Clayton et al. 2006). The idea that the innate status of an individual can influence the
outcome of exposure to a drug is akin to pharmacogenomics, whereby the genetic type of
an individual determines the handling and response to a drug. In pharmacometabonomics,
multivariate analysis of the pre-dose or early post-dose metabolome when integrated with
post-dose outcomes (such as biomarkers of injury and histopathology score) can group
individuals based on their differential response to a drug, i.e. through drug efficacy, safety,
metabolism and pharmacokinetics.
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An example of the pharmacometabonomic approach in practice is in drug-induced liver
injury caused by acetaminophen (APAP). APAP research was conducted to determine if pre-
dose metabolic profiles were predictors of APAP metabolism in humans (Clayton et al.
2009; Clayton et al. 2006). Multivariate analysis of 1H-NMR spectra from baseline urine
samples from patients given a single dose of APAP found that individuals with a greater
level of para-cresol sulphate in their pre-dose urine had lower post-dose ratios of APAP
sulphate to glucuronide, potentially indicative of metabolic competition between gut
microbial para-cresol and APAP in the liver (Clayton et al. 2009). This finding highlights the
importance of microbial influences on the handling of drugs which has the potential to
explain the inter-individual variability in the response to aminoglycoside nephrotoxicity.
Another demonstration of the utility of pharmacometabonomics was in a series of proof-of-
principle studies on liver injury induced by galactosamine hydrochloride, allyl alchohol and
APAP in rats (Clayton et al. 2006). The APAP study identified the pre-dose amount of the
metabolites TMAO, taurine and betaine as associated with the histology score after a single
toxic-threshold dose of 600 mg/kg (Winnike et al. 2010). When integrated with other
measurements of toxicity such as liver biomarkers, early intervention
pharmacometabonomics identified that changes in endogenous metabolites such as glycine
and creatine, gut microbial-related metabolites TMAO, betaine and hippurate, and drug-
related metabolites separated responders from non-responders of APAP exposure.
After more than a decade since its inception, pharmacometabonomics has demonstrated
its applicability and value across a variety of drugs in the study of their efficacy and toxicity
(Everett et al. 2013). It is clear that in the future the pharmacometabonomic approach to
understanding human health and disease will play a large role in the pursuit of personalised
healthcare.
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5.2 Aims
To identify pre-dose and early-intervention metabolite biomarkers that predict and chart
the onset of gentamicin nephrotoxicity. This was achieved by;
 Analysing early-intervention metabolite signatures in gentamicin-induced
nephrotoxicity by integrating a biomarker of kidney injury with 1H-NMR spectra
using OPLS-regression analysis.
 Examining pre-dose metabotypes in relation to kidney injury molecule-1 to predict
the extent of gentamicin-induced nephrotoxicity.
 Characterising the discriminatory pre-dose metabolite(s) and investigating their
relationship to aminoglycoside-induced nephrotoxicity.
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5.3 Methods
5.3.1 Animals
5.3.1.1 Gentamicin study 1
The animals and samples used for the initial biomarker and metabolite investigations were
also described in Chapter 4. Male 8-week old Sprague-Dawley rats were administered
gentamicin (200 mg/kg I.P, n=5) or 0.9% saline (n=5) once daily at 10:00 h for 9 days. Blood
was obtained by sampling from the tail vein prior to the first injection. Animals were
housed individually in metabolic cages 12 hours prior to the first injection and 12 hours
after the first injection; animals were housed in metabolic cages again for the 24 hours
after the fourth injection and finally for 24 hours after the final injection. 12 hour urine was
collected into chilled vessels with a minimum of 0.1% wt/v sodium azide. Animals were kept
on a 12 h light/dark cycle throughout the study with free access to food and water. On day
10 of the study all animals were culled by an overdose of pentobarbitone followed by
cardiac puncture.
5.3.1.2 Gentamicin study 2
The animals and samples used for the secondary study were collected and analysed as
described in Chapter 3. In brief, urine was collected overnight from twenty male Sprague
Dawley rats (aged approx. 8 weeks) prior to the first I.P injection of 120 mg/kg gentamicin
(n=8) or 0.9% saline (n=4). The remaining eight animals were administered tobramycin but
post-dose measurements were not required for the purposes of this chapter. Solutions
were administered once daily at 10:00 h for 7 days, followed by overnight urine collection
and on day 8, schedule 1 culling by a rising concentration of CO2. Urine was stored at -80°C
until analysis for biomarkers of kidney injury and the acquisition of 1H-NMR urine spectra.
All animal protocols were undertaken in accordance with a licence granted under the
Animals (Scientific Procedures) Act 1986 and approved by the University of Liverpool Ethics
Committee.
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5.3.2 Biochemical measurements
5.3.2.1 Urine creatinine
Urine (25 µL of urine diluted 1 in 25) was incubated with 125 µL of alkaline picrate solution
(0.14 M NaOH, 10 mM Na2HPO4, 90 mM sodium borate, 10 mM sodium dodecyl sulphate,
25% v/v picric acid, 2.7% v/v DMSO) for 2 min at room temperature. An acid solution (5 µL
of 10:2:88 v/v acetic acid: concentrated H2SO4:distilled water) was added and incubated at
room temperature for a further 10 min with shaking. Plates were read at 490 nm and urine
creatinine (UCr) was estimated using creatinine calibration standards (2.5-40 mg/dL).
5.3.2.2 Kidney injury molecule-1
In the gentamicin study urinary kidney injury molecule-1 (kim-1) was quantified using a
sandwich ELISA (Vaidya et al. 2006). In gentamicin study 2 kim-1 was quantified using the
rat kim-1 MesoScaleDiscovery assay, as described in Chapter 3.
5.3.3 Sample processing and acquisition of 1H NMR spectra
Samples from the preliminary gentamicin study were processed and spectra were acquired
as described in Chapter 4. Urine from gentamicin study 2 was processed in a slightly
different manner. Urine was diluted with buffer (1.5M KH2PO4/D2O, pH 7.4 (with D2O),
2mM NaN3, 0.1% TSP (3-(trimethyl-silyl)propionic acid-d4) 9:1 v/v before addition of 600 µL
to a 5 mm NMR tube. Spectra were acquired on a 600 MHz Bruker spectrometer and
automatically phased, baseline corrected and calibrated to TSP (0.0 ppm) using TopSpin 3.2
software. Spectra were imported into MATLAB 2013 using MetaSpectra 4.1.1 and were
aligned as described in Chapter 4. Water, urea, the high ppm region and TSP-related peaks
were excised from the spectra before probabilistic quotient normalisation (Dieterle et al.
2006) with in-house scripts.
5.3.4 Multivariate analysis
Urine spectra were subjected to supervised multivariate methods: Orthogonal Partial Least
Squares-Regression Analysis. OPLS-regression analysis was performed by comparison of
metabolic profiles time-matched with kim-1 excretion measurements.
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Metabolite identification was performed using Chenomx Profiler software (Chenomx NMR
Suite) and databases: the Human Metabolome Database
(www.hmdb.ca/spectra/nmr_one_d/search), and the Biological Magnetic Resonance Data
Bank (www.bmrb.wisc.edu/metabolomics), statistical total correlation spectroscopy
(STOCSY) analysis (Cloarec et al. 2005a) and spike-in experiments.
STOCSY is an analysis method that displays the correlation between the intensity of a given
driver peak and all other peaks in a set of 1D NMR spectra. In this way, for an unknown
metabolite of interest, molecular or biochemically associated (or correlated) peaks are
highlighted and can aid in the metabolite’s identification.
Data are presented as OPLS-DA loadings coefficient plots and OPLS-regression loadings
coefficient plots (Cloarec et al. 2005a; Cloarec et al. 2005b) where the loadings are back-
scaled to highlight the urinary metabolites which have a significant correlation (r2) with kim-
1 or in the case of STOCSY analysis, a significant correlation with the peak of interest. The
plots display the covariance together with the associated correlation coefficient (r2) with a
colour scale demonstrating the strength of the correlation; dark red indicates a very
significant correlation between the groups and at the other end of the scale, dark blue
indicates little variation between the groups.
5.3.5 Spike-in experiment
The identification of 3-HPPA was confirmed using a spike-in experiment. A 1H-NMR
spectrum was acquired for a pre-dose urine sample; it was then spiked with 5 µL of a 3-
HPPA standard (0.5 mg/mL in sample buffer) and a 1H-NMR spectrum was acquired. A
further 10 µL of standard was added to the sample before another 1H-NMR spectrum was
acquired. The process was repeated by adding 30 µL of 3-HPPA standard. Spectra were
overlayed using TopSpin 3.2 software to compare the resonances in spectra from un-spiked
and spiked urine.
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5.3.6 Estimation of metabolite excretion
The integral of the metabolite of interest 3-HPPA in the urine 1H-NMR spectra was adjusted
according to the number of protons; excretion was estimated using the calculated
creatinine excretion which was based on the proton-adjusted integral of the creatinine
singlet at 4.04 ppm and the concentration of creatinine as measured by the Jaffe assay (see
Chapter 4). Integration was achieved using MATLAB 2013 and in-house scripts (Imperial
College, London) by selecting the upper and lower ppm scale boundaries of the region of
interest.
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5.4 Results
5.4.1 Biochemical measurements
The extent of nephrotoxicity was determined by measurement of kidney injury molecule-1
excretion in the urine of rats pre- and post-gentamicin exposure.
5.4.1.1 Gentamicin study
Pre-dose urinary excretion of kim-1 was measured as 0.39±0.22 ng/mg UCr. Throughout the
study the excretion of kim-1 ranged from 0.25 – 1.73 ng/mg UCr in the saline group. Kim-1
excretion was significantly greater in the gentamicin group relative to the saline group from
day 5 to the end of the study on day 10 (Kruskal-Wallis, Dunn’s correction, p=0.0002),
Figure 5.1. Variability in kim-1 excretion within the gentamicin group was evident; on day 4
the range was 1.93 – 23.98 ng/mg UCr with similar patterns seen on subsequent days.
Animals 7 and 9 tended to have a lower, but significant from control, excretion of kim-1
relative to the other gentamicin animals peaking at 17.66 ng/mg UCr (day 9) and 17.11
ng/mg UCr (day 10), respectively, compared to animals 1, 3 and 5 with kim-1 excretion of
46.06, 32.37 and 30.87 ng/mg UCr on day 9, day 10 and day 9, respectively.
5.4.1.2 Gentamicin study 2
Pre-dose kim-1 excretion was 2.49±0.99 ng/mg UCr and at the end of the study the
excretion of kim-1 in saline-treated rats was not significantly different at 2.10±0.64 ng/mg
UCr. The excretion of kim-1 in the gentamicin group after 7 days of dosing was significantly
greater than pre-dose (p<0.001, T test, paired) and relative to saline group (p<0.001, T test,
unpaired) at 37.84±19.54 ng/mg UCr.
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Figure 5.1 Urinary kim-1 excretion in rats administered (A) 0.9% saline and (B) 200 mg/kg
gentamicin. Data are presented as aligned scatter plots with mean (-) and individual values
(n=5).
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5.4.2 OPLS-DA regression models
OPLS-regression models were generated using time-matched biomarker data and 1H-NMR
spectra. Firstly, the changes in urinary kim-1 excretion in relation to metabolic
perturbations throughout the study were analysed. Secondly, the relationship between pre-
dose metabotype and post-dose kim-1 excretion was investigated.
5.4.2.1 Kim-1 and metabolic changes
Models of time-matched urine spectra from gentamicin-treated animals at pre-dose, day 4
and day 10 against corresponding kim-1 data were analysed for correlating metabolites
(Q2Y=0.5784, R2Y=0.7295, p<0.0001); the singlet at 3.6 ppm, 2-oxoglutarate, succinate,
citrate, trigonelline, fumarate and formate had a negative relationship with increasing kim-
1. These changes are illustrated in Figure 5.2 and the statistics of the significant metabolites
are described in Table 5.1.
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Figure 5.2 OPLS-DA loadings coefficient plot of pre-dose, day 4 and day 10 urine 1H NMR
spectra regressed against time-matched urinary kidney injury molecule -1 excretion.
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Table 5.1 Urinary metabolites that were identified to have an inverse relationship with
changes in kim-1 after daily exposure to 200 mg/kg gentamicin. r2 denotes correlation value
Metabolite r2 Classification
2-oxoglutarate -0.77
TCA cycle
intermediate
Succinate -0.84
Citrate -0.76
Fumarate -0.80
Formate -0.77
Trigonelline -0.86 Nicotinamide metabolism& GSH depletion
3.6 ppm (s) -0.90 unknown
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5.4.2.2 Pre-dose urine spectra and kim-1
Pre-dose urine spectra were modelled against urinary kim-1 values from day 4, 5, 9 or 10 of
the study. Day 1 kim-1 was not used for modelling because the values were not raised from
pre-dose. A negative relationship between an uncharacterised singlet at 2.04 ppm and kim-
1 was identified in all models of pre-dose spectra and urinary kim-1 (e.g. r2=-0.85 with day
10 kim-1). Pre-dose citrate (r2=-0.84) and glucose (r2=-0.86) levels also had a negative
relationship with day 10 kim-1. Pre-dose 3-(3-hydroxyphenyl) propionic acid (3-HPPA) and a
putative sugar (5.415 ppm, doublet) had a positive correlation with urinary kim-1 in day 4, 9
and 10 models, see Figure 5.3.
5.4.3 Identification of 3-HPPA
Assignment of 3-HPPA to the multiplet at 6.76 ppm was confirmed by STOCSY analysis, a
review of the literature and a spike-in experiment of a synthetic 3-HPPA standard. STOCSY
analysis of the resonance at 6.76 ppm found significant correlations with several other
resonances in the urine spectra; multiplets at 2.48, 2.84, 6.8, 6.87 and 7.24 ppm were
identified, see Figure 5.4, which are consistent with 3-HPPA as reported in the literature
(Stanley et al. 2005). 1H-NMR spectra of rat urine before and after the spike-in of 3-HPPA
are shown in Figure 5.5. The intensity of the resonances at 6.76, 6.87 and 7.24 increased
with each addition of the standard, further confirming that the metabolite of interest is 3-
HPPA.
3-HPPA is a gut microbial-host co-metabolite that is produced from the dietary metabolites
chlorogenic acid and caffeic acid. The strong correlation between pre-dose levels of 3-HPPA
and kim-1 in multiple models in the preliminary study prompted further investigation of
pre-dose 3-HPPA and its relationship to gentamicin nephrotoxicity in a separate animal
cohort.
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Figure 5.3 OPLS-regression coefficient plot of pre-dose urine 1H NMR spectra and post-dose urinary kim-1 excretion on day 10 of the study. Pre-
dose 3-HPPA had a positive relationship with kim-1 whereas pre-dose citrate and α-glucose had and inverse relationship with kim-1.
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Figure 5.4 STOCSY analysis of the multiplet at 6.76 ppm identified in the pre-dose rat urine spectra to have a relationship with kim-1 excretion. (A)
Correlation of 6.76 ppm with all resonances, (B) The metabolite was identified as 3-HPPA. Enlargement of the STOCSY analysis (C) 6.5-7.6 ppm and
(D) 2.2-3.2 ppm labelled with the 3-HPPA resonances described in the literature (Stanley et al. 2005).
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Figure 5.5 Spike-in 1H-NMR experiments confirming identify of 3-HPPA. (A) 1H-NMR spectra of high ppm region of 0.5 mg/mL 3-HPPA standard
prepared in buffer and (B) Progressive spike-in of 0.5 mg/mL 3-HPPA standard into rat urine.
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5.4.4 Analysis of 3-HPPA in separate gentamicin cohort
The strong relationship between pre-dose 3-HPPA and kim-1 in the initial study was
investigated in pre-dose 1H-NMR spectra of a separate group of animals which were
administered either 0.9% saline or 120 mg/kg gentamicin for 7 days.
5.4.4.1 Variation in urinary biomarkers
Pre-dose kim-1 excretion ranged from 1.40 ng/mg UCr to 4.31 ng/mg UCr whereas post-
dose day 7 kim-1 excretion ranged from 27.0-80.5 ng/mg UCr (n=7). Pre-dose urinary
mevalonic acid ranged from 10.2-15.2 µg/mg UCr (n=7). As detailed in Chapter 3, there was
a positive relationship between pre-dose mevalonic acid and post-dose kim-1 excretion.
5.4.4.2 OPLS-regression model
Pre-dose 1H-NMR spectra were regressed against post-dose kim-1. However the model did
not highlight any pre-dose urinary metabolites as significantly correlated to end-point
urinary kim-1 excretion (data not shown).
5.4.4.3 Regression of 3-HPPA with biomarkers
As an alternative to the OPLS-regression model, pre-dose 3-HPPA was measured in the 1H-
NMR spectra and regressed against pre-dose mevalonic acid, see Figure 5.6A and B, and
with end-point kim-1, see Figure 5.6C. A significant positive relationship was found
between pre-dose mevalonic acid and the 3-HPPA integral (p=0.0027) and the calculated
excretion of pre-dose 3-HPPA (p=0.0127). A positive trend was observed between the pre-
dose excretion of 3-HPPA and toxicity of gentamicin (Figure 5.6C), although the linear
regression was not statistically significant. There was a weak positive correlation between
the 3-HPPA integral and the calculated excretion of 3-HPPA (p=0.0279), see Figure 5.6D.
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Figure 5.6 Regressions of pre-dose urinary 3-HPPA. (A) Pre-dose integral of 3-HPPA and pre-
dose mevalonic acid (n=18), (B) pre-dose excretion of 3-HPPA and pre-dose mevalonic acid
(n=18), (C) relationship between pre-dose excretion of 3-HPPA and end-point kim-1 in
animals administered 120 mg/kg gentamicin (n=7), (D) correlation between pre-dose 3-
HPPA 1H-NMR integral and calculated excretion (n=18).
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5.5 Discussion
Pharmacometabonomics aims to use metabolite signatures pre- and post-drug exposure
and end-point measures of toxicity to predict the response to the drug (Clayton et al. 2006).
The approach has been used to predict the extent of APAP-induced liver injury by
identifying early changes in metabolites (Winnike et al. 2010) after drug exposure and pre-
dose metabolites such as p-cresol sulphate (Clayton et al. 2009) and taurine (Clayton et al.
2006). Herein, a 1H-NMR based methodology was used to probe the pre-dose and post-
dose metabolic signatures of rats administered gentamicin and to analyse their relationship
to kidney injury molecule-1 (kim-1), a biomarker of proximal tubule injury, with a view to
identifying metabolites which predict the variability in gentamicin-induced nephrotoxicity.
The OPLS-regression analysis of 1H-NMR urine spectra with matched urinary kim-1 data
revealed multiple metabolites that had an inverse relationship to the increasing excretion
of kim-1. The majority of the metabolites identified as having a negative relationship to
kim-1 were TCA cycle intermediates (succinate, citrate, formate, fumurate and 2-
oxoglutarate) which were identified in OPLS-DA models as depleted post-dose relative to
pre-dose following administration of gentamicin (Chapter 4). Regression of the spectra
against the biomarker data demonstrated that the depletion of the TCA cycle metabolites
was correlated to kim-1 and therefore the extent of nephrotoxicity. Similarly, trigonelline, a
metabolite implicated in GSH homeostasis (Sun et al. 2008), was also observed to have a
negative relationship with increasing kim-1. Further characterisation of the relationship of
these metabolites with kidney injury and with other aminoglycosides is warranted but
certainly, changes in the TCA cycle intermediates and trigonelline could potentially serve on
a panel of biomarkers to monitor the response to exposure to gentamicin.
The OPLS-regression analysis with kim-1 also highlighted that the singlet at 3.6 ppm had a
strong negative relationship with kim-1 excretion. This ‘unknown’ was also highlighted in
multiple OPLS-DA models in Chapter 4. Given its position at 3.6 ppm this metabolite could
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be glycine which is typically observed as a singlet around 3.56 ppm. Glycine is a component
of GSH and was reported to be elevated in the urine of responders to APAP hepatotoxicity
(Winnike et al. 2010) and differential changes in glycine were suggested to be linked to
inter-individual susceptibility to toxicity. Equally this metabolite could be malonate, which is
a mitochondrial complex II inhibitor which can induce cell death through a loss of
mitochondrial membrane potential, cytochrome C release and GSH depletion (Fernandez-
Gomez. 2005). Perturbations in GSH homeostasis were identified in the metabonomic
analysis in Chapter 4, therefore if the singlet at 3.6 ppm is malonate or glycine its depletion
relative to increasing kim-1 supports the idea that oxidative stress is key player in the
development of gentamicin-induced nephrotoxicity.
STOCSY analysis of this unknown and investigation of the literature did not lead to its
identification; as it is a singlet resonance identification is more difficult as 2D experiments
do not lead to spin-system coupling information. Although its identity has not been
confirmed, this endogenous metabolite does appear to be important to gentamicin
exposure and toxicity, and, whilst the multivariate methods used in this research are
powerful tools for interrogating vast, complex sets of data, a limitation of the metabonomic
approach, as demonstrated here, is our ability to identify unknowns in a complex mixture.
Computational approaches have been developed that can aid in the assignment of
metabolites of interest, such as STOCSY analysis and the collation of metabolites in the
Human Metabolome Database, but these resources are finite and often further 2D NMR
experiments are required to elucidate structures.
Pharmacometabonomics also considers baseline or pre-dose metabotypes and their
relation to responses to drug exposure. In this preliminary investigation 3-(3-
hydroxyphenyl)-propionic acid (3-HPPA) was highlighted by the OPLS-regression analysis of
pre-dose 1H-NMR urine spectra and post-gentamicin exposure kim-1 excretion. A strong
positive relationship was observed between pre-dose 3-HPPA and kim-1 excretion on
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multiple days of the study (e.g. r2=0.93, day 10), which developed the hypothesis that there
may be a mechanistic relationship between 3-HPPA metabolism and gentamicin
nephrotoxicity.
3-HPPA is a metabolite of microbial origin which is assimilated by the MCT transporter
(Konishi and Kobayashi 2004) and excreted in the urine. Along with hippurate, 3-HPPA is a
major end product of the metabolism of dietary chlorogenic acid (Tomas-Barberan et al.
2014), see Figure 5.7 . It is estimated there are >1000 species of gut microbes accounting
for approximately 1 kg of weight in an individual (Nicholson et al. 2005) and there is strong
evidence of a mammalian-microbial ‘co-metabolome’, whereby the host and microbes
share metabolites (Nicholson and Wilson 2003); Indeed microbial and host metabolites can
exchange between the intestines and human circulation from the superior and inferior
mesenteric veins which drain into the hepatic portal vein and the bile ducts, allowing direct
interaction between gut microbe metabolism and human physiology. With such a
substantial presence in the human body, the potential influence of gut microbial
metabolism on the handling and toxicity of drugs cannot be overlooked.
Whilst the physiological or pathogenic effects of 3-HPPA have not been investigated,
precursors of the metabolite, dietary chlorogenic acid and caffeic acid, have been studied
with regards to their anti-hyperlipidemic properties (Cho et al. 2010; Karthikesan et al.
2010) which, given the role of HMG-CoA reductase (HMGR) in gentamicin accumulation in
the proximal tubule (see Chapter 3), could have wider implications for susceptibility to
aminoglycoside nephrotoxicity. A feeding study in streptozotocin-induced diabetic rats,
which have greater HMGR activity than healthy rats, showed that chlorogenic acid and
caffeic acid treatment lowered the activity of this enzyme (Karthikesan et al. 2010). Later
studies identified that caffeic acid, not chlorogenic acid, is an activator of AMPK (Tsuda et
al. 2012) which is an inhibitor of HMGR activity.
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To examine the relationship of 3-HPPA, HMGR activity and gentamicin nephrotoxicity
further, an independent set of urine samples from rats treated with gentamicin (120 mg/kg
IP for 7 days) were analysed for pre-dose levels of 3-HPPA by 1H-NMR and correlated to
pre-dose mevalonic acid (MVA) and end-point kim-1; again, positive trends were observed
between pre-dose 3-HPPA and MVA, the biomarker of HMGR activity, and pre-dose 3-HPPA
and kim-1. Together, the relationship between pre-dose 3-HPPA and kim-1 excretion, pre-
dose 3-HPPA and MVA and the inhibitory effect of chlorogenic and caffeic acid on HMGR in
vivo, suggest that the gut microbial chlorogenic acid metabolites could influence the activity
of host HMGR and therefore the toxicity of gentamicin.
Only 8% of chlorogenic acid and 19% of caffeic acid is absorbed from the gut in rats (Lafay
et al. 2006b), with the bioavailability of chlorogenic acid and caffeic acid dependent on the
composition and activity of the microbiome (Gonthier et al. 2003; Nicholson et al. 2005). A
change in the gut metabolism of these phenolic compounds could affect systemic exposure
and inhibition of the cholesterol biosynthetic pathway. Research into intestinal ecology has
demonstrated that modulation of bacterial populations by the antibiotics penicillin and
streptomycin had a profound effect on the co-metabolome, leading to a reduction in the
degradation of typically metabolised metabolites thus increasing their bioavailability. In
addition, the recolonisation conditions following a disruption in intestinal ecology plays a
significant role in the re-establishment of intestinal microbiota and their inherent metabolic
capacity (Swann et al. 2011). At a clinical level, patients repeatedly exposed to antibiotics
throughout their lives could inadvertently develop health issues, such as susceptibility to
adverse drug reactions, based on the recolonisation of their intestinal microbiota. In the
context of gentamicin nephrotoxicity, differential systemic exposure to chlorogenic acid
and caffeic acid could have a downstream effect on mevalonic acid production, megalin
endocytosis and the accumulation and cytotoxicity of gentamicin.
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Interestingly, metabonomic analysis has identified sex differences in 3-HPPA excretion in
Han Wistar rats with larger amounts of 3-HPPA excreted by female rats in comparison to
males (Stanley et al. 2005). Likewise, sex differences in the severity of aminoglycoside
nephrotoxicity have been reported, but they are contradictory depending on the species,
strain and choice of aminoglycoside (Goodrich and Hottendorf 1995; Sweileh 2009).
Nonetheless if the relationship between 3-HPPA, HMG-CoA reductase and gentamicin
nephrotoxicity is confirmed and translational, inter-individual and gender differences in
susceptibility to gentamicin nephrotoxicity could be, in part, caused by the handling of
chlorogenic acid by the gut microbes and its effect on HMGR activity.
Studies in chlorogenic acid-dosed rats indicate that it is rapidly hydrolysed to caffeic acid in
the gut and the liver (Gonthier et al. 2003; Lafay et al. 2006a) whereas the first pass
metabolism of caffeic acid is low (<7% metabolised) (Gumbinger et al. 1993); as such it is
likely that chlorogenic acid is a poorly absorbed metabolic pre-cursor and caffeic acid is the
effector on HMGR via AMPK. A preliminary study was carried out to determine whether
HMGR activity could be lowered by daily intraperitoneal administration of caffeic acid,
however in this experiment mevalonic acid excretion was unchanged after 7 days, data are
shown in Appendix 3. It may be that the route of administration (I.P as opposed to oral or
I.V), the dose (10 mg/kg) or the duration of the study requires adjustment to see the
sustained effect on HMGR activity. There is also evidence that 3-HPPA precursors have
antioxidant effects with investigations into ischemia (Sato et al. 2011), paraquat (Tsuchiya
et al. 1996) , APAP and carbon tetrachloride toxicity (Janbaz et al. 2004). In addition, a study
into iron overload demonstrated that caffeic acid supplemented diets reduced oxidative
stress and hypercholesterolemia caused by high dose iron (Lafay et al. 2005). Therefore the
relationship seen between 3-HPPA metabolism and gentamicin nephrotoxicity could be as a
result of HMGR inhibition and/or antioxidant capacity.
Figure 5.7 The metabolic fate of chlorogenic acid is the result of both gut microbial and mammalian metabolism. The end-products of chlorogenic acid
metabolism, hippurate and 3-HPPA are competing pathways and the prevalence of one over the other is dependent on the composition of the microbiota.
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Pharmacometabonomics, as demonstrated here, has enormous potential as a hypothesis-
driving tool in not only the investigation of mechanisms of toxicity, but also the discovery of
novel biomarkers related to therapeutic efficacy and the susceptibility to and progression
of drug-induced organ damage. Even so, what is restrictive of this powerful technique is the
management of the data, i.e. identifying every metabolite in a complex mixture, and the
progression of these multivariate analyses into targeted experiments with specific
questions, with the ultimate aim of changing those metabolite correlations into biochemical
mechanisms.
6. GENERAL DISCUSSION
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6.1 Introduction
The aim of this research was to develop a deeper understanding of the mechanism of
aminoglycoside nephrotoxicity by pursuing molecular factors which influence the
susceptibility of individuals to this adverse drug reaction. The current clinical strategy to
manage aminoglycoside nephrotoxicity lacks the personalised stratification of patients
based on risk and although mechanistic information is available it does not address the
presence of susceptibility factors at the biochemical level. To address the aims of this
research, targeted and non-targeted molecular approaches and a rat model of
aminoglycoside nephrotoxicity were applied to detect biomarkers that can be used to
understand the mechanism, to identify susceptibility factors and to guide therapeutic
interventions of aminoglycoside nephrotoxicity.
The leading hypothesis of the targeted research was that the activity of the rate-limiting
enzyme of the mevalonate pathway, HMG-CoA reductase, influences the accumulation and
cytotoxicity of aminoglycosides in the proximal tubule. The primary hypothesis of the non-
targeted studies was that comprehensive analysis of the metabolome, when integrated
with biomarkers of toxicity, will reveal underlying molecular mechanisms and highlight
specific metabolites related to the susceptibility and progression of aminoglycoside
nephrotoxicity.
6.2 Measuring HMG-CoA reductase activity
In vitro investigations had established that inhibition of HMGR with statins could reduce
megalin activity and the accumulation and toxicity of gentamicin (Antoine et al. 2010). It
was postulated that the diurnal and inter-individual variation in HMGR activity could affect
megalin-mediated endocytosis and therefore aminoglycoside nephrotoxicity. Before this
could be investigated, it was necessary to develop and validate a LC-MS/MS method to
quantify the product of HMGR, mevalonic acid, to serve as a biomarker of its activity. An LC-
MS/MS method was validated to be accurate and precise over a biologically relevant range
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for use in both rat and human urine. The method does have its limitations. The dynamic
range is not suitable for the quantification of serum mevalonic acid which may be a more
sensitive biomarker of systemic HMGR activity as only 30% of mevalonic acid filtered by the
kidney is excreted in the urine. However these studies have demonstrated a good
concordance between renal HMGR activity and urinary excretion and in addition, urine
collection is less invasive than blood sampling and the sensitivity of the analytical method
could be enhanced with a more sensitive MS instrument if deemed necessary.
The development and publishing of the assay is useful not only to studies of HMGR activity
in relation to aminoglycoside nephrotoxicity but also to the multifarious health and disease
states associated with the mevalonate pathway including, HMGR inhibitors administered
for the treatment of hyperlipidemia (Woollen et al. 2001b), the diagnosis of mevalonate
kinase deficiency (characterized by mevalonic aciduria) (Haas and Hoffmann 2006) and
recently the treatment of cancer (Kato et al. 2010; Nilsson et al. 2011). Furthermore, HMGR
activity has been observed to increase in a protective response to acute renal injury,
causing cholesterol accumulation (Zager et al. 2002). The mevalonate pathway is clearly an
important target in human pathology, toxicology and pharmacotherapy and the assay
presented in herein will facilitate its investigation.
The biomarker method was employed to initially detect patterns of natural variation in rat,
mouse and human HMGR activity and then to examine HMGR activity relative to
aminoglycoside nephrotoxicity. Diurnal variation in mevalonic acid excretion was
demonstrated in adult male Sprague-Dawley rats; this is the first demonstration of a
significant diurnal rhythm of mevalonate production as previous attempts to quantify this
variation in rats did not reach significance (Kopito et al. 1982). Oscillations in mevalonic acid
excretion over a 24 h period in adult male CD-1 mice were also detected, which is another
novel observation. The diurnal variation was translational, with paired samples from
healthy volunteer children also showing contrasts between morning and evening urinary
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mevalonic acid excretion. The diurnal activity of HMGR is clearly a conserved mammalian
phenomenon and these translational findings add weight to the significance of the rat
model of gentamicin nephrotoxicity used in these experiments.
6.3 HMG Co-A reductase activity and aminoglycoside nephrotoxicity
Measures of gentamicin accumulation and nephrotoxicity regressed against the pre-dose
mevalonic acid data showed significant positive relationships with a distinct temporal
component. These data are supportive of a causal relationship between HMGR activity and
the accumulation and cytotoxicity of gentamicin. This is an important finding for
aminoglycoside nephrotoxicity and certainly upholds the idea that the occurrence of this
adverse drug reaction may be governed by susceptibility factors at a molecular level, i.e.
the activity of HMGR in an individual.
The temporal component identified in these studies corroborates the concept that the time
of administration is important in the development and extent of aminoglycoside
nephrotoxicity. With the adoption of the once-daily dosing regimen into clinical practice
(Chuck et al. 2000), circadian variation in the handling and toxicity of the aminoglycosides
should be of concern. Previous studies suggested that the chronotoxicology of the
aminoglycosides is related to the individual’s activity period, whereby in rats
aminoglycoside clearance and toxicity is greater and lesser, respectively, which was
attributed to the circadian variation in glomerular filtration rate (Prins et al. 1997). However
the temporal separation between the extent of gentamicin accumulation and
nephrotoxicity could essentially be related to fluctuations in HMGR activity.
The study of urinary mevalonic acid in morning and evening samples from healthy
volunteer children poses another issue related to temporal changes and HMGR activity.
Whilst the majority of individuals had greater mevalonic acid excretion in the morning,
several individuals had the opposite rhythm, which in clinical practice would complicate the
formulation of dosing guidelines. Prior knowledge of an individual’s HMGR status would be
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useful in a dosing strategy. That being said, any influence this information might have on
the clinical guidelines to aminoglycoside administration will be a result of balancing the risk
of developing nephrotoxicity against optimising the efficacy of treating a life-threatening
bacterial infection.
Unexpectedly, no relationship between HMGR activity and tobramycin nephrotoxicity was
observed. With this result in mind, it is tempting to suggest that mevalonic acid excretion is
a gentamicin-specific susceptibility biomarker. However, whilst gentamicin accumulation in
the proximal tubule has been demonstrated to be megalin and HMGR-dependent,
tobramycin proximal tubule accumulation has not been demonstrated to be caused by
megalin, rather it has been presumed as a result of the definitive research with gentamicin,
amikacin and netilmicin (Nagai et al. 2001). The result that tobramycin shows no
relationship with HMGR activity is interesting as it is supporting evidence that tobramycin
may have additional mechanisms of uptake into the proximal tubule aside from megalin.
Indeed, there has been recent debate over endocytic-dependent and endocytic-
independent uptake mechanisms regarding the aminoglycosides (Nagai and Takano 2014)
with the suggestion that renal cation channels can also facilitate the influx of the
aminoglycosides, although this research was conducted in cell lines with gentamicin rather
than tobramycin, and some of the cation channels are distal tubule-specific.
It is clear that this is just the beginning of investigations into the differential uptake
mechanisms of the aminoglycosides and it is likely that one mechanism of uptake may not
fit every compound in the aminoglycoside class. Nevertheless, the observations with
gentamicin and tobramycin have influenced the design of animal studies and a Phase IIb
clinical trial in which statins are being investigated as prophylactic treatment for
aminoglycoside nephrotoxicity. If statins prove to be a successful method of reducing
aminoglycoside accumulation via megalin, statins could be utilised to augment the uptake
of other megalin ligands such as the nephrotoxin polymyxin B (Abdelraouf et al. 2014).
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6.4 A non-targeted approach to candidate biomarker identification
The non-targeted approach to identifying biomarkers of aminoglycoside nephrotoxicity
detected numerous metabolic perturbations after exposure to gentamicin as early as 12 h
after the first dose. Given the biochemical roles of the metabolites that were affected by
gentamicin exposure, they are likely to be toxicity related changes and, prospectively, they
could be biomarker candidates for the onset of adverse reactions to aminoglycoside
exposure.
A major criticism of the technique is that the changes in metabolites that are deemed the
‘usual suspects’ appear in metabonomic studies independent of the type of toxin or its
pharmacology and are a result of the physiological, unified response to stress. While such
criticisms are valid and should be considered when interpreting the data, researchers
should not overlook that metabonomics is a multivariate tool whereby the data set should
be considered comprehensively. Just as kidney injury molecule-1, serum creatinine and
blood urea nitrogen are individually useful, when used together they provide a greater
depth of information.  For metabonomics, it is the panel of metabolites and the patterns of
change, rather than a metabolite in isolation, which paints a picture of the metabolic
perturbation caused by drug exposure and will be useful in informing the diagnosis,
prognosis and stratification of patients.
In Chapter 5 the pharmacometabonomic strategy identified that a pre-dose gut microbial
metabolite, 3-HPPA, had a significant relationship to gentamicin nephrotoxicity and pre-
dose mevalonic acid excretion, suggesting that not only could gut microbes affect the host
response to gentamicin but that this could be biochemically connected to HMGR activity.
The comprehensive analysis of the metabolome spurred new lines of investigation into 3-
HPPA precursors and has addressed the notion that HMGR is influenced at multiple levels
by the host, the gut microbiota and the environment.
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Much attention has been focussed on the human genome for answers about human health,
disease and the cause of inter-individual responses to drug efficacy and toxicity. While
there have been some successes, many disease states and adverse drug reactions are likely
to be as a consequence of host-environment interactions. There is a growing recognition of
the role of gut microbes in human health and adverse drug reactions (Nicholson et al. 2005)
and metabonomics permits the non-discriminant analysis necessary to encompass both
human-derived and gut microbial metabolites, providing a comprehensive metabolic
signature that can be assessed in relation to toxicity. However metabonomic studies are
only as valuable as the samples used in the analysis; this research was limited by the
number of animals that could be in experiment at any one time and thus the ‘n’ number
used in the multivariate analyses was lower than optimum. As a result, stringent criteria
were placed on the analysis (i.e. the strength of the correlation) and a follow up sample set
was obtained to confirm the 3-HPPA result in the preliminary study.
There is no doubt that metabonomic approaches to understanding drug exposure and
toxicity can rapidly yield a vast amount of information. The translation of ‘big data’ into
useful targeted experiments that advance the field and influence clinical and
pharmaceutical practice appears to be the drawback here. Since the inception of ‘omics
approaches we have not seen the surge in the number of drug approvals that was the
promise of the ‘omics era. However it is fair to say that metabonomics and its cousins,
proteomics, transcriptomics and genomics, are still in their data-amassing infancy which
with time will be converted to scientific understanding to inform drug development
paradigm shifts and clinical practice.
6.5 Recommendations for future studies
Future experiments should be considered to further characterise the relationship of HMGR
and gentamicin nephrotoxicity. Thresholds of HMGR activity should be examined, i.e. what
is the tipping point between the minor and major accumulation and cytotoxicity of
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gentamicin relative to mevalonic acid? Importantly, the relationship between pre-dose
mevalonic acid and aminoglycoside toxicity should be examined in a clinical setting to
examine whether this phenomenon is a translational finding. However it may be
problematic to obtain baseline urine samples from patients that are in a critical condition
and require immediate antibiotic treatment. Given the result with tobramycin, it is
imperative that other aminoglycosides are studied; netilmicin and amikacin are proven
ligands of megalin and might have a similar relationship with HMGR as observed with
gentamicin.
Other factors which influence HMGR activity should also be explored. In addition to the
known dietary influences on HMGR activity and cholesterol biosynthesis, HMGR activity is
known to be influenced by hormones such as insulin, estrogens (Ness and Chambers 2000)
and gender. In a clinical study 31.6% of females and only 6.7% of males experienced
nephrotoxicity after amikacin treatment (Sweileh 2009) whilst in  animal studies gender
differences are dependent on strain and the aminoglycoside in question (Goodrich and
Hottendorf 1995; Pai et al. 2013). The administration of testosterone to female rats did not
exacerbate toxicity (Bennett et al. 1982) but estradiol worsened toxicity in both sexes
(Carraro-Eduardo et al. 1993). There is a tendency to believe that most gender differences
in physiology and disease are related to morphology and body size, but, it is important to
consider differences at the molecular level that could influence an individual’s response to
drug exposure. Notably, sex differences in HMGR activity have been observed in rats
(Carlson et al. 1978; De Marinis et al. 2008) which could contribute to inter-individual
susceptibility to aminoglycoside nephrotoxicity. The issue of gender and susceptibility is
complex and may vary depending on the species, strain and aminoglycoside in question but
it is certainly an important avenue of investigation.
Finally, the role of 3-HPPA and chlorogenic acid metabolism on gentamicin nephrotoxicity is
worth pursuing. An experiment which may be interesting to complete is a concerted
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analysis of differential gut microbial populations relative to the chlorogenic acid
metabolites, HMGR activity and aminoglycoside nephrotoxicity. The nature of gut microbial
populations can be determined by fluorescent in situ hybridisation analysis of faeces,
probing for specific species (Swann et al. 2011). Characterisation of the effect of gut
microbes on drug toxicity is an exciting area of research that could prove very clinically
useful in the reduction of adverse drug reactions and improvement of drug efficacy.
6.6 Contributions to toxicity research
In the research presented here, the overriding aim was to pursue susceptibility factors by
using existing mechanistic knowledge to perform targeted investigations and to probe the
mechanism of toxicity by employing non-targeted analytical techniques. A promising
susceptibility biomarker of gentamicin nephrotoxicity, urinary mevalonic acid, has been
identified and a robust analytical method has been developed and validated; multivariate
analysis has highlighted the important intracellular mechanisms of gentamicin
nephrotoxicity and revealed a relationship between pre-dose gut microbial metabolism and
toxicity. What this research has also pin-pointed is that when it comes to mechanistic
studies of drug toxicity, whilst there are unifying observations to be made between drugs in
one class, one size does not fit all. Tempting as it is to assume a mechanism of toxicity fits a
whole drug class and wide demographic, structurally related toxins may not have the same
mechanism and more importantly, an individual’s response to drug exposure may be
influenced by an intricate endogenous-exogenous dynamic.
Toxicity continues to be a major concern to drug development and to the clinical efficacy
and safety of therapeutics. Drug-induced kidney injury is just one of the types of adverse
drug reaction that is encountered but the commonality between all adverse drug reactions
is that they impede the approval and prescription of novel and existing therapies. Research
is operating in an era where it has been accepted that biomarkers can aid in the detection
and prognosis of disease but the search for and validation of these biomarkers is still a work
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in progress. The techniques used in this research can be adapted to a wide range of
diseases and adverse drug reactions and as presented here, significant advances in
knowledge can be made, but it will be the continuation of this research that will effectively
drive pharmaceutical and clinical change towards safer medicines.
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Appendix 1
Gentamicin dose-ranging study in mice
Strains: wild type C57BL/6, Nrf2-/- and wild type CD-1 mice
Dosing groups: 0.9% saline, 50, 100 or 200 mg/kg I.P gentamicin sulphate once daily (10:00-
11:00 h) for 7 days or single I.P 20 mg/kg cisplatin. n= 2 animals per genotype per dosing
group.
Free access to food and water.
Overnight urine collection day 3 to day 4.
Daily body weight change recorded, animals checked for signs of ill health before injections.
Overnight urine collection day 7 to day 8
Day 4 schedule 1 (rising CO2 & cardiac puncture) of cisplatin group
Day 8 schedule 1 of gentamicin animals.
Outcome
The dose ranging study in wild type and Nrf2-/- mice (C57 background) and CD-1 albino
mice indicated that gentamicin 50-200mg/kg once daily for 7 days did not cause
nephrotoxicity, as determined by estimation of BUN, urinary excretion of NAG, body weight
change and kidney weight ratio (no differences between gentamicin treated and saline
treated animals). There we no overt visible signs of distress or ill health during the study
and the kidneys were not visibly different to animals treated with 0.9% saline. Cisplatin-
treated animals (positive kidney injury control) experienced significant body weight loss,
raised BUN and urinary NAG.
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Appendix 2
Histology results
Animal Treatment Organ Histology
1
200 mg/kg
gentamicin
once daily
Liver (x2) Diffuse glycogen (variable amount; PAS); NHAIR
Kidney (x3) - tubular protein casts +++ (PAS)
- cortical tubules: dilated and devoid of epithelial cells, with individual or numerous apoptotic cells (caspase-3:
pos.), with scattered mitotic cells, with hyaline droplets and vacuolation
- multifocal, mononuclear (lymphocytes, macrophages) interstitial infiltration +
Score: 4
2 0.9% salineonce daily
Liver (x2) Diffuse glycogen (variable amount; PAS); NHAIR
Kidney (x3) NHAIR; caspase-3: neg
3
200 mg/kg
gentamicin
once daily
Liver (x2) Diffuse glycogen (variable amount; PAS) and slight mononuclear portal infiltration; NHAIR
Kidney (x2) - tubular protein casts ++/+++ (PAS)
- cortical tubules: dilated and devoid of epithelial cells, with individual or numerous apoptotic cells (caspase-3:
pos.), with scattered mitotic cells, with hyaline droplets and vacuolation
- multifocal, mononuclear (lymphocytes, macrophages) interstitial infiltration ++
Score: 3-4
4 0.9% salineonce daily
Liver (x2) Diffuse glycogen (variable amount; PAS) and slight multifocal random mononuclear infiltration; NHAIR
Kidney (x3) NHAIR, apart from occ. tubular protein casts; caspase-3: neg
5
200 mg/kg
gentamicin
once daily
Liver (x2) Patchy and generally low amount of glycogen (PAS); NHAIR
Kidney (x3) - tubular protein casts ++/+++ (PAS)
- cortical tubules: dilated and devoid of epithelial cells, with individual or numerous apoptotic cells (caspase-3:
pos.), with scattered mitotic cells, with hyaline droplets and vacuolation
- multifocal, mononuclear (lymphocytes, macrophages) interstitial infiltration +
Score: 3-4
6 0.9% salineonce daily
Liver (x2) Diffuse glycogen (PAS); NHAIR
Kidney (x3) NHAIR, apart from some tubular protein casts (PAS) ; caspase-3: neg
7 200 mg/kg Liver (x2) Diffuse glycogen; NHAIR
200
gentamicin
once daily
Kidney (x3) - tubular protein casts +++ (PAS)
- cortical tubules: dilated and devoid of epithelial cells, with individual or numerous apoptotic cells (caspase-3:
pos.), with scattered mitotic cells, with hyaline droplets and vacuolation
- glomeruli: some with swollen and hyaline appearance of glomerular tufts
- multifocal, mononuclear (lymphocytes, macrophages) interstitial infiltration ++
Score: 4
8 0.9% salineonce daily
Liver (x2) Diffuse glycogen (PAS); NHAIR
Kidney (x3) NHAIR (PAS: ditto); caspase-3: neg
9
200 mg/kg
gentamicin
once daily
Liver (x2) Diffuse glycogen (PAS); mild increase in leukocytes between hepatic cords
Kidney (x3) - tubular protein casts +++ (PAS)
- cortical tubules: dilated and devoid of epithelial cells, with individual or numerous apoptotic cells (caspase-3:
pos.), with scattered mitotic cells, with hyaline droplets and vacuolation
- glomeruli: occ. with swollen and hyaline appearance of glomerular tufts
- multifocal, mononuclear (lymphocytes, macrophages) interstitial infiltration (+)
Score: 4
10 0.9% salineonce daily
Liver (x2) Diffuse glycogen (PAS); NHAIR
Kidney (x2) NHAIR; caspase-3: neg
Comments:
Histological analyses were completed by A. Kipar. The scoring system used is that previously published by Zhang J et al., 2009. Toxicol. Path. 37, 629-643.
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Appendix 3
The effect of caffeic acid on HMGR activity
The effect of daily I.P injections of 6 mg/kg caffeic acid on HMGR activity was investigated.
HMGR activity was measured on day 1, day 4 and day 7 by quantifying mevalonic acid in the
urine. HMGR activity in rats was also monitored in animals given vehicle.
Study design
10 x male SD rats
2 dosing groups – vehicle or 6 mg/kg caffeic acid I.P
Vehicle – 1 x PBS
n=5 per group
I.P injection once daily (15:30 h)
Outcome
Caffeic acid 6 mg/kg per day I.P for 7 days did not decrease the excretion of mevalonate:
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